Transcriptional regulation of the anti-inflammatory protein tristetraprolin (TTP) by Cunliffe, Helen Elizabeth
  
 
Transcriptional Regulation of the Anti-Inflammatory Protein 
Tristetraprolin (TTP) 
 
Helen Elizabeth Cunliffe 
 
 
A thesis submitted to the University of Birmingham for the degree of  
DOCTOR OF PHILOSOPHY 
 
 
 
 
 
 
 
 
 
 
Centre for Translational Inflammation Research 
School of Immunity and Infection 
University of Birmingham 
March 2015 
 
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
  ii 
Abstract 
Feedback node genes (FNGs) are essential for negative feedback control of inflammatory responses. 
By definition, their expression is controlled by both pro- and anti-inflammatory stimuli, often in a 
cooperative manner. This thesis investigates three FNGs, namely Dual specificity phosphatase 1 
(DUSP1), Tumour necrosis factor alpha inducible protein 3 (TNFAIP3) and Tristetraprolin (TTP, 
encoded by the Zfp36 gene). DUSP1 is a negative feedback regulator of mitogen-activated protein 
kinases, TNFAIP3 negatively regulates the nuclear factor κB (NF-κB) signalling pathway and TTP is a 
destabiliser of pro-inflammatory mRNAs. 
All three FNGs were induced by pro-inflammatory stimuli, with very different dependence on NF-κB 
signalling. Tnfaip3 expression was strongly dependent on NF-κB, Zfp36 was minimally affected by an 
NF-κB inhibitor, and Dusp1 expression was actually increased. The anti-inflammatory agonists 
dexamethasone, prostaglandin E2 (PGE2) and transforming growth factor β (TGFβ) all impaired NF-κB 
activity, yet cooperated with pro-inflammatory agonists to increase expression of all three FNGs. 
Experiments in primary mouse knock-out macrophages suggested that DUSP1 may be necessary for 
some anti-inflammatory effects of PGE2, and for the cooperative regulation of other FNGs by pro- 
and anti-inflammatory agonists. 
To try to identify mechanisms of cooperative regulation of FNGs by pro- and anti-inflammatory 
agonists I concentrated on the relatively small Zfp36 locus. Three putative regulatory elements were 
identified on the basis of evolutionary conservation and scanning chromatin immunoprecipitation 
across the locus, using an antibody against RNA polymerase II. Those elements were cloned into a 
luciferase reporter construct and demonstrated to mediate cooperative transcriptional regulation by 
various combinations of pro- and anti-inflammatory agonists. Chromatin immunoprecipitation 
experiments also demonstrated dynamic remodelling of the locus in response to a pro-inflammatory 
stimulus, RNA polymerase being "transferred" from an upstream enhancer region to the Zfp36 gene 
itself.  
Taken together, the data in this study identify novel mechanisms by which FNG expression is 
maintained and even augmented during treatment with anti-inflammatory stimuli. These findings 
can be applied to the development of anti-inflammatory agents as therapeutic compounds.   
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1.0 INTRODUCTION 
 
 
1.1 Inflammation 
Inflammation is a host protective response to invasion by an infectious agent, antigen 
challenge or simply physical, chemical or traumatic damage. The main function of the 
inflammatory response is to facilitate the delivery of proteins and cells of the immune 
system capable of eliminating the initiating agent and promoting the healing process 
(Newton & Dixit 2012). The classical symptoms of inflammation are heat, redness, swelling, 
pain and loss of tissue function. Each of the symptoms described can be related to the 
physiological changes that take place. Local vasodilation of the inflamed area increases 
blood flow, allows extravasion of fluid, cellular influx, elevated cellular metabolism and the 
subsequent release of the soluble mediators of inflammation. Thus inflammation is not 
ancillary to, but an active function of the immune response, effectively evolved to defend 
and heal host tissues and processes (Beutler 2004). The benefit of an evolved immune 
system comes at a cost since inflammation is essentially injurious to host tissues. Indeed, 
immune dysfunction can be detrimental, resulting in any number of chronic inflammatory 
syndromes that may be a primary pathology or the secondary outcome to another 
condition. Often, the treatments prescribed to alleviate symptoms of numerous conditions 
act to reduce inflammation and other immune processes. The link between cancer and 
inflammation is significant and bi-directional. Carcinogenesis is often contributory to or the 
corollary of deregulated inflammation. The treatment of cancer-related inflammation with 
anti-inflammatory agents is not only effective in modulating host-response mediated 
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symptoms but has an anti-tumour effect on several hallmarks of cancer, including; 
proliferative capacity; evasion from apoptosis; and cell cycle regulation (Park et al. 2014). 
 
1.2 Dysregulation of inflammation 
 
Inflammation is a host protective mechanism, intended to remove the injurious stimulus 
and promote healing. However, the progressive destruction of tissue in the absence of 
inflammation can lead to inflammatory disorders and chronic inflammatory diseases 
including rheumatoid arthritis (RA), inflammatory bowel disease (IBD), diabetes and cancer. 
Thus, a functioning immune response is both rapidly induced and transiently executed. To 
this end, powerfully cytotoxic pro-inflammatory factors are actively curtailed by equally 
potent anti-inflammatory mediators (Figure 1.1). 
 
Whilst pro-inflammatory factors negatively feedback and activate anti-inflammatory 
mechanisms, they also positively feed-forward on themselves (Hu et al. 2008). That is, pro-
inflammatory messengers directly increase their own expression at multiple levels of 
regulation in order to elicit a precipitous response. Equally, anti-inflammatory factors 
positively regulate themselves also. Thus the inflammatory response is a precise and acutely 
controlled balance between potent factors protecting the host from noxious stimuli and 
powerful watchdogs that harness that initial response. 
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These “negative feedback” mechanisms are critical to limiting the inflammatory response 
and preventing excess tissue damage. Imbalances of ‘on’ and ‘off’ processes can lead to 
dangerous unchecked inflammatory responses that may be inadequate or excessive in 
magnitude or duration, becoming detrimental to the host. A disproportionate inflammatory 
response then results in debilitating chronic inflammatory conditions that cause severe and 
irreversible tissue destruction.  
 
  
Figure 1.1 Negative regulation of inflammation 
 
The rapid and powerful biosynthesis and secretion of pro-inflammatory mediators 
is efficiently curtailed by the succinct activation of regulatory factors with anti-
inflammatory effects. 
 
      4
1.2.1 Rheumatoid arthritis (RA) 
For example, in RA, spontaneously activated leukocytes infiltrate the joint and, unchecked 
secrete the inflammatory mediators responsible for the debilitating joint inflammation. The 
exact cause of erroneous leukocyte activation in the RA joint pannus is unknown; however 
the role of TNFα, a potent inflammatory cytokine, is pivotal. Feldman’s lab (Williams et al. 
1996; Feldmann) were able to show that blockade of TNFα in cells of activated synovium 
significantly reduced the level of pro-inflammatory cytokines. Additionally, synovial 
inflammation in collagen induced murine models of arthritis (CIA) was abolished in mice 
treated with anti-TNFα antibodies (Williams et al. 1992).  
The endogenous TLR ligands of the RA joint drive excessive production of pro-inflammatory 
cytokines TNFα, IL-1, IL-6, IL-8, IFNγ and VEGF, amongst many more as a positive feed-
forward process (Brennan & Feldmann 1996). A number of anti-inflammatory factors, 
including IL-10, TGFβ and TNFR are equally up-regulated in RA, though the pathways of 
inflammatory resolution are evidently debilitated (Feldmann et al. 2009). Indeed, 
microarray analysis by the Ivashkiv group revealed that macrophages isolated from RA 
synovium express significantly less IL10 responsive genes than control macrophages 
(Antoniv & Ivashkiv 2006). 
1.2.2 Inflammatory bowel disease (IBD) 
Inflammatory bowel disease (IBD) refers to inflammation of the colon, mucosal membrane 
and regions of the gastrointestinal tract (GI). This system of diseases includes ulcerative 
colitis (UC) and Crohn’s disease (CD) and is characterised by an over-activation of 
transcription factor NF-κB and subsequent overexpression of pro-inflammatory cytokines 
(Beck & Wallace 1997; Rogler et al. 1998; Schreiber 2005). Indeed, neutralisation of TNFα in 
Crohn’s effectively reduces inflammation and anti-TNFα therapy has proved successful 
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(Marini et al. 2003; Present et al. 1999). IBD is a complication of the failure to supress an 
immune response to luminal bacteria and the consequential exacerbated expression of pro-
inflammatory molecules including TNFα (Korhonen et al. 2013). Here, inadequacy of anti-
inflammatory feedback transforms miss-directed acute inflammation into a chronic 
inflammatory syndrome. Genome wide association studies and the use of IL10-/- mice has 
revealed a central role for the IL10 axis in patients with early onset UC and CD (Büchler et al. 
2012; Barnett et al. 2010; Hansen et al. 2009). Polymorphisms in the IL10 locus and 
homozygous IL10R loss of function mutations impair ligand-associated signalling and cause 
severe intestinal inflammation and increased secretion of pro-inflammatory cytokines 
critically involved in the development of spontaneous colitis. Three recent publications in 
Immunity (Zigmond et al. 2014; Shouval et al. 2014; Mantovani & Marchesi 2014) highlight  
IL10R signalling in murine macrophages as key to driving their homeostatic tolerogenic 
functions in gut health and inflammation. They also outline that ability to respond to, rather 
than release of, IL10 is fundamental to macrophage anti-inflammatory phenotype in the GI 
tract. 
 
1.2.3 Cancer 
For decades, microbial infection, injury, inflammation and tissue repair have been linked to 
the development of cancer (Balkwill & Mantovani 2001). Bacterial infection and immune 
activation can negatively regulate cancer, primarily through tumour necrosis factor –α 
(TNFα) (Cullen & Martin 2015). A number of therapeutic compounds have been developed 
based on the actions of microbial-compounds that activate immune signalling (Vacchelli, 
Eggermont, et al. 2013; Vacchelli, Vitale, et al. 2013). Used for the treatment of cervical, 
gastric and oral squamous cell carcinomas, OK-432 (Picibanil) is a lyophilized mixture of 
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group A Streptococcus pyogenes with antineoplastic activity (Rebuffini et al. 2012) that 
stimulates receptor signalling upstream of TNFα release (Hovden et al. 2012). The BCG 
vaccine triggers similar pathways and has been therapeutically successful in the treatment 
of bladder cancer (Jinesh G & Kamat 2012). Additionally, the administration of purified 
bacterial compounds lipopolysaccharide and flagellin in phase II clinical trials of colorectal 
and lung cancer has yielded positive results (Burdelya et al. 2008; Garaude & Blander 2012). 
Evidently, carcinogenesis is negatively affected by a functional immune and anti-tumour 
response. However, aberrant activation of inflammatory signalling in the tumour 
microenvironment can lead to immune suppression, tumour angiogenesis, tumour 
progression and chemoresistance (Yuntao Zhang et al. 2012; Yan Zhang et al. 2012; Galluzzi 
et al. 2012). A number of immune functions are responsible for driving malignancy, 
particularly the anti-apoptotic and proliferative effects of NFκB, a transcription factor 
abundantly expressed during inflammation (Chen et al. 2013; Alexopoulou et al. 2001). 
Additionally, numerous inflammatory mediators cause oxidative damage, including iNOS 
and NADPH. Coupled with the tissue repair response, this system can promote the 
incorporation of DNA damage and cell survival. Neoplasms reach a threshold of 1mm3 
before requiring their own vasculature. Pertinently, VEGF, another inflammatory target, is 
aberrantly expressed by cancer-associated fibroblasts and facilitates tumour angiogenesis 
(Riddell et al. 2012).  
Inflammatory skin conditions such as lupus can predispose patients to squamous cell 
carcinomas (SCCs) by way of immune cell infiltration and stromal cell remodelling. 
Interestingly, by reducing the CD4+ T-cell population in SCC-susceptible mice, tumour 
emergence and progression is delayed (Nakao et al. 1995; Itoh et al. 1995). Inflammatory 
bowel disease is a well-recognised and formidable risk factor for colorectal cancer. There is 
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strong evidence to suggest that the endogenous intestinal microbiota is central to the 
development of IBD-driven colorectal carcinoma (Hale & Greer 2012; Ock et al. 2011). As 
mentioned previously, IL10 knock out mice present with IBD as well as rectal dysplasia, 
adenocarcinoma and colitis, induced by Enterococcus faecalis (Chichlowski et al. 2010). Pro-
biotic modification of the enteric flora in mice null for IL10 associated with reduced mucosal 
inflammation and colon cancer (O’Mahony et al. 2001). Another potent inflammatory 
antagonist, TGFβ, inhibits inflammatory signalling and cell activation. Disruption to TGFβ 
signalling through ligand depletion or receptor knock out amplifies immune cell infiltration, 
metastasis and malignant growth potential in a number of SCCs (Gasparoto et al. 2012; 
Oshimori et al. 2015). 
Here I will focus on understanding the processes of anti-inflammatory mechanisms and 
determining how the inflammatory response escapes limitation in chronic 
immunopathologies.  
 
1.3 The immune system 
1.3.1 Innate and adaptive immunity 
Vertebrates have two components to their immune system: innate and adaptive. The innate 
response is evolutionarily ancient and present in all metazoans, whereas the adaptive 
system is an asset of vertebrates only (Iwasaki & Medzhitov 2010).  
The innate immune response consists of two sequential parts. Initially, the invading 
pathogen is identified by host cell surface receptors with the ability to recognise pathogen 
or host-damage associated products. Subsequently, the recruitment of effector cells and 
release of inflammatory mediators results in the destruction and elimination of the 
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infectious agent (Iwasaki & Medzhitov 2015). The receptors of innate immunity are 
numerous in type but non-specific i.e. they do not distinguish between individual 
pathogens. The non-specific nature of innate immunity is necessary to assist a rapid 
inflammatory response and prevent the onset of infection. In fact, the efficiency of the 
mammalian innate immune system is such that everyday infections are cleared before 
painful and clinically relevant symptoms are experienced. Thus our knowledge of innate 
immunity is quite rudimentary, relative to what we understand of the adaptive immune 
system, which becomes activated when infection persists and the innate immune system 
‘calls’ for help. 
The adaptive response is activated when effectors of the innate immune system present 
antigen to lymphocytes with the appropriate pathogen-specific receptors (Vincenzo et al. 
2015). Thus the adaptive immune system is antigen dependent and pathogen specific, since 
only cells expressing the cognate receptor become activated. This specificity results in an 
immunological memory that allows the host to inaugurate a much stronger attack each 
subsequent time the pathogen is encountered. Protective immunity has been manipulated 
in medicine for the use of vaccines that introduce live-attenuated organisms or inactivated 
toxins to the host, which cause long-lasting immunity without causing disease. 
 
1.4 Cells of the immune system 
The immune system incorporates numerous cell types and molecular mediators, accounting 
for its heterogeneity of actions and allowing agonists to deliver specific but also potentially 
innumerable cellular responses. Pluripotent haematopoietic stem cells (HSCs) are the 
progenitors to leukocytes; which is the umbrella term for cells of the immune system (Kanji 
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et al. 2011). A large class of cell types, Leukocytes may be further subcategorised into; 
erythroid, including red blood cells and the megakaryocytes that give rise to platelets; 
myeloid, including granulocytes, monocytes, macrophages and dendritic cells; and finally 
lymphoid, comprising the large and small cells that stem from the lymph. The lymphoid 
organs offer niche environments that cater for the maturation of HSCs but however, do not 
give rise to de novo leukocyte precursors. These tissues include, non-exclusively, the thymus 
and spleen. 
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1.4.1 Origins of myeloid cells 
The myeloid lineage encompasses the largest population of leukocyte cells and includes 
granulocytes, monocytes, macrophages and dendritic cells. This subpopulation of leukocytes 
comprehends the first line of defence against pathogenic invasion and is key in coupling 
systems of innate and adaptive immunity. 
 
1.4.1.1 Myelopoiesis and embryonic haematopoiesis 
Myelopoiesis is the process by which early monocyte progenitors colonise tissues and 
organs and differentiate into resident macrophages that will self-maintain throughout adult 
life (Baron et al. 2012; Bellantuono 2004). Quite recently the early genesis of tissue 
macrophages has come under scrutiny and been reconsidered. Embryonic haematopoiesis 
begins at E8.5 in mice, when primitive macrophages migrate to the central nervous system 
and form a stable compartment in the yolk sac (Ginhoux et al. 2010; Kierdorf et al. 2013; 
Schulz et al. 2012). A number of adult tissue macrophages, including Kupfer cells of the liver 
(Schulz et al. 2012) originate from this early population of myeloid precursors. Subsequent 
to this stage, the first haematopoietic stem cells are formed in the aorta–gonad–
mesonephros (AGM) region from cells of the ventral aortic wall (Medvinsky & Dzierzak 
1996). From here, the foetal liver becomes the foremost site of haematopoietic maturation 
and expansion, giving rise to erythroid, lymphoid and myeloid cells (Medvinsky et al. 1996; 
Kumaravelu et al. 2002). Up-regulation of foetal PU.1 favours the maturation of monocyte, 
macrophage and dendritic cell precursors by enhancing the expression of myeloid specific 
factors including IRF8, ERG1 and KLF4 and inhibiting mediators of other differentiation 
pathways (Kierdorf et al. 2013). It is at this point, following colonisation of the foetal liver, 
that pro-monocytes enter the circulation and seed niches such as the thymus and spleen 
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and postnatally, the bone marrow. During adult life, cells of the bone marrow niche are 
responsible for maintenance and replenishment of HSCs (Godin & Cumano 2005).  
 
1.4.1.2 Monocyte, macrophage and dendritic cell precursors 
HSCs develop in the foetal liver through multipotent progenitor stages and under the 
influence of PU.1 specify monocyte/macrophage and dendritic cell precursors (MDPs) (Dahl 
et al. 2003). MDPs precede common monocyte progenitors and dendritic cell precursors but 
have lost the ability to enter the granulocyte lineage.  
The balance of growth factors and cytokines involved in MDP differentiation and maturation 
is crucial to defining the fate and specific function of cells. Up-regulation of PU.1 enhances 
the expression of IRF8, ERG1, KLR4 and MCSFR (Kanji et al. 2011). Mice null for PU.1 exhibit 
reduced granulocyte and macrophage populations and die perinatally (Dahl et al. 2003). In 
addition, conditional deletion of MCSFR or its ligand in vivo results in severe osteoporosis, 
reproductive defects and abnormal organ development (Felix et al. 1994; Dai & Holland 
2003). Adult, tissue resident macrophages derive from essentially three origins, the yolk sac 
macrophages, foetal liver monocytes and the bone marrow and most importantly, at 
different and multiple stages of development (Gekas et al. 2005; Ottersbach & Dzierzak 
2005; Kumaravelu et al. 2002). Furthermore in response to infection or injury, classical 
monocytes may be recruited to target sites and differentiate into specialised macrophages.  
Still, even in their mature form macrophages remain a highly heterogeneous group of cells 
and may adopt different phenotypes depending on the needs of the tissue and prevailing 
cytokine milieu. For example, two extreme macrophage polarisation states include 
classically (M1) and alternatively (M2) activated (Gordon 2003; Sica & Mantovani 2012). In 
response to IFNγ and TLR activation, type M1 macrophages release ‘pro-inflammatory’ 
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cytokines associated with immune resolution. M2 macrophages on the other hand, respond 
to signalling through IL3 and IL4 and are associated with wound healing and tissue repair 
(Wynn et al. 2013). In vitro we can program monocytes to become enriched for classic or 
alternative macrophages using various stimuli, for example GM-CSF for ‘more M1’ and M-
CSF for ‘more M2’ –like. These classifications of macrophages exist on a spectrum which, as 
aforementioned reflect cellular microenvironment and therefore serve tailored roles in 
homeostasis, immunity, tissue repair, fibrosis, scavenging and angiogenesis (Wynn et al. 
2013; Gautier et al. 2012).  
Dendritic cells are the major antigen processing and presenting cells of the immune system, 
forming the bridge that links innate and adaptive immunity (Banchereau et al. 2000; 
Mellman & Steinman 2001). Conventional DCs (cDCs) fall under two categories expressing 
either CD8α or CD103/CD11b cell surface markers in mice and, equivalently CD141/BDCA3+ 
or CD1c/BDCA1+ in humans (Ginhoux et al. 2009; Varol et al. 2009; Shortman & Naik 2007). 
CD8α+ cDCs present viral antigens to CD8+ T-Cells and may also be involved in driving 
Th1/Th1 cytokine synthesis and release. CD11b cDCs on the other hand present to CD4+ T-
Cells and utilise transcription IRF4 to induce pro-inflammatory cytokine production (Schlitzer 
& Ginhoux 2014).  
The common cDC lineage is selected by high concentrations of PU.1. idr specifies the 
differentiation of conventional DCs, whereas and inhibition of idr leads to the production of 
plasmacytoid DCs (pDCs) (Shortman & Naik 2007). Present in all adult lymph and non-
lymphoid tissues, cDCs undergo constant replenishment from bone marrow common 
dendritic cell precursors (CDPs) expressing haematopoietic cytokine receptor Flt3 (Tahoori 
et al. 2015). The common DC lineage is driven by PU.1, Gfil and Cbfβ expression and gives 
rise to non-conventional plasmacytoid- and pre-cDCs also (Wynn et al. 2013). In the blood, 
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so called ‘monocyte derived’ or ‘inflammatory’ DCs may differentiate under activated 
conditions, on-site from pre-cDCs or monocyte infiltrates (Seillet et al. 2013; Seillet & Belz 
2013). Plasmacytoid cells produce a large amount of interferon on activation and play a key 
role in protection against viral infection ((Kim et al. 2014; Kim & Lee 2014; Domínguez & 
Ardavín 2010).  
1.4.1.3 Granulopoeisis 
Finally, within the most abundant classification of the myeloid lineage are the granulocytes 
or polymorphonuclear leukocytes, so called because of their five-lobed, irregularly shaped 
nuclei. The granulocyte family includes neutrophils, eosinophils and basophils, all of which 
stem from granulocyte/monocyte progenitors (GMPs) that mature into eosinophil-
committed progenitors in the foetal liver under conditions of C/EBPα, PU.1 and GATA2 
(Panopoulos & Watowich 2008; Dunn et al. 1994). Basophils and mast cells mature from 
respective precursors after this step. Neutrophils comprise a large proportion of the 
granulocyte lineage, however a common progenitor is yet to be described. 
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1.4.2 The lymphoid system of cells 
1.4.2.1 Natural killer cells 
Large lymphoid cells include natural killer (NK) cells that are involved in the destruction of 
viral machinery and virally-infected host cells. Although NK cells are activated by DCs 
(amongst other effectors), the non-specific nature of NK cells places them within the innate 
immune system of cells (Moretta et al. 2002; Moretta 2002; Chauveau et al. 2010). 
1.4.2.2 B- and T- lymphocytes 
Small lymphoid cells however incorporate the highly evolved, antigen specific cells of the 
adaptive immune system. The effector cells (monocytes and dendritic cells) of innate 
immunity are recruited to and subsequently activate T- and B- lymphocytes, thus initiating 
the adaptive immune response. T-lymphocytes express T-cell receptors on their cell surface. 
Whereas Immunoglobulins (IgGs) are expressed either as B-cell surface receptors or may be 
secreted by plasma B-cells as soluble mediators of adaptive immunity known as antibodies 
(Vazquez et al. 2015). Antigens are molecules recognised by specific B- and T-cell receptors 
that in turn elicit a strong and precisely targeted immune response. The pathogen-specific 
B- and T- lymphocytes expressing antibodies proliferate and are retained long after the 
infection is cleared thus creating an immunological memory, which enables efficient clearing 
of a secondary infection. Both B- and T- lymphocytes originate as bone marrow precursors, 
however their maturation processes occur in the spleen and thymus respectively. 
T-cells undergo a process of accelerated somatic hypermutation and VDJ recombination that 
allows a small number of genes to generate a vast number of different T-cell surface antigen 
receptors coupled to numerous effector functions (Kaech et al. 2002). T-cell Random 
hypermutation introduces a potentially injurious disadvantage in that the adaptive immune 
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system cannot distinguish self from non-self. In the thymus, self-antigen presenting cells 
strongly activate those potentially deleterious T-cells leading to apoptosis; a self-tolerising 
process known as negative selection (Germain 2002; Germain et al. 2002).  
During maturation in the spleen, B-lymphocytes undergo random isotype switching of the 
IgG receptor heavy chain, which is relevant to the effector function (Lin & Chen 1993). The 
light chain however, carries the unique and specific antigen receptor and is not subject to 
random mutation (Esser & Radbruch 1990). Thus the cell types of adaptive immunity are 
few – but their variety is both infinite and random. 
Following maturation and positive selection, T-lymphocytes migrate to the peripheral lymph 
organs as either CD8+ cytotoxic T-cells or CD4+ helper T-cells (Kaech & Ahmed 2001; 
Germain et al. 2002). 
Cytotoxic T-cells are the adaptive equivalent of NK cells; they kill host cells infected with 
virus or bacteria. Helper T-cells (Th) on the other hand act as mediators of adaptive 
immunity, interacting with both macrophages and B-cells and facilitating a more direct 
response against a specific antigen infection. Linked recognition allows B-cells to become 
activated by cognate Th cells i.e. those that bear the same antigen receptors. Th2 cells are a 
subdivision of helper cells that primarily mediate the humoral response and support B-cell 
proliferation and class switching (Cantor & Boyse 1977; John et al. 2008). The Th2 response 
produces, namely IL4, IL5, IL6, IL10 and IL13. IL10 is inhibitory to IFNγ and IL12, which 
potentiate the Th1 response (Rissoan 1999). Th1 cells are associated with increasing 
macrophage killing potential by producing IFNγ, TGFβ, IL10 and increasing IL12 as a type of 
feed-forward response (Cherwinski et al. 1987; Santana & Rosenstein 2003). Additionally, 
Th17 and Treg have been identified and characterised as subsets of helper T cells. Th17 cells 
characteristically release IL17 and IL22 in response to bacterial compounds (Infante-Duarte 
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et al. 2000). Whereas Treg supress autoimmunity and release IL10 and TGFβ (Sakaguchi et al. 
2009). 
 
1.5 Soluble mediators of immunity 
Macrophages and other cells of the immune system are potent producers of pro-and anti-
inflammatory cytokines and chemokines. Chemokines are small cytokines able to induce 
chemotaxis, some of which are considered to be pro-inflammatory and are induced at the 
site of infection during the inflammatory response (Arango Duque & Descoteaux 2014). 
Cytokines are intercellular signalling proteins, peptides and glycoproteins including 
interferons (IFN) and interleukins (IL) that, generally, have immunomodulatory effects 
(Davoine & Lacy 2014).  Most cytokines are pleiotropic and show redundancy, acting as part 
of a cascade where they are released in succession to one-another, can be synergistic and 
often counter-regulated by inhibitory cytokines and soluble receptors. Thus, through 
complex signalling cascades, cytokines are able to influence the regulation of genes, 
transcription factors, additional cytokines or cytokine receptors and also negative feedback 
regulators of inflammation (Cruvinel et al. 2010).   
 
1.5.1 The role of TNFα in inflammation 
TNFα was identified following observations of tumour regression in patients who had 
contracted bacterial infection (St-Pierre & Chadee 2014). Bacterial lipopolysaccharide (LPS) 
is a potent activator of the immune response and subsequently, TNFα biosynthesis. The 
biological roles of TNFα are somewhat double edged (Aggarwal 2003). Cytokines of the 
TNFα superfamily mediate basic cellular functions, including the intricate interplay between 
      17
cellular proliferation, differentiation and apoptosis in inflammation (Zelová & Hošek 2013; 
Sessler et al. 2013; Gaur & Aggarwal 2003). Accordingly, inappropriate expression of these 
potent yet crucial factors can be damaging and as such have been implicated in the 
pathogenesis of a number of inflammatory diseases and cancers (Landskron et al. 2014). 
Currently, we recognise 19 TNF ligands and all except 1; VEGI, are expressed by cells of the 
immune system (Figgett et al. 2014; Cabal-Hierro & Lazo 2012). Major sub-types TNFα/ β 
share 30% sequence homology and bind to cell surface TNFα receptors (TNFRs) 1 and 2. 
Perhaps accounting for diversity of function and non-specific toxic potential, TNFR1 is 
expressed in every cell type, while TNFR2 can be found in immune and endothelial cells 
(Cabal-Hierro & Lazo 2012). Receptors of TNFα do not trigger a biological response 
themselves but recruit adaptor proteins including TRAFs or death domain (DD) containing 
TRADD/ FADD. TNF binding and DD interaction in turn activates TNFR1 accessory proteins 
RAF2, cIAP1, cIAP2 and RIP1 and signalling ultimately leads to the activation of AP1 and 
NFκB (Schneider-Brachert et al. 2013; Cabal-Hierro & Lazo 2012). Additionally, ligand bound 
TNFR1 may undergo endocytosis thus altering accessory protein binding –potential. This 
secondary pathway is associated with promoting cell death by apoptosis and necroptosis 
(Cabal-Hierro & Lazo 2012). 
TNFα is a mediator of inflammation and tumour development, due to its pivotal roles in 
NFκB activation and promoting cell death. Accordingly, dysregulated expression of TNFα is, 
invariably central to the processes of systemic inflammation and autoimmune disease and in 
many instances responsible for tumour cell proliferation and survival (Landskron et al. 
2014). TNFα is implicated in a number of cancers including B-cell chronic lymphoid 
leukaemia, acute leukaemia, ovarian cancer and glioblastoma (Yang et al. 2014; Ji et al. 
2013; Eisele & Weller 2013; Zhu et al. 2012).  TNFα biosynthesis and expression is also 
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fundamental to the development of inflammatory conditions such as type II diabetes, IBD, 
ankylosing spondylitis, glomerulonephritis and SLE and rheumatoid arthritis (Bradley 2008). 
1.5.1.1 Regulation of TNFα expression 
Due to the significant pathological consequences of either over-expression or under-
expression of TNFα, biosynthesis is subject to multiple levels of complex regulation (Juhász 
et al. 2013). In response to activation by TLR stimulation, lipid or cytokine interactions, 
myeloid and T-cell populations transcribe TNFα rapidly and independently of de novo 
protein synthesis. Additionally, there are major mechanistic distinctions in TLR signalling 
which drive the expression of such rapidly expressed genes as TNFα. For example, prior to 
induction by pro-inflammatory pathways, the TNFα promoter, like many immediate early 
gene promoters, is pre-bound with TBP and exhibits RNAPII pausing directly upstream of the 
TSS. Sequences ‘poised’ in this way are subject to rapid synthesis following RNAPII release 
and activation of transcriptional elongation (Adamik et al. 2013). Productive elongation of 
nascent transcripts requires the dynamic posttranslational modification of RNAPII; a 
mechanism which is now recognised as a key phase in the regulation of transcription. In 
promoter-proximal pausing, RNAPII is associated with promoter regions at, downstream and 
occasionally even upstream of the transcription start site (TSS). Phosphorylation of the 
accessory protein DRB-sensitivity-inducing factore (DSIF) and the carboxy terminal of RNAPII 
by positive transcription elongation factor b  (P-TEFb), leads to rapid activation of 
transcription. Thus promoter proximal pausing negates the lag-time that would be imposed 
by active recruitment of RNAPII (Jonkers & Lis 2015).  
Depending on cell type and stimulus, TNFα may be regulated by an array of transcription 
factors and the promoter region is littered with binding motifs including CRE, ATF, C/EBP, 
AP1/2, Egr1 and NFκB (Pauli 1994; Kotlyarov et al. 1999). A considerable number of studies 
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have focused on NFκB dependent TNFα transcription, largely due to the significant 
abundance of inflammatory conditions in which NFκB function is perturbed and TNFα is 
characteristically overexpressed. Cell and tissue specific expression of TNFα may also be 
defined by epigenetic mechanisms of regulation. DNAse hypersensitivity generally confers 
genomic regions of relaxed chromatin and associated DNA that is accessible to transcription 
factors.  Regions of DNAse hypersensitivity at the TNFα locus differs between cell type and 
implicate enhancer regions under epigenetic control (Skoog et al. 2006; Barthel & Goldfeld 
2003; Chen et al. 2009). Additionally, glucose-rich microenvironments induce proximal 
histone acetylation in myeloid cells, increasing transcription factor binding and enhanced 
TNF expression. Cytokine biosynthesis is commonly regulated at the epigenetic level 
(Vanden Berghe et al. 2006; Csaba 2014). 
 
1.5.2 Interleukins 
The interleukins were coined as early as 1977 with the discovery of IL1, previously identified 
as human leukocytic pyrogen (Onozaki 2013). They are a large family of cytokines that are 
synthesised and expressed by leukocytes. Based on sequence homology, receptor chain 
similarities or functional properties, the interleukins are further categorised into a number 
of other sub-groups, for example the IL1, IL10, common γ-chain, Th2-like and a handful of 
other families. A functioning immune system depends on interleukin production, mostly by 
CD4 Th-cells, monocytes, macrophages and some endothelial cells.  
1.5.2.1 Interleukin 1α (IL1 α) 
Originally entitled human leukocytic pyrogen, IL1α is the archetypal member of the IL1 
family of cytokines. Both IL1α and IL1β were identified almost simultaneously to exert 
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similar effects through the IL1 receptor I (IL1RI) (Garlanda et al. 2013). Inappropriate 
expression of IL1β is key to a number of auto-inflammatory or periodic fever syndromes, 
with which patients experience recurrent episodes of systemic and organ specific 
inflammation. Autoinflammatory syndromes differ from autoimmune diseases in that the 
latter involve misdirection of adaptive immunity as opposed to the former, which are 
resultant of innate immune dysfunction. IL1α is a mediator of the acute phase of 
inflammation and induces pain sensitivity, fever, vasodilation and hypotension and patients 
suffer fever, pain in the joints and abdomen, skin rashes and in severe cases, amyloidosis. 
Therefore synthesis of and exposure to IL1α is critically regulated. Precursor of IL1α is 
synthesised without a signal peptide fragment and may be processed into a mature form by 
calpain (Martinon et al. 2009). However cleavage of pro-IL1α is not a requirement for 
binding to IL1RI. Similarly, IL1β is cleaved post induction. The inflammasome is an NLR-
multiprotein complex required for the biological activation of inflammatory proteins 
including IL1β and IL18. Upon stimulation, NLR subsets NALP1, 2 and 3 assemble into 
common cytoplasmic structures that recruit and activate caspases responsible for the 
cleavage and activation IL1β (Martinon et al. 2009). 
As an additional means of regulatory control, IL1α and β may also bind to IL1RII; a decoy 
receptor that associates ligand without prompting a signalling cascade. Thus IL1RII acts as a 
natural inhibitor of the IL1α/ β pathway (Gabay et al. 2010).  
Following activation of membrane bound TLRs, for example by endotoxin or LPS, active pro-
IL1α is produced by a number of immune effector cells including macrophages, monocytes, 
lymphocytes, fibroblasts and neutrophils (Dinarello 2009; Feldmeyer et al. 2010). Cells 
responding to IL1α include T-cells, B-cells, fibroblasts, epithelial cells and endothelial cells to 
name a few, all of which co-express IL1RII with IL1RI (Akdis et al. 2011). Binding of IL1α to 
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IL1RI provokes signal transduction via the adaptor molecule MyD88, subsequent activation 
of IL1R-associated kinases (IRAKs) and induction of NFκB and MAPK- regulated factors such 
as p38 and JNK. By inducing the expression of pro-inflammatory genes such as COX2 and 
iNOS amongst many more, IL1α plays an important role in potentiating local and systemic 
inflammation (Weber et al. 2010). Therefore IL1α has a major role in numerous 
autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease and 
multiple sclerosis as well as immune-associated conditions like atherosclerosis and 
Alzheimer’s disease. 
Somewhat complementary to IL1RII, IL1Ra shares sequence similarity to and is produced in 
response to the same stimuli as IL1α (Jesus & Goldbach-Mansky 2014)but lacks the 
necessary IL-1AcP accessory protein binding domain and therefore competitively binds to 
IL1RI without instigating signal transduction (Dinarello 2009; Akdis et al. 2011) . Mice lacking 
IL1Ra develop a spontaneous inflammatory syndrome similar to human rheumatoid 
arthritis, where overexpression of inflammatory cytokines IL1β, TNFα and IL6 is pathogenic 
(Fantuzzi & Dinarello 1996; Cartmell et al. 2001). Concurrently, therapies for some immune 
disorders involve administration of IL1Ra for effective neutralisation of IL1α (Bao et al. 2014; 
Hu et al. 2015). 
1.5.2.2 Interleukin 6 (IL6) 
Originally identified as a B-cell differentiation factor (BSF2), IL6 is a pleiotropic cytokine and 
myokine with a significant role in immune regulation (Scheller et al. 2011). Membrane 
bound or soluble, IL6 has functions in T-cell proliferation, B-Cell differentiation, survival and 
production of IgG, IgA and IgM antibodies and has effects on leukocyte trafficking, including 
recruitment of neutrophils and mononuclear cells. IL6 is also expressed in muscle and, 
independent of preceding TNFα or NFκB expression, is up-regulated by Ca2+/NFAT and 
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glycogen/ p38 MAPK signalling and is anti-inflammatory. As a cytokine, IL6 is released by 
monocytes, macrophages and fibroblasts during systemic inflammation (Scheller et al. 
2011).   
The IL6 cell surface receptor is found coupled to gp130 (/CD130) an adapter protein which is 
shared with other receptor molecules including leukaemia inhibitory factor (LIF), IL11, ciliary 
neurotrophic factor (CNTF), oncostatin-M and cardiotrophin-1 (CT-1) (Taga & Kishimoto 
1997; P. Wang et al. 2010). Target cells lacking the membrane bound receptor can respond 
to IL6 through expressing the soluble IL6R (sIL6R), which, subsequent to ligand binding 
forms a complex with sgp130 (Boulanger et al. 2003; Xu et al. 2010). Downstream of ligand 
binding, phosphorylation of gp130 Y759 leads to Ras-ERK-MAPK signal transduction and 
activation of the transcription factor C/EBP. Posttranslational modification of gp130 Y767, 
Y814, Y904 or Y915 in response to IL6 is required for survival and instigates JAK activation 
and the induction of STAT3 target genes (Taga & Kishimoto 1997; Hemmann et al. 1996; 
Feng et al. 1997). 
Signalling through sIL6R is considered to be important for T-cell function and survival in 
inflamed tissues whereas membrane bound IL6R is plays a key role in Treg activity. By 
suppressing Treg responses, through driving Th17 and Th2 differentiation, IL6 promotes a pro-
inflammatory milieu and therefore may be a relevant target for the treatment of chronic 
inflammatory and autoimmune disease (Eulenfeld et al.; Babon et al. 2014). Evidence 
supporting the involvement of IL6 in autoimmune disease burgeoned from a study that 
identified that approximately one third of patients with cardiac myxoma also experience 
symptoms of autoimmune disease. Successively, cardiac myxoma cells and their 
supernatants were identified to contain elevated IL6 mRNA and protein (Kishimoto 1992). 
Latterly, substantial evidence has been obtained to support a role for IL6 in the 
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pathogenesis of numerous chronic inflammatory and autoimmune diseases including 
chronic inflammatory proliferative disease (CIPD), SLE, B-cell malignancy, RA and IBD 
(Scheller et al. 2011; Rossi et al. 2015).  
Expression of IL6 is required for experimentally induced models of arthritis in which T-cells 
overproduce Th1 and Th17 cytokines. Furthermore, blockade of IL6 in these models reduces 
the level of Th17 synthesis and release as well as alleviates the clinical symptoms and 
histopathological signs of arthritis (Alonzi et al. 1998; Yen et al. 2006).  
Serum levels of IL6 are substantially elevated in the synovial fluid of arthritis patients. 
Indeed, drugs that are clinically effective have been shown to suppress IL6 secretion, a 
function that correlates with patients’ response to therapy (Kishimoto 1992; Rossi et al. 
2015; Moghaddami et al. 2014). Patients with SLE often develop arthritis, which increases in 
severity proportionally with the level of IL6 overexpression. As a B-cell stimulatory factor, 
IL6 stimulates autoantibody production and immunoglobulin secretion. The involvement of 
IL6 in SLE pathogenesis is clear. Immunoglobulin anti-DNA antibodies are produced by the 
low density B-cells of SLE patients, and supressed by anti-IL6 antibodies. Anti-DNA antibody 
accumulation is also key to the development of glomerulonephritis and kidney dysfunction 
observed in SLE sufferers (Rönnelid et al. 2003; Ball et al. 2014; Zhu et al. 2013).  
A number of studies have highlighted the positive correlation between IL6 expression and 
IBD severity in humans. Serum IL6 is higher in patients with CD when compared to those 
with UC. Mice lacking STAT3 expression in macrophage and gut-epithelia develop a much 
milder form of dextran induced colitis than those with full inducibility. Additionally, those 
mice overexpressing STAT3 suffer a much more severe disease (Yen et al. 2006). In a clinical 
study, 80% of CD patients receiving anti-IL6 antibody showed a positive response, compared 
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to 30% of a placebo group, highlighting the potential of anti-IL6 strategy for the treatment 
of IBDs (Allocca et al. 2013). 
Further to this, IL6 appears to play a predominant role in linking chronic inflammation with 
tumour growth. The JAK/STAT3 pathway is linked to the development of solid tumours, 
including colorectal cancer. Through downstream STAT3 activation, IL6 generates an 
inflammatory microenvironment in which anti-tumour mechanisms are supressed and 
therefore promotes tumour proliferation, survival and invasion. Concurrently, SOCS3, a 
repressor of JAK/STAT3 signalling, is silenced in a number of malignancies. Additionally, 
antiviral infection of CRC cells with SOCS3 significantly inhibited proliferation (Wei et al. 
2014). 
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1.5.2.3 Interleukin 10 (IL10) 
Interleukin 10 (IL10) is produced by activated macrophages and dendritic cells and limits the 
expression of pro-inflammatory cytokines and chemokines (Smallie et al. 2010; de Waal 
Malefyt et al. 1991; Akdis et al. 2011).  
In response to ligand binding, IL10R signals through the JAK pathway, activating STAT 
transcription factors, particularly STAT3 (Finbloom & Winestock 1995; Chen et al. 2014). In 
fact, STAT3 is essential for the anti-inflammatory actions of IL10 and vice versa (Takeda 
1999; Lang 2002; Yasukawa 2003). Anti-inflammatory and pro-inflammatory targets of 
STAT3 may, respectively be activated or directly inhibited at the level of transcription 
(Schottelius et al. 1999; Murray 2005). Through up-regulation of soluble TNFR, tissue 
inhibitor of MMPs (TIMPs) IL1Ra and IL1RII, IL10 is able to down regulate a multitude of pro-
inflammatory factors including TNF, IL6, IL1, MCP1/5, CCL5 and GMCSF (Kontoyiannis et al. 
2001; Denys et al. 2002; Schaljo et al. 2009).  
The central role of IL-10 in restraint of inflammation is demonstrated by the development of 
severe IBD in Il10-/- mice (Kühn et al. 1993). Production of IL10 by protective Treg cells is 
central to suppression of the inflammatory response to commensal bacteria in the gut 
(Barnes & Powrie 2009a; Barnes & Powrie 2009b). Moreover, mice deficient in IL10 develop 
severe inflammatory bowel disease (Kühn et al. 1993; Kuhn & Stappenbeck 2013). 
Additionally, patients with early onset colitis are often homozygous for IL10R mutations and 
demonstrate reduced IL10 signalling and activation of the critical STAT3 (Glocker et al. 
2009). It is also important that the immunosuppressive effects of IL-10 are limited. 
Aberrantly enhanced expression of IL-10 has been implicated in a number of conditions 
including SLE and multiple scleprosis (MS), where patients and family members alike have 
high numbers of cells that spontaneously produce and are less responsive to IL-10 (Beebe et 
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al. 2002; W. Yuan et al. 2011; Sun et al. 2012). Additionally, IL-10 is also known to enhance 
proliferation and survival of melanoma cells (Krüger-Krasagakes et al. 1994; Itakura et al. 
2011). 
 
1.5.3 Interferon γ (IFNγ) 
Type I and II interferons were first identified as inhibitors of viral replication and categorised 
according to sequence similarity and receptor specificity. As the only type II member, IFNγ 
has a distinct structure and binds specifically to the interferon gamma receptor (IFNGR). 
Ligand binding catalyses a JAK-STAT auto-phosphorylation cascade that leads to nuclear 
translocation of STAT1 homodimers and altered IFNγ target gene expression (Rauch et al. 
2013).  
The production of IFN γ by CD4+ T-cells and NK cells is induced mostly by IL12 and its 
synergism with IL18, secreted by macrophages, dendritic cells and neutrophils. The 
immunostimulatory and immunomodulatory functions of IFNγ include lymphocyte 
recruitment and prolonged tissue activation, macrophage production of TNFα, iNOS and 
hydrogen peroxide and enhanced antigen presentation by MHC class I and II (Watford et al. 
2003; Smith & Denning 2014). Prototypic of cell-mediated immunity, IFNγ and IL12 are the 
key cytokines driving the Th1 primary response. The humoral response is powered mainly by 
IL4, which is strongly antagonised by IFNγ. A robust positive feedback loop between IL12 
signalling and IFNγ release, in addition to Th1 inhibition of IL4 ensures further polarisation 
towards a cell-mediated response. 
Macrophage biosynthesis of a number of genes, including iNOS, in response to TLR agonism 
requires IFNγ ‘pre-treatment’. This phenomenon, whereby IFNγ facilitates a more rapid and 
heightened response to inflammatory stimuli in previously exposed macrophages is called 
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priming (Schroder et al. 2004). The physiological significance of this mechanism is 
highlighted in IFNGR knock out mice which are highly resistant to LPS-induced toxicity 
(Vermeire et al. 1997; Manoury-Schwartz et al. 1997; De Klerck et al. 2004). In RAW264.5 
cells, IFN pre-treatment improved DNA binding kinetics and enhanced degradation of IκBα 
to instigate a superior NFκB response in LPS-activated macrophages when compared to 
untreated cells. 
The role of IFNγ in autoimmune disease is, like its function, pleiotropic and complex. 
Autoimmune diseases characteristically present with chronic activation of macrophages 
and/ or neutrophils at sites of inflammation. Th17-mediated disease, generally speaking, is 
affiliated with neutrophil infiltration, whereas Th1-immunity plays a large role in 
macrophage activation (Steinman 2008). In EAE, ablation of IFNγ or the IFNGR increases 
morbidity and mortality (Ferber et al. 1996). Similarly, in the CIA model of disease, IFNGR 
deficiency significantly reduced time of onset and increased the incidence of disease 
(Manoury-Schwartz et al. 1997; Vermeire et al. 1997). The apparent protective role of IFNγ 
in these two animal models of chronic inflammation is attributed to its ability to suppress 
the Th17 response (Seery et al. 1997). Indeed, the symptoms of arthritis in animal models 
that lack IFNγ are alleviated by treatment with Th17 antibodies. However, various other 
autoimmunities showcasing Th1-mediated pathogenesis and affiliated macrophage 
activation are exacerbated by IFNγ expression (Luger et al. 2008). For example, MS is a Th1 
condition that is severely aggravated by administration of exogenous IFNγ (Kroenke et al. 
2008), as is proteoglycan induced arthritis. The role of IFN in autoimmune pathogenesis is 
complicated. Various models of disease result from a combination of dysregulated Th1, 
Th17 (Steinman 2008) and, indeed Th2 and other ‘unrelated’ responses. Therefore it is 
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important to consider IFNγ-related pathogenesis in a context that is specific for each 
autoimmune disease 
 
1.5.4 Transforming growth factor β (TGFβ) 
Transforming growth factor –β (TGFβ) is an inhibitor of growth-related cytokines and 
additionally is critical to modulating the progression and resolution of inflammatory 
processes (Dennler et al. 2002; Massagué 2012). Importantly, TGFβ is a central mediator of 
wound healing where its transient expression activates fibroblasts and extracellular matrix 
(ECM) synthesis (Walraven et al. 2015). During the inflammatory and tissue formation 
phases of an immune response, TGF is required for the activation and recruitment of, 
amongst other cells, macrophages and fibroblasts. Transient expression of this growth 
inducing cytokine promotes ECM synthesis, keratinocyte migration and proliferation and re-
epithelialisation (Hameedaldeen et al. 2014). However in episodes of fibrotic disease, TGFβ 
does not abate, ensuing chronic fibroblast activation and ECM expansion (Massagué 2012). 
TGF also promotes angiogenic factors. Taken together, these properties of TGFβ, when 
dysregulated, have high tumourogenic potential. 
Translated as a pro-protein coupled to latency associated protein (LAP) and latent TGF 
binding protein (LTBP), TGFβ is sequestered on the extracellular matrix. The bioactive form 
of TGFβ is made available through cleavage by a number of constitutive and inducible 
proteases (Shi & Massagué 2003). Canonical TGFβ-receptor signalling leads to the 
phosphorylation of receptor associated smads -2 and 3 which may have direct effects on 
gene expression (Shi & Massagué 2003). The TGFβ receptors are unusual in that they are 
able to directly transduce extracellular signals to the nucleus via smad intracellular 
mediators. Binding of TGFβ to type II receptor (TβRII) homodimers on the surface of target 
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cells subsequently engages TβRI homodimers, forming a heterotetrameric complex. 
Autophosphorylation by TβRII facilitates transphosphorylation of the TβRI kinase domain, 
which instigates recruitment and phosphorylation of R-smads 2 and 3 (Zi et al. 2012). 
Activation of R-smads-2 and 3 promotes smad4 binding to form a complex, which may 
translocate to the nucleus and drive the transcription of numerous target genes 
(Kretzschmar & Massagué 1998; Kretzschmar et al. 1997; Macías-Silva et al. 1996). In a non-
canonical, smad-independent pathway TGFβ can activate MAPKs via Ras, Rho and TAK1 
upstream mediators (Kamato et al. 2013). Additional to DNA binding activity, smads may 
also facilitate chromatin remodelling as a form of gene expression regulation, by associating 
with accessory proteins that modify DNA accessibility (Weiss & Attisano). 
 Selective alterations to TGFβ signalling that promote survival, invasion and metastasis of 
malignant cells are implicated in the pathogenesis of many cancers including colorectal 
tumourogenesis (Zhu et al. 1998; Ogawa et al. 2003; Sambuelli et al. 2000). The 
consequence of TGFβ dysregulation in regards to inflammatory pathways may also be 
detrimental. Disruption of TGFβ and downstream smad signalling in mice results in a severe 
and multifocal inflammatory response (Ogawa et al. 2003; Shull et al. 1992; Yang et al. 
1999). Mice lacking TGFβ develop multiple organ inflammatory response and lethal cachexia 
within 2 weeks (Christ et al. 1994). TGFβ has been implicated in SLE and glomerulonephritis 
(GN) following over expression of the downstream effector smad7, which resulted in the 
production of auto antibodies against the basement membrane (Kanamaru et al. 2001). 
Furthermore systemic administration of TGF alleviates autoinflammatory disease whilst 
anti-TGFβ antibodies drive pathogenesis (Kajdaniuk et al. 2013). 
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1.5.5 Prostaglandin E2 (PGE2) 
The prostaglandins are homeostatic compounds derived from phospholipids via arachidonic 
acid (AA) which is converted to prostaglandin H2 (PGH2) and PGE2 by cyclooxygenases (COX-
1 and COX-2) and prostaglandin E synthase, respectively (Honda et al. 2006; Díaz-Muñoz et 
al. 2012). Aside from having significant roles in neuronal signalling, haematopoiesis, 
regulation of blood flow and pressure, vascular permeability and renal filtration, PGE2 is a 
mediator of immune responses (Kawahara et al. 2014; Gomez et al. 2005; Konya et al. 
2013). Importantly, PGE2 regulates the activation, maturation, migration and cytokine 
secretion of innate immune cells, which are a primary source of PGE2 production during 
inflammation (Kalinski 2012). 
In response to inflammatory agonists like LPS, IL1β and TNFα, PGE2 is released by mostly 
myeloid and stromal cells and binds to one of the four specific soluble and membrane-
bound PGE2 receptors EP1-EP4 (Sugimoto & Narumiya 2007). Receptors EP1 and EP2 are 
low affinity and require an abundance of PGE2 to become activated, whereas EP3 and EP4 
are high affinity and are subject to ligand-desensitisation. The variety of receptor functions 
available to PGE2 outlines its versatility and adaptability to differences in agonist, cell type, 
temporal expression and effector function (Yokoyama et al. 2013; Sugimoto & Narumiya 
2007). Generally, prostaglandins are considered to be pro-inflammatory. Indeed, some of 
the most clinically relevant compounds; non-steroidal anti-inflammatory drugs (NSAIDs), 
reduce prostaglandin biosynthesis indirectly via COX inhibition. However, PGE2 also up-
regulates anti-inflammatory factors such as IL10 and even dampens the phagocytic 
properties of macrophages (Shi et al. 2010; Hata & Breyer 2004). 
The anti-inflammatory and suppressive activities of PGE2 are dependent on receptors EP2 
and EP4; both of which are Gs coupled and instigate the cAMP/ PKA/ CREB pathway. 
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Additionally, EP4 can trigger signalling via PI3K and ERK1/2 (Fujino et al. 2003). On the other 
hand, EP1 and EP3 are not cAMP-dependent. Although splice variants of EP3 exist, signalling 
is primarily via Gi coupled receptors, which inhibit adenylate cyclase and, consequently 
cAMP.  
Downstream of cAMP and PKA, cAMP response element binding (CREB) protein mediated 
the transcription of target genes and inhibits NFκB, thus limiting pro-inflammatory gene 
transcription. 
 
1.5.6 Anti-inflammatory signalling by cAMP  
Generated in response to neurotransmitters, lipid mediators, hormones and chemokines 
amongst other first messengers, increased intracellular cAMP has mostly anti-inflammatory 
effects (Aronoff et al. 2006). The cellular functions of cAMP elevation are ultimately 
mediated by the ability of effectors such as PKA and Epac I to regulate the activation of 
transcription factors and signalling molecules such as protein kinases, calcium and small 
GTPases. Inhibition of leukocyte activation by cAMP may be at the level of mediator 
generation, modulation of phagocytosis and inhibition of microbicidal activity (Serezani et 
al. 2008). Transcriptional suppression of pro-inflammatory mediators such as cytokines TNF, 
IL12 and chemokines MIF1α, MIF1β and LBβ4 alongside activation of anti-inflammatory 
IL10, SOCS3 decisively reduces the activation potential of macrophages, monocytes and 
neutrophils (Aronoff et al. 2006; Luo et al. 2004; Gasperini et al.). Secondly, through 
modulating cell surface expression of opsonin-dependent complement receptors (CR) and 
FcγR I, cAMP is able to modulate phagocytosis. In addition, cAMP also drives expression of 
inflammatory receptor FcγR 11β (Makranz et al. 2006). Leukocyte microbicidal activity is 
also suppressed by elevated cAMP expression (Lin et al. 2005). Reactive oxygen 
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intermediates (ROI), reactive nitrogen intermediates, phagosomal acidification and 
lysozyme enzyme are all targets of cAMP-mediated down-regulation (Won et al. 2004). 
Generally, overexpression of cAMP associates with infectious disease, due to the primary 
effects of cAMP signalling on phagocytosis. The respiratory pathogen Bordetella pertussis is 
one such which overwhelms the innate immune response by overwhelming the system with 
cAMP. Two toxins produced by B. pertussis, pertussis toxin (PT) and AC-toxin CyaA augment 
cAMP in target cells by blocking activity of Gαi and catalysing the unregulated conversion of 
ATP to cAMP respectively (Kamanova et al. 2008). Two other well-known pathogens capable 
of compromising innate immunity through amplification of cAMP are Vibrio cholera and 
Escherichia coli. Both toxins cause constitutive activation of adenylate cyclase through Gαs 
ADP-ribosylation (Vanden Broeck et al. 2007).  
Effectors of cAMP include PKA, EPAC and the cyclic-nucleotide gated ion channels (Sassone-
Corsi 2012). Activation of PKA, through cAMP binding to two regulatory subunits, has the 
potential to affect a number of signalling pathways. Phosphorylation and activation of the 
metabolic enzymes glycogen synthase and phospholipase kinase reduces glycogen 
expression whilst acetyl CoA carboxylase inhibits lipid synthesis (Gasperini et al.; Fujino et al. 
2005). Phospholipase C is phosphorylated but inactivated by PKA, whilst the MAPKs are 
activated by PKA-mediated dissociation of inhibitory tyrosine phosphatase. Direct 
phosphorylation of CREB, CREM and ATF1 by PKA in response to cAMP signalling is a crucial 
event which facilitates interactions with co-activators of transcription including CBP and 
p300 and enhancing CRE sequences in the promoters of target genes (Schindler et al. 2013). 
The cAMP pathway of gene activation is subject to negative feedback through up-regulation 
of the CREM gene, which encodes the powerful repressor ICER (Della Fazia et al. 1997; De 
Cesare & Sassone-Corsi 2000; Sassone-Corsi 1998). 
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1.6 Cell signalling and the immune response  
Cell signalling is a complex system that allows cells to perceive and correctly and accurately 
respond to the microenvironment. It is essential for coordinating basic cellular activities 
including development, tissue repair, homeostasis and immunity. 
In some instances, ligand binding and consequent receptor activation is able to elicit a direct 
cellular response. However, for many cellular actions an activated receptor must first 
interact with other cellular factors before the ligand has its ultimate physiological effect on 
the target cell. Signal transduction is the process by which a ligand sets off an intracellular 
cascade of events involving protein production, interaction and modulation, allowing 
precise yet reactive control of cell actions. An effective immune response is specifically 
targeted and stringently controlled in a multitude of cell types, tissue types and under 
temporal constraints. By layering levels of control in a signalling cascade, it is possible to 
elicit a direct, operational and efficient immune response.  
 
1.6.1 Pattern Recognition receptors 
The initial sensing of infection or injury is mediated by cell surface pattern recognition 
receptors (PRRs). There are four different classes of PRR; including transmembrane toll-like 
receptors (TLRs) and c-type lectin receptors (CLRs); as well as cytoplasmic proteins such as 
retinoic acid inducible gene (RIG)-1-like receptors (RLRs) and NOD-like receptors (NLRs) 
(Takeuchi & Akira 2010). Pathogen recognition receptors are expressed on non-professional 
innate-immune cells as well as on macrophages and dendritic cells.  Ligands of PRRs are 
expressed as pathogen associated molecular patterns (PAMPS) on foreign microorganisms 
or macromolecules. Damage associated molecular patterns (DAMPS) produced by the host 
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in response to tissue insult or injury are also detected by PRRs. DAMPs may be heat shock 
proteins or those produced by the ECM in response to injury. Non-protin DAMPs include AT, 
uric acid and nucleic acids. Activation of PRR signalling pathways, whether by PAMPs or 
DAMPs, results in the transcriptional expression of inflammatory mediators, the elimination 
of pathogens or alien agents, repair processes and restoration of tissue homeostasis 
(Newton & Dixit 2012).  
 
1.6.2 Toll-like receptor signalling and bacterial lipopolysaccharide 
The TLRs are the best understood family of PRRs, which characteristically contain an 
evolutionarily conserved C-terminal Toll-IL-1R (TIR) domain (Bowie & O’Neill 2000; Takeuchi 
& Akira 2010) and an N-terminal leucine rich repeat (LRR). The TIR-domain is responsible for 
the recognition of various PAMPS/DAMPS and, as the name would suggest, is common 
between TLRs and the IL1R. To date ten different TLRs have been identified, each of which 
able to recognise different host and non-host molecular patterns and elicit unique signalling 
responses accordingly. Further sub-categorisation of TLRs includes those expressed on the 
plasma membrane; TLR1, TLR2, TLR4, TLR5 and TLR6 or the endosome; TLR3, TLR 7, TLR 9. 
The latter, along with TLR 8, recognise unmodified bacterial, viral and endogenous nucleic 
acids and lead to the production of type I interferons (IFNs) (O’Neill 2000; Medzhitov et al. 
2011). Lipoproteins related to viruses, fungi, bacteria and mycoplasma activate surface TLR2 
and TLR 1 or TLR6 heterodimer signalling and the production of various inflammatory 
cytokines (Barbalat et al. 2009). 
Lipopolysaccharide (LPS) is a component of gram-negative bacteria and a potent inducer of 
Inflammatory signalling through TLR4. LPS activation of TLR4 is facilitated by two accessory 
proteins. LPS binding protein (LBP) is a shuttling molecule that catalyses transfer of LPS from 
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bacterial plasma membrane to CD14, which presents LPS to TLR4. TLR4 then forms a 
complex with myeloid differentiation factor 2 (MD2) (Miyake 2006; Takeuchi & Akira 2010).  
In the presence of LPS, two homodimers of this complex interact to initiate signalling (Park 
et al. 2009). TLR4-MD2-LPS homodimer formation instigates two different signalling 
pathways. On the one hand, translocation of TLR4 to the endosome activates TLR3 and TRIF-
dependent signalling; activating inflammatory gene transcription via NF-κB and IRF3. 
Alternatively, homodimers of TLR4-MD2-LPS signal through the MyD88-dependent pathway, 
common to TLR2-TLR1/6 signalling also. This pathway relies on TIRAP (/MAL) to facilitate the 
recruitment of adaptor protein MyD88 and TIR domain containing adaptor inducing IFNβ 
(TRIF) to the TLR. MyD88 engages IL-1 receptor associated kinase (IRAK) -4, which in turn 
activates IRAK1 and IRAK2 and their interaction with TNFR associated factor (TRAF) -6. Self-
ubiquitination by E3 ubiquitin ligase TRAF6 in turn establishes TGFβ activated kinase (TAK) -
1, TAK1 binding protein (TAB) -1 and TAB2/3 complex formation. This TAK1-TAB1-TAB2-
TAB3 complex subsequently phosphorylates and activates MAP kinase (MKK) -6 and IκB 
kinase (IKK). Consequently, degradation of IκB releases NFκB for nuclear translocation and 
inflammatory gene transcription (Medzhitov 2001).    
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Figure 1.2 TLR4 and IL1R signalling pathways  
Members of the IL-1/TLR superfamily activate a common signalling pathway. 
Ligand-activation of IL1 or TLR transmembrane receptors by IL1 or LPS 
respectively, causes the recruitment of MyD88, IRAK and its phosphorylation 
followed by activation of TRAF6/TAB/TAK1 complex. Subsequent phosphorylation 
of IKK and MAPKK leads to the activation of NFƙB and MAPK pathways. 
Independently of MyD88, TLR4 also signals through TIRAP. Figure adapted from 
Nature reviews Immunology (Medzhitov et al. 2011) 
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1.7 MAPKS and inflammatory gene regulation. 
The MAPK signal transduction cascade is a three tiered phosphorelay system that ultimately 
has the power to directly affect transcription factors and regulate gene transcription. 
Additionally, MAPKs are also involved in post-transcriptional regulation of gene expression 
through modulating the mechanisms of mRNA stability and decay (Wilusz et al. 2001; 
Garneau et al. 2007). Downstream of TIR stimulation, activated MAP3Ks (/MKKK) 
phosphorylate MAP2Ks (/MKK). In turn, MAP2Ks transfer phosphate groups to MAPK 
specific ‘TXY’ (T = threonine, X = glutamic acid/ glycine/ proline and Y = tyrosine) motifs. 
These pathways are highly conserved and responsible for the regulation of a vast array of 
cellular processes, including the immune modulation.  The three conventional MAPK 
families described below are most relevant to this study. However, there are a number of 
atypical or minor MAPKs, including extracellular signal related kinase (ERK) -3/4, ERK5, 
ERK7/8 and NLK (Moens et al. 2013). 
 
1.7.1 ERK1/2 
The first mammalian MAPKs to be identified were the extracellular signal related kinases 
(ERKs), encoded by the ERK1 and ERK2 genes. Insulin and mitogen activation of ERK1/2 
begins with the upstream engagement of RAS proto-oncogene, followed by recruitment of 
RAS MAP3K and ERK specific MAP2Ks MEK -1 and -2. ERK-1 and -2 require dual 
phosphorylation of Thr203-Glu-Tyr205 and Thr185-Glu-Tyr187 for activation respectively 
(Raman et al. 2007). ERK MAPKs may also be activated independently of RAS by pro-
inflammatory stimuli, through PRR signalling (McKay & Morrison 2007). 
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1.7.2 JNK  
Acutely responsive to environmental stressors, the c-Jun NH2 terminal kinases (JNKs) are 
key facilitators of the immune response. MAP2K7 (MKK7) specifically phosphorylates the 
JNK activation motif Thr-Pro-Tyr. MAPK kinase 4 (MKK4) has a high affinity for JNK but will 
also phosphorylate p38 MAPK (Jiang & Gong 2000).  
JNKs are encoded by three genes, JNK-1, JNK-2 and JNK-3 (MAPKs 8, 9 and 10), each of 
which may be differentially spliced to produce numerous JNK isoforms, which are largely 
similar to one-another within their catalytic cores. JNK is essential for the activation of AP-1, 
a heterodimeric transcription factor consisting of proteins belonging to the c-Fos, JDP, c-Jun 
and ATF families, of which the latter two are directly phosphorylated by JNK. Through JNK 
activation, AP1 up-regulates the transcription of genes containing a specific DNA response 
element and in turn controls a number of cellular processes including differentiation, 
proliferation, and apoptosis (Davies & Tournier 2012; Raman et al. 2007). 
 
1.7.3 MAPK p38 
Also activated by growth factors and immune agonists via TLRs, MAPK p38 is pivotal to 
initiating, and restraining the inflammatory response. MKK3 and MKK6 are specific and 
selectively activate p38 MAPK (Cuenda et al. 1996; Cuenda et al. 1997; Raingeaud et al. 
1996; Dérijard et al. 1995). Two MKK3/6 independent pathways of p38 MAPK activation 
have been identified and involve autophosphorylation through direct interaction of TAB1 
and TRAF6 or Zap70 in T-lymphocytes. However the fundamental roles of these activating 
mechanisms are unclear (Salvador, Mittelstadt, Guszczynski, et al. 2005; Salvador, 
Mittelstadt, Belova, et al. 2005). 
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The p38 family of MAPKs consists of four members, p38α, β, γ, δ (MAPK 14, 11, 12, 13 
respectively). Of the four p38 kinase isotypes, α and β share the most sequence homology 
and have a similar function central to immune modulation. A group of anti-inflammatory 
pyridinyl compounds known to specifically block p38αβ phosphorylation activity and 
subsequently IL1 and TNFα expression downstream of p38 MAPK, have been invaluable to 
the investigation of this pathway (Clark et al. 2003).  
Downstream substrates of p38 MAPK include protein kinases, transcription factors and 
chromatin remodelling agents, all with a variety of effector functions in protein degradation, 
mRNA stability, endocytosis, apoptosis and cell migration. Through activation of MNK1/2 
and subsequent phosphorylation of eukaryotic initiation factor (eIF4E), p38 may regulate 
gene expression at the level of protein synthesis (Clark et al. 2003; Moens et al. 2013). The 
MAPK-activated protein kinases 2 and 3 (MK2/3) primarily phosphorylate mRNA binding 
protein tristetraprolin (TTP), mediating p38 posttranscriptional effects on gene expression 
(Clement et al. 2011; Brook et al. 2006; Marchese et al. 2010; MacKenzie et al. 2013). MK2 
can also recruit and initiate CREB interaction with DNA. Mitogen and stress activated kinases 
(MSKs) 1 and 2 modify gene expression by histone modification and chromatin remodelling 
as well as direct activation of transcription factors CREB, ATF1, p65 (NFκB) and STATs 1 and 
3 (McKay & Morrison 2007). 
Additionally, p38 MAPK may also act on gene transcription directly by recruiting and 
phosphorylating transcription factors or facilitating their binding to DNA through histone 
modification. In response to immune stimuli, a number of pro-inflammatory genes are 
enriched for p38-dependent H3 phosphorylation at their promoter regions, thus enabling 
interaction of DNA and transcription factors; particularly NFκB (Healy et al. 2012; Kikuchi et 
al. 2014; Arthur 2008).  
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Figure 1.3 Overview of classic MAPK signalling cascades 
MAPK activation is preceded by a phosphorylation cascade involving at least two 
other kinases; The MAP3Ks at the top of the cascade activate MAP2Ks, which in 
turn activate MAPKs via phosphorylation of the Thr-x-Tyr motif. ERK1/2 MAPKs 
are regulated by the MAP2Ks MKK1 and MKK2, which themselves are substrates 
for RAF and TPL2 in response to growth factor/ antigen receptor activation and in 
innate immunity following stimulation of TLR, TNFR or IL1R subtypes. MOS is 
involved in activation of the ERK1/2 MAP2Ks in fertilised oocytes. The four 
isotypes of p38 MAPK lie downstream of MKK3 and MKK6 and whilst the three 
JNK subtypes are activated by MKK4 and MKK7, the four MAP2Ks of these two 
pathways share common MAP3Ks. Tertiary MAPKs including MEKKs 1-4, TAO1/2, 
ASK1 and MLK2/3 and TAK1 all activate JNK/P38 associated MAP2Ks through 
mechanisms dependent on cell type and stimulus. Figure adapted from Nature 
Reviews Immunology (Arthur & Ley 2013) 
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1.8 The role of NF-κB in inflammation 
For a subset of genes and transcription factors, prior activation of MAPK p38 is required, the 
most notable of which being NFκB. Consisting of five related proteins, the NFκB family exist 
as either homo- or hetero-dimers or both, each with the ability to initiate transcription, they 
are Rel (c-rel), Rel A (p65), Rel B, NFƙB-1 (p50 and its precursor p105) and NF-κB-2 (p52 and 
its precursor p100) (Hayden & Ghosh 2014). By far the most common dimer is the p65/p50 
heterodimer and, as all of these dimers, is retained in the cell cytoplasm bound to inhibitor 
of NF-κB (IƙB) (Hinz et al. 2012). The IκB kinase (IKK) is an enzyme complex composed of 
catalytic subunits IKKα, IKKβ and IKKγ and is essential for the activation of NFκB by pro-
inflammatory agents. Specific phosphorylation of the IκBα subunit by IKK causes dissociation 
of the inhibitory complex, unmasking the nuclear localisation signals (NLS) of NFκB proteins 
and consequentially allowing translocation of the latter to the nucleus (Ghosh & Baltimore 
1990; Lin et al. 1995; Henkel et al. 1993). In the nucleus, NFκB binds to variants of a 
consensus motif (GGGGACTTCCC) on target genes, enabling their transcription. Targets of 
NFκB are many and often associated with immune modulation; they include pro-
inflammatory TNFα, COX2, IL6, IL1α, IFNγ and IL8 and anti-inflammatory IL10, TGFβ, A20, 
TTP, DUSP1 to name just a few (Hayden & Ghosh 2014). 
 
  
      42
1.8.1 A20 & ubiquitin editing in the NFκB pathway  
Central to so many cellular processes, NFκB is subject to tight regulatory controls and 
transient expression that depends on continuous pro-inflammatory stimulation (Catrysse et 
al. 2014). Ubiquitination is one such mechanism by which NFκB signalling is controlled in 
order to maintain tissue homeostasis. Ubiquitin editing proteins may be deubiquitinating 
(deubiquitinases), polyubiquitinating (ubiquitin ligases) or both. An important ubiquitin 
editing enzyme involved in the NFκB signalling cascade is A20, which contains an amino-
terminal deubiquitinating activity and a carboxy-terminal zinc finger domain that facilitates 
E3 ubiquitin ligase activity (Wertz, O’Rourke, Zhou, et al. 2004). The first substrate of A20 to 
be recognised was receptor interacting protein 1 (RIP1). TNFR-mediated lysine 63 (K63) 
polyubiquitination of RIP1 by cellular inhibitor of apoptosis proteins (cAIPs) 1 and 2 is 
promptly counteracted by the deubiquitinating activity of A20 (Verstrepen et al. 2010). 
Deubiquitination renders RIP1 unable to interact with NFκB essential modulator (NEMO) 
and consequently stunts the NFκB activation cascade.  In addition, A20 targets RIP1 for 
degradation by the proteasomal pathway through E3 ubiquitin ligase-mediated addition of 
chains to lysine 48 (K48), further constraining this key signalling module (Bertrand et al. 
2008). In addition to blocking TNF-dependent mechanisms, A20 also protects cells from IL1, 
CD40, T-/ B- cell antigen activation and PRR driven NFκB signalling pathways. The TLR4, IL17 
and NOD2 pathways are also subject to A20 mediated deubiquitination of TRAF6 and RIP2 
respectively (Shembade & Harhaj 2012). Furthermore, A20 utilises a number of non-
catalytic mechanisms. For example, through preventing the E3 ligase interaction of TRAF6 
and two key ubiquitin conjugating enzymes Ubc13 and UbcH5c, subsequently targeting both 
of which for degradation by polyubiquitination of K48. In addition, A20 directly blocks 
interactions between Ubc13 and TRAF2/5 and cIAP1/2 (Shembade et al. 2010). 
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More recent evidence provides a role for A20 in restraining TNF-induced apoptosis. 
Experimental overexpression of A20 revealed its ability to inhibit apoptotic signalling 
through deubiquitination and subsequent inactivation of caspase-8 (Jin et al. 2009; Bellail et 
al. 2012). Indeed, within the death-inducing signalling complex (DISC), A20 is positioned 
proximal to said activator of TNF-induced apoptosis. Physical interaction of A20 with 
caspase 8 prevents ubiquitination of caspase-8 by cullin3-associated E3 ligase and opposes 
apoptotic signalling. Following activation of the TNF-related apoptosis-inducing ligand 
(TRAIL), A20 has been shown to block apoptotic pathways through polyubiquitination of 
RIP1 K63 – via a mechanism dependent on the E3 ligase domain. This contrasting action of 
A20 on RIP1 in an alternate pathway prevents cleavage of caspase-8 and limits cell death 
signalling (Won et al. 2010; Jin et al. 2009). 
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Figure 1.4 Regulatory activities of A20 in multiple signalling pathways 
(A) During TNFR signalling, A20 removes K63 ubiquitin chains from RIP1 and 
subsequently polyubiquitinates K48, targeting this crucial activator of NEMO for 
degradation and therefore blocking NFκB activation. Furthermore, A20-mediated 
K48 ubiquitination of Ubc13 prevents cAIP1/2 ubiquitination of TRAF2/5. (B) In 
response to TLR activation by, for example LPS or IL1β, A20 inhibits the MyD88 
signalling pathway of NFκB activation by removing TRAF6 K63 ubiquitin chains, 
both catalytically and through additional mechanisms that prevent physical 
interaction between TRAF6 and Ubc13/H5. Similarly for IL17 signalling (F), A20 
removes TRAF6 K63, preventing direct interaction with NEMO. Deubiquitination 
of RIP2 and MALT1 K63 by A20 (C&D) curbs signalling via NOD1/2 and TCR 
complexes respectively. Finally, IRF signalling and NFκB activation instigated by 
the RIG1/Mda5 receptor complex (E) are inhibited by interaction of A20 with and 
removal of K63 from TBK1.Figure adapted from Trends in Immunology (Catrysse 
et al. 2014) 
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It was the use of overexpression studies that first determined a role for A20 in immune 
signalling. Mice deficient in A20 suffered TNFα hypersensitivity and died prematurely 
because cells lacked the ability to prevent NFκB induced TNFα production and consequent 
apoptosis (Turer et al. 2008; E. G. Lee et al. 2000). Several large GWAS studies have 
identified TNFAIP3 as a major susceptibility locus for many chronic inflammatory 
pathologies including RA, Junior Idiopathic Arthritis, SLE, IBD, Type I Diabetes, psoriasis, 
coronary artery disease and systemic sclerosis (Mele et al. 2014; Tejasvi et al. 2012; Fan et 
al. 2011; Zammit & Grey 2014; Kawasaki et al. 2010; Trynka et al. 2009; Wang et al. 2013; 
Vereecke et al. 2014). Most of the SNPs identified in these studies are located within 
intragenic regions and therefore are likely linked with regulatory enhancer elements. For 
example the TT>A transition associated with SLE results in reduced NFκB binding to the 
TNFAIP3 promoter region and consequently decreased gene expression (Li et al. 2012). Two 
nonsynonymous mutations in exon 3 affect the DUB activity of A20 and therefore its ability 
to regulate NFκB signalling (Musone et al. 2011). Additionally, polymorphisms linked with 
psoriasis have also been implicated in patient responsiveness to anti-TNF therapy (Tejasvi et 
al. 2012). Conceivably because of its anti-apoptotic propensities, aberrant regulation of A20 
is also implicated in glioma stem cell survival, oestrogen-resistant and aggressive breast 
carcinomas (Verstrepen et al. 2010).  In addition, un-abated NFκB signalling owing to 
reduced A20 activity can also contribute to multiple B-cell lymphomas (Wang et al. 2014).  
In contrast to most cell types, where basal concentrations of A20 are low and rapidly 
increase following inflammatory activation, leukocytes express high initial levels of A20. A20 
is a primary response gene and harbours two NFκB binding motifs within its promoter 
region (De Valck et al. 1999; Opipari et al. 1990). Following the initial inflammatory stimulus, 
protein concentrations of A20 rapidly deplete to facilitate optimal NFκB signalling, before a 
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rapid resurgence in response to NFκB-mediated transcriptional up-regulation and elevated 
protein synthesis and stability. The primary fall in leukocyte A20 concentrations is a 
consequence of proteasomal degradation and MALT-1 driven cleavage (Düwel et al. 2009). 
Posttranslational modification of A20 is key to its functional potential, purportedly by 
affecting stability. For example, phosphorylation by IKK2 augments the ability of A20 to 
inhibit NFκB by incompletely understood mechanisms (Heyninck et al.; Wagner et al. 2008; 
Iha et al. 2008; Shembade et al. 2007). Similarly, A20 binding inhibitor of NFκB (ABIN) and 
TAX1 binding protein 1 (TAX1BP1) associate with A20 and not only increase its stability but 
also relocate A20 proximal to its substrate (Shembade et al. 2007). In addition, the stability 
of Tnfaip3 mRNA is subject to regulation via consensus binding sequences for miRNA-29a 
and miRNA-125 within its 3’UTR (Kim et al. 2012; Gantier et al. 2012; Wang et al. 2011). 
miRNA-29a protects the Tnfaip3 message by interacting with mRNA binding protein HuR, 
whereas miRNA-125 promotes instability of Tnfaip3 (Balkhi et al. 2013).  
 
1.9 Regulation of MAPK signalling; DUSP1 
The spatiotemporal regulation of MAPKs is critical to the physiological outcome of their 
activation. Stringent control the magnitude, duration and spatial distribution of activated 
MAPKs serves for an efficient and precise response (Ebisuya et al. 2005; Owens & Keyse 
2007) 
The transient activation of MAPKs is delimited most efficiently, by phosphorylation.  A 
number of phosphatases exist, each with different catalytic actions and substrate 
specificities.  
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MAPK phosphatases (MKPs) are a family of negative regulators that catalyse the removal of 
phosphate groups from MAPKs and terminate their signalling processes. MKPs can be 
separated into three subgroups depending on the MAPK residue(s) that they 
dephosphorylate; tyrosine phosphatases; serine/threonine phosphatases; and dual 
specificity phosphatases (DUSPs). Most specific to this system are Protein phosphatase 2-A 
(PP2A), a broad spectrum Ser-Thr phosphatase and the DUSPs, which are also known as 
MAPK phosphatases (MKPs). At least 13 DUSP family members show substrate specificity for 
MAPKs. Since all MAPKs are substrates for a number of MKPs, there is a level of functional 
redundancy within the cluster; however this provides selectivity through sensitive 
expression kinetics and sub-cellular compartmentalisation (Salojin & Oravecz 2007). 
Although generally widely expressed, there is some cell-lineage specificity of DUSP 
expression, as well as the subcellular localisation of their activity. 
The archetypal MKP and perhaps most important to this study, because of its negative 
regulatory role in p38 MAPK signalling, is DUSP1/MKP1.  DUSP1 is a nuclear protein, 
containing the fundamental dual specificity region as well as an N-terminal MAPK binding 
sequence.  
With specificity for p38 MAPK > JNK ≫ ERK (Chu et al. 1996; Wu & Bennett 2005), DUSP1 is 
widely distributed within the immune system. Basal expression levels of DUSP1 are low but 
strongly and transiently up-regulated in response to pro-inflammatory stimuli, downstream 
of the MAPKs it inactivates (Chi et al. 2006). The temporal expression of DUSP1 is so that it 
correlates with the off phase of p38 MAPK (Clark & Dean 2012).  
DUSP1 knockout (Dusp1-/-) mice are viable, have no observable developmental defects and 
appear normal under standard conditions. However, in response to bacterial - LPS challenge, 
Dusp1-/- mice show significantly increased serum cytokines and related factors when 
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compared to wild type. Susceptible to gram negative and positive sepsis (Frazier et al. 2009), 
LPS induced bone loss (Sartori et al. 2009; Valerio et al. 2015), cardiac dysfunction (T. Zhang 
et al. 2012) and lethal endotoxemia (Salojin et al. 2006), the DUSP1-/- phenotype results 
from a lack of negative feedback control and subsequent exaggerated MAPK activation 
(Salojin et al. 2006). A number of chronic inflammatory conditions are exacerbated by an 
absence of DUSP1-/- including experimental colitis (Matta et al. 2012), contact 
hypersensitivity, anaphylaxis (Maier et al. 2007), TNF-induced systemic inflammatory 
disease (Vandevyver et al. 2012) and experimental models of RA, in which the severity, 
penetrance and time to onset of disease are all increased (Vattakuzhi et al. 2012). These 
observations, along with the greatly increased rate of DUSP1-/- mortality due to endotoxin 
shock outline the significance of DUSP1 in negative feedback regulation of MAPK during the 
inflammatory response (Zhao et al. 2005; Chen et al. 2002; Wu & Bennett 2005; Nimah et al. 
2005; Shepherd et al. 2004). 
 
A classic negative feedback regulator, DUSP1 effectively limits its own expression profile. In 
a p38 MAPK dependent manner, DUSP1 is induced by pro-inflammatory agonists and 
therefore, rationally, negatively controlled by anti-inflammatory inhibition of the p38 MAPK 
pathway. However a wide variety of inflammatory mediators act upon DUSP1 and a number 
of anti-inflammatory factors powerfully enhance its expression. For example, LPS-driven 
transient expression of DUSP1 is enhanced and extended by immunosuppressive cytokine 
IL-10 (Hammer et al. 2005; Hammer et al. 2006) and correlates with more rapid MAPK 
down-regulation. Additionally, MKP1 deficiency has been shown to enhance IL-10 
production, due to increased activity of p38 MAPK. On the other hand, pro-inflammatory 
IFNγ attenuates MKP1 expression and prolongs MAPK activity (Zhao et al. 2006).  
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1.10 Glucocorticoids  
Glucocorticoids are endogenous steroid hormones produced by the adrenal cortex in 
response to a neuro-endocrine cascade involving the hypothalamic-pituitary-adrenal axis 
(Newton 2000; Buckingham 2006; Whitehouse 2011). They are fundamental to a vast 
number of physiological processes, including growth, metabolism, apoptosis and 
importantly, modulation of the inflammatory response (Buckingham 2006; Clark & Belvisi 
2012; Taves et al. 2011). Inflammatory cytokines cause excitation of the hypothalamus, 
which responds by secreting corticotrophin releasing hormone (CRH). In turn, the anterior 
pituitary is prompted to generate and release adrenocorticotropic hormone (ACTH), which 
acts on the adrenal cortex, in turn releasing glucocorticoids like cortisol. In this way, GCs are 
antagonistic to pro-inflammatory signalling and act systemically as a negative feedback 
mechanism to prevent a potentially irrepressible immune response. 
For decades, synthetic glucocorticoids have been prescribed for and remain the cornerstone 
of treatment in numerous chronic inflammatory conditions (Hillier 2007). They are 
fundamental in the treatment of asthma and rheumatoid arthritis and exert genuine disease 
modifying effects (Kirwan et al. 2007; Gorter et al. 2010; Hoes et al. 2007; Clark & Belvisi 
2012). However, prolonged use of glucocorticoids can give rise to serious, often life-
threatening side effects such as osteoporosis, diabetes or hypotension and often patients 
experience GC insensitivity (Kanis et al. 2007; Hofbauer & Rauner 2009; Weinstein et al. 
2011). The therapeutic effectiveness of GCs has conventionally been associated with their 
ability to reduce inflammatory gene expression.  
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1.10.1 Glucocorticoid receptor and GRE 
Glucocorticoid actions are mediated entirely by the glucocorticoid receptor (GR); a ligand 
activated nuclear receptor with the ability to bind directly to DNA. Inactive GR resides in the 
cytoplasm bound to a multiprotein complex containing numerous heat shock proteins, 
including Hsp90. On ligand binding, GR undergoes a conformational change and dissociates 
from the inhibitory multiplex, unmasking dimerization, nuclear localisation and DNA binding 
domains (Grad & Picard 2007). Once in the nucleus, the GC-bound receptor complex is able 
to modify target gene expression either directly or through co-activator/repressor 
interaction (Lefstin et al. 1994; Meijsing et al. 2009).  
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Figure 1.5 Glucocorticoid receptor mediated regulation of target-gene 
expression 
Ligand-activated glucocorticoid receptor (GR) translocates to the nucleus and 
transcriptionally regulates target genes through discrete mechanisms. GR may 
interact with (+) GRE or nGRE DNA binding sequences and directly have either 
positive or negative effects on gene transcription respectively. Engagement of (+) 
GRE leads to recruitment of co-activators of transcription including SRC2/3 and 
RNAPII, whereas dimeric GR-complex activation of (IR) nGRE amasses HDAC2/3, 
SMRT and NCoR repressors of gene activation. Ligand-associated GR may also 
affect transcript production indirectly via tethering to previously bound 
transcription factors such as NFκB (p65/p50 heterodimer). Similarly, activated GR 
may directly bind to other sites that lack specific GREs but accept synergistic 
binding of GR and additional coactivators and repressors of transcription. Figure 
adapted from Cell (Surjit et al. 2011) 
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The glucocorticoid response element (GRE) is a conserved palindromic DNA sequence that 
directly interacts with ligand-bound GR at target genes (So et al. 2008). At ‘simple’ (+) GREs, 
GR homodimers bind directly to DNA and confer transcriptional transactivation through 
association with RNA polymerase II (RNAPII) and steroid receptor co-activator (SRC) 2 & 3 
(Lonard & O’malley 2007; Gronemeyer & Bourguet 2009; Meijsing et al. 2009)). ‘Simple’ 
nGREs contain evolutionarily conserved palindromic GR-binding sequences different to 
those observed at (+) GRE sites. Through recruitment of transcriptional repressors including 
SMRT, NCoR and HDACs 2/3 dimeric GR may directly repress transcription through binding 
nGREs local to target genes (Surjit et al. 2011). The GR-nGRE complex has been linked to the 
anti-inflammatory actions of glucocorticoids (Newton 2000; Dostert & Heinzel 2004). 
However the immunomodulatory effects of GCs are diverse and very few genes are 
regulated in this way. Monomeric GR on the other hand, has the power to interact with 
cognate DNA motifs and sites relating to other factors that act synergistically to mediate 
transactivation (CBP/p300, p60) or transrepression (TIF2/GRIP1) ‘composite’ GREs (Surjit et 
al. 2011). Additionally, glucocorticoids have the ability to induce indirect transrepression 
through ‘tethering’ GREs, which do not contain specific GR DNA binding sequences but 
recruit GR indirectly through other sequence bound factors including NFκB and AP1 (Karin 
1998; Kassel & Herrlich 2007). 
 
1.10.2 Glucocorticoid-mediated transrepression 
As aforementioned, glucocorticoids are powerful anti-inflammatory steroids that inhibit the 
production of countless pro-inflammatory cytokines, including TNFα, IL-1β, GM-CSF and IL-6, 
chemokines such as IL-8 and MIP1α, inducible enzymes iNOS and COX-2 and adhesion 
molecules ICAM-1 and E-selectin (Mukaida et al. 1994; Kleinert et al. 1996; van de Stolpe et 
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al. 1994; Brostjan et al. 1997). However, none of the above genes possess nGREs proximally 
located within their promoters, nor does the underwhelming selection of genes that do 
account for GC-mediated systemic down-regulation of pro-inflammatory mediators. 
Fittingly, GCs repress inflammatory gene expression via additional mechanisms at the level 
of transcription and also post-transcriptionally. Transrepression refers to a mechanism in 
which ligand-bound monomeric GR is "tethered" indirectly to DNA via protein-protein 
interaction with interferon response factor (IFN), NFκB or AP-1 (Schäcke et al. 2005; Newton 
& Holden 2007; De Bosscher 2010; Glass & Saijo 2010).  In this context, GR blocks 
transcriptional activation by NFkB or AP-1 either by preventing co-activator recruitment or 
engaging co-repressors, or both (Auphan et al. 1995; R I Scheinman et al. 1995; Reily et al. 
2006; Flammer & Rogatsky 2011).  
Transcription activating protein AP-1 is involved in the induction of several growth factors 
and pro-inflammatory cytokines, to which GCs are repressors. Using co-precipitation 
experiments, a number of groups were able to detect low-affinity interactions between AP-
1 and GR and subsequently EMSA experiments revealed a mutual inhibition of one another 
(Bogdarina et al. 2009). It was later shown that AP1- remained bound to its site within the 
promoter during GR repression and that the latter was likely to prevent the former from 
interacting with transcription initiation machinery or an essential co-activator complex 
(Biddie et al. 2011; Dobrovolna et al. 2012; Karmakar et al. 2013). Scores of pro-
inflammatory moderators contain NFκB binding sites within their promoters, including 
TNFα, IL-1α, IL-6, COX2, IL8 and many more. Numerous anti-inflammatory genes are also 
known to contain NFƙB binding sites, for example A20, TTP and DUSP1.  
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In order to act rapidly and in a direct manner, GR-mediated transrepression is downstream 
of DNA binding and is mediated by pre-existing factors (Clark & Belvisi 2012; Newton & 
Holden 2007; King et al. 2013). This was highlighted in a study by King et al. (2013) where 
treatment of A549 cells with cycloheximide was unable to diminish the repressive effects of 
DEX on IL6, ICAM1 and COX2 gene expression. Furthermore, the 50-100% reduction in gene 
expression did not alter NFκB activation or DNA binding (King et al. 2013). Thus 
transrepression is mediated by pre-existing factors, allowing a rapid and direct mode of 
action. 
 
1.10.3 Separating transactivation and transrepression 
Conventionally, transcriptional activation has been connected with the unpredictable side 
effects associated with glucocorticoid therapy and little else. To this end, intensive research 
is being focused on finding GR ligands with inferior transactivating properties that lead 
preferentially to GR-mediated transrepression. These selective glucocorticoid receptor 
modulators (SGRMs) are receiving a lot of attention; however there have been few positive 
results and this simple dualistic theory of GC action is not supported by substantial scientific 
evidence (Joanny et al. 2012). It is apparent that transrepression is not solely responsible for 
the therapeutic effects of GCs and transactivation plays a partial if not significant role (Clark 
2007; Newton & Holden 2007). In fact, glucocorticoids up-regulate transcription of 
numerous anti-inflammatory molecules, including IL10, IL1Ra, annexin1, GC-inducible 
leucine zipper (GILZ) and DUSP1. Interestingly, a considerable number of glucocorticoid anti-
inflammatory targets contain upstream NFκB and AP1 binding motifs and yet are not 
affected by transrepression. 
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The inducibility of a GR-target gene is increased by the number and proximity of GREs within 
its promoter region. GR binding to GRE causes confined changes in chromatin structure that 
facilitate transcription factor binding and the formation of a stable transcription initiation 
complex. Simultaneous local unwinding of DNA and recruitment of RNA polymerase II 
(RNAPII) instigates transcription of the target gene. There are a number of co-activators that 
associate with GR/GRE, including CREB binding protein (CBP), Glutamate receptor-
interacting protein 1 (GRIP-1), transcriptional mediators/intermediary factor 2 (TIF2), 
p300/CBP and steroid receptor coactivator-1 (SRC-1). When combined, these co-activators 
enhance transcription by increasing histone acetyltransferase (HAT) activity, which increases 
DNA accessibility and stabilises the RNAP II initiation complex. 
 
1.10.4 Post-transcriptional effects of glucocorticoids 
It is widely documented that GCs have powerful posttranscriptional effects on pro-
inflammatory genes (Stellato 2004; Clark 2007; Newton & Holden 2007). In order to resolve 
inflammation and down-regulate pro-inflammatory cytokines, GCs must be able to suppress 
an on-going response, i.e. using a mechanism that acts on pre-existing mRNA. Many pro-
inflammatory genes, including IL-1, IL-6, TNFα and COX-2 are inhibited by GCs at the 
posttranscriptional level, which is unaccountable for by transrepression (Lee et al. 1988; 
Amano et al. 1993; Swantek et al. 1997; Gille et al. 2001; Lasa et al. 2001). Transrepression 
can only be effective if GCs are present during the period of active transcription, thus there 
must exist, suppressive mechanisms at the posttranscriptional level (Clark 2007). Newton 
and colleagues showed that DEX could down-regulate cyclooxygenase-2 (COX-2) even when 
administered long after the inducing stimulus, whereas the transcription inhibitor 
actinomycin D was ineffective at this time (Newton, Seybold et al. 1998). Dexamethasone 
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was shown to destabilise COX-2 mRNA, acting via adenosine/uridine rich elements (AREs) in 
its 3’ un-translated region (UTR) (Newton et al. 1998; Lasa et al. 2001). The majority of pro-
inflammatory mRNAs targeted by GCs in this manner contain AREs in their 3’ UTR (Saklatvala 
et al. 2003) and associate with trans-acting ARE-binding proteins, which regulate mRNA 
stability (Garneau, Wilusz et al. 2007).  
 
1.11 Post-transcriptional regulation of gene expression 
Transcription is responsible for just half of the changes in gene expression and protein 
biosynthesis during the inflammatory response (Hao & Baltimore 2009; Raghavan & 
Bohjanen 2004; Cheadle et al. 2005; Clark & Dean 2012). Posttranscriptional control of gene 
expression is especially valuable in the precise regulation of highly active proteins like 
cytokines, growth factors and cell-cycle regulators due to context-dependent, rapid and 
reversible modes of action (Gingerich et al. 2004). Indeed the aberrant control of mRNA 
processing has been implicated in a number of inflammatory disease states and likely 
contributes to a number of disease processes (López de Silanes et al. 2007; Hitti & Khabar 
2012; Schott & Stoecklin). Posttranscriptional methods of limiting cytokine expression are 
more rapid than de novo gene synthesis and therefore the regulation of RNA stability and 
rate of decay is an especially efficient system of delimiting the inflammatory response.  
 
1.11.1 Pathways of mRNA decay 
RNA is an adaptable intermediate of gene transcription and protein production that, in 
response to cellular signals, may be targeted in a way that facilitates rapid modification of 
gene expression profiles. Therefore RNA exists in a dynamic state of stability and responds 
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to specific signals that may initiate or protect the transcript either by removal or 
stabilisation of protective terminal structures. Further to this, the pioneer round of 
translation is a surveillance mechanism that initiates on nuclear export of mature transcripts 
to the cytoplasm (Brooks & Blackshear 2013). Should any RNA message contain aberrant 
splicing, interruptive sequences or stop codons, either non-sense (Silva & Romão 2009; Neu-
Yilik & Kulozik 2008), non-stop (Frischmeyer et al. 2002) or no-go mediated (Harigaya et al. 
2010)mechanisms ensure rapid degradation and removal. 
All eukaryotic mRNAs are co-transcriptionally fitted with, a 3’ stretch of ~25-200 adenine 
nucleotides known as the Poly (A) tail and a 5’ 7-methylguanosine cap. These protective 
structures associate with Poly (A) binding protein (PABP) and eIF4E in the cytoplasm and 
form a complex which safeguards the transcript from exonuclease-mediated decay. The 
canonical mechanism of mRNA degradation is known as deadenylation dependent mRNA 
decay and involves removal of the Poly (A) tail followed by hydrolysis of the 5’-cap. 
However, a number of other, ‘atypical’ mechanisms of decay also exist. Shortening of the 
poly (A) is reversible and those mRNAs specifically marked may be readenylated as a unique 
form of regulation and returned to the polysome for further processing.  In mammals, the 
poly (A) nuclease (PAN) 2 – PAN3 complex catalyses initial shortening of the Pol (A) tail and 
further removal is carried out by the carbon catabolite repressor protein (CCR) 4 – CCR4 
associated factor (CAF) 1 complex. As an initiator of decay, PAN2-PAN3 is dependent on the 
presence of PABP, whereas CCR4-CAF1 is inhibited by it (Tucker et al. 2002). Poly (A)-specific 
ribonuclease (PARN) is a cap-dependent deadenylase.  
Following deadenylation, to about 30-60 nucleotides in mammals, the message may be 
degraded by two non-mutually exclusive pathways; decapping and 5’ to 3’ digestion; or 3’ to 
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5’ decay. Several enzymes stimulate decapping activity (Dcp1, DCP2 and Hedls) and are 
associated with various accessory factors (Lsm proteins, pb1) (Steiger et al. 2003; Fenger-
Grøn et al. 2005; Yu et al. 2005). Once deadenylated and decapped, the mRNA body can be 
degraded 5’ to 3’ by exoribonuclease Xm1. Without the need for initial decapping, the 3’ to 
5’ pathway employs a 10-12 subunit complex known as the exosome to digest the transcript 
using 3’ to 5’ exoribonuclease activity. Decapping of the remaining oligomer is catalysed by 
the scavenger enzyme Dcps (Liu et al. 2002).  
P-bodies are transitory cytoplasmic structures formed in the presence of mRNA. Enriched 
for the components necessary (Anderson & Kedersha 2006), it is generally accepted that p-
bodies are sites of messenger transcript decay (Sheth & Parker 2006; Parker & Sheth 2007). 
It is also probable that these granular foci provide compartmentalisation of those mRNAs 
tagged for degradation (Garneau et al. 2007). 
Other transcript degrading processes include the aptly named deadenylation-independent 
decapping whereby transcripts bypass poly (A) removal and undergo direct decapping. 
Although this process does not require the catalytic activity of a deadenylase, study has 
shown that some subunits of the CCR4-CAF1 complex are required (Muhlrad & Parker 
2005). Endoribonucleolytic decay uses endonuclease activity to cleave the transcript and 
produce two fragments of mRNA which are susceptible to exonuclease attack; a highly 
efficient and specific process (Hollien & Weissman 2006; Yang & Schoenberg 2004) 
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1.11.2 Regulation of messenger transcript stability; mRNA binding proteins and 
AU-rich sequence characteristics 
Trans-acting factors known as mRNA binding proteins have an affinity for regulatory 
sequences, predominantly located in the 3’ UTR of target transcripts. These factors may be 
constitutive or induced and, via association with cis-acting motifs, regulate transcript 
stability either by facilitating or inhibiting mRNA decay. By far the most well understood cis-
acting 3’UTR sequence that modulates mRNA stability is the adenosine-uridine rich element 
or ARE. Located in the 3’ UTR of up to 15% of all transcripts (Bakheet 2001; Bakheet et al. 
2006), ARE motifs exist on a spectrum from indefinite U-/AU-rich sequences to distinct 
repeats of the signature AUUUA pentameter and everywhere in-between (Beisang & 
Bohjanen; Khabar 2010). The UUAUUUAUU nonomer is minimally required for ARE 
functionality. 
 
Transcript binding proteins may be stabilising or destabilising, although these functions are 
not mutually exclusive and depending on varying conditions, some mRNA binding proteins 
may be capable of either process. Perhaps one of the most recognised AREBPs, HuR typically 
stabilises the RNA message and is thought to enhance associations between transcript and 
terminal protective structures through interaction with PABP and eIF4 (Nagakoa et al. 2006). 
In addition, HuR has been shown to compete with AUF1, KSRP and TTP for transcript 
binding, displacing their destabilising effects and relocating the transcript to the polysome 
for translation initiation (Bhattacharyya et al. 2006).  
Destabilising AREBPs on the other hand rapidly eliminate transcripts by facilitating 
associations with deadenylases, decapping enzymes and the exosome. High turnover 
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transcripts like cytokines, growth factors and cell cycle regulators that have a potentially 
deleterious effect if not properly regulated are quite often degraded by mRNA destabilising 
proteins. Examples of destabilising proteins include AUF1, KSRP and BRF1/2 however in the 
context of inflammation, tristetraprolin (TTP) is perhaps the most studied AREBP.  
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1.12 Tristetraprolin (TTP) 
 
1.12.1 TTP & the ZFP36 locus 
The earliest descriptions of TTP recognise Nup475 from serum-stimulated fibroblasts 
(DuBois et al. 1990); G0S24, a human lymphocyte G0/G1 switch gene (14); TPA-induced 
sequence (TIS) -11 (Varnum et al. 1989; Ma & Herschman 1991); and Zinc finger protein 36 
(Zfp36) as the same factor. Originally, TTP was cloned from the mouse cDNA of 3T3-L1 
murine fibroblasts simulated with insulin (Lai et al. 1990).   The TIS11 family of 
nucleocytoplasmic shuttling proteins consists of three members, TTP (TISS11/ ZFP36), BRF1 
(TIS11b/ ZFP36L1) and BRF2 (TIS11d/ ZFP36L2) (Sanduja et al. 2012), all of which are 
characterised by a highly conserved cysteine-cysteine-cysteine-histidine (CCCH) Zinc finger 
domain (Phillips et al. 2002)(Varnum, Ma et al. 1991). TTP was initially identified as an 
immediate-response gene whose expression was rapidly and transiently induced in 
response to numerous cellular stimuli including (12-O-tetradecanoylphorbol-13 acetate) TPA 
(hence TPA-induced sequence), insulin, serum and other mitogenic agents (Sanduja et al. 
2012; DuBois et al. 1990; Lai et al. 1990; Varnum et al. 1989; Gomperts et al. 1990). 
Characteristic of an immediate-early gene, induction of Zfp36 is independent of protein 
synthesis and in fact cycloheximide treatment enhances the level of transcript expression. 
 
The Zfp36 locus is small, occupying approximately 12kb on human chromosome 19q13.1. 
Murine Zfp36 lies within a linkage group at the proximal end of chromosome 7 that is 
conserved within a segment of human chromosome 19 (Taylor et al. 1991; Saunders & 
Seldin 1990). The ZFP36 gene-region its self is correspondingly small, comprising just two 
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exons and one intron. The entire sequence of ZFP36 is just ~2.5kb, which comprises the 
5’UTR ~49/ 28bp, exon1 ~35/ 27bp, intron1 ~381/ 681bp, exon2 ~962/ 932bp and the 3’UTR 
711/763bp (human/mouse data from UCSC). The upstream and downstream genes that 
flank the ZFP36 sequence are mediator complex subunit 29 (MED29) and plekstrin 
homology domain containing family-G member 2 (PLEKHG2), both of which are transcribed 
in the same direction as TTP. MED29 is a multiprotein coactivator of transcription and forms 
interactions with factors including RNAPII and other general initiators of gene synthesis 
(Sato et al. 2003). PLEKHG2 is involved in the signalling pathways leading to actin-
cytoskeletal reorganisation and is activated by G-protein Gβγ subunits (Sato et al. 2003). The 
newly identified micro RNA 4530 (MIR4530) is also located within the human ZFP36 locus 
and lies downstream of the 3’UTR, in a 3’ to 5’ direction (Jima et al. 2010). Micro RNAs are 
known for their role in posttranscriptional regulation of gene expression through 
modification of target transcript stability and translation efficiency (Pritchard et al. 2012). 
 
1.12.2 TTP gene regulation 
The full serum inducibility of TTP is dependent on a number of elements identified within 
the 5’ proximal promoter as well as the intron of TTP. These sequences were found to 
contain essential binding motifs for factors including SP1, EGR1, AP2 and NFκB (Lai et al. 
1990). In addition, a TGFβ-dependent smad responsive binding region (known as ‘TRR’) has 
been identified approximately 500bp upstream of the Zfp36 promoter (Rounbehler et al. 
2012; Ogawa et al. 2003; Sohn et al. 2010).  
Evidence suggests that a varied selection of endogenous factors and natural compounds 
stimulate the transcription of Zfp36. Green tea, cinnamon, β-adrenergic receptor agonists, 
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nicotinic acetylcholine receptor ligands, interferons and glucocorticoids have all been shown 
to enhance TTP expression.  
Investigation of glucocorticoid-mediated up regulation of TTP has provided mixed results, 
however there are three putative glucocorticoid receptor binding elements surrounding the 
Zfp36 sequence. This intensity of regulatory input requires complex sequence organisation 
and therefore the comparatively small Zfp36 locus comprises a highly functional domain. 
Interestingly, the nucleotide base pairs surrounding the ZFP36 region are highly conserved 
through the mammalian lineage and this might indicate the presence of ‘distal’ functional 
regulatory elements. As aforementioned, there have been a handful of studies that focused 
on the 5’ proximal promoter region of Zfp36 and also the single intron, however little work 
has been carried out to identify regulatory elements in the more distal upstream and 
downstream elements regardless of the evident evolutionary conservation. 
Following processing, the mature Zfp36 transcript is approximately 1.7kb in length and 
subject to posttranscriptional regulation by mRNA-binding factors. Indeed, TTP has been 
shown to directly interact with its own mRNA in an ARE-dependent manner (Brooks et al. 
2004; Tchen et al. 2004). 
 
1.12.3 TTP protein function & regulation 
As the nomenclature might suggest, the amino acid sequence of TTP is rich in proline 
residues, which are arranged in three motifs containing four proline residue repeats i.e. 
PPPP in Figure 1.12.1 (Lai et al. 1990) Characteristically, TTP expression is low in quiescent 
cells and rapidly upregulated in response to mitogenic stimulation (Sanduja et al. 2009; 
Gomperts et al. 1990). When active, TTP is found located in the cytoplasm, where it can 
target mature mRNA transcripts. The integrity of the two conserved CCCH zinc finger 
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domains is essential for the ARE-binding mechanism of TTP function as well as nuclear-to-
cytoplasmic shuttling (Taylor et al. 1996; DuBois et al. 1990; Varnum et al. 1991; Phillips et 
al. 2002; Carballo et al. 1998). However the residues involved in TTP function and shuttling 
are distinct and the latter requires a nuclear export sequence (NES) (Phillips et al. 2002). TTP 
has an affinity for the minimal AREBP nonamer ‘UUAUUUAUU’ however may also bind to 
UAUUUAU (Brooks & Blackshear 2013). Whereas HuR and most HuR-related AREBPs will 
recognise a U-rich motif, TTP on the other hand requires the presence of adenylate residues 
within the core element. The competition and exchange between HuR and TTP for target 
transcript AREs is well documented and part of the functional mechanism for each AREBP. In 
fact, TTP and HuR have been shown to compete for the same ARE sequences within the 
TNFα transcript (Tiedge 2012).  
 
Figure 1.6 TTP gene, mRNA and protein structure configuration 
Cartoon schematic detailing the arrangement of the Zfp36 gene, mRNA and TTP 
protein. MAPK p38 /MK2 target sites for phosphorylation of mouse/human TTP 
protein are illustrated. Figure adapted from Sanduja Blanco et al 2012 
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TTP is expressed constitutively, at very low levels, in an active form. Upon binding to its ARE-
containing mRNA target, TTP relies on C-terminal associations with Not-1 that facilitate 
recruitment of the CCR4-CAF1 complex (Sandler et al. 2011) in order to initiate 
deadenylation (Carballo et al. 2001; Sawaoka et al. 2003; Clement et al. 2011; Marchese et 
al. 2010). TTP also interacts with decapping enzymes, PARN deadenylase, Xrn1 and 
specifically recruits several components of the exosome (Fabian et al. 2013; Marchese et al. 
2010; Sandler et al. 2011; Clement et al. 2011). In response to TGFβ, TTP is also critical to 
the induction of p-bodies, which comprise the structures necessary for mRNA degradation 
(Blanco et al. 2014).  
TTP-interaction with the CAF1/CCR4 complex however, is critical and in fact depletion of 
either component results in ARE-transcript stabilisation (Brooks & Blackshear 2013; Clement 
et al. 2011; Marchese et al. 2010). This mechanism is strongly influenced by TTP 
phosphorylation and inactivation downstream of p38 MAPK. MAPK p38 and its substrate 
MK2 are both capable of TTP phosphorylation at two specific sites, they are serine 52 and 
178 in mouse and serine 60 and 186 in human protein (Cao et al. 2003; Carballo et al. 2001; 
Mahtani et al. 2001; Chrestensen et al. 2004). This specific posttranscriptional modification 
event prevents recruitment of CAF-1; the main catalytic unit of deadenylation dependent 
mRNA decay (Marchese et al. 2010) and therefore renders TTP in reserve and promotes 
stress-dependent mRNA stabilisation. Cessation of p38 MAPK signalling and consequential 
dephosphorylation of TTP by PP2A (Sun et al. 2007) unleashes its degradation potential 
upon target mRNAs and effectively restrains inflammation. 
MAPK p38 is necessary but not sufficient for inhibition of TTP function and it must be noted 
that posttranslational modification of TTP is extensive. It is therefore likely that additional 
signalling pathways also contribute deadenylase recruitment and TTP-mediated mRNA 
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destabilisation. For example a mutant form of TTP, wherein serines 52 and 178 are mutated 
to alanine residues, is un-phosphorylatable by MK2 and acts as a potent mRNA destabilising 
factor regardless of its reduced affinity for deadenylase (Clement et al. 2011). Fittingly, 
evidence suggests that both the ERK and p38 kinase pathways work in concert to inhibit TTP 
mediated mRNA decay (Deleault et al. 2008; Essafi-Benkhadir et al. 2010; Brook et al. 2006).   
As a target for ERK2, p38 MAPK, JNK, MK2, glycogen synthase kinase and protein kinases A, 
B and C (Cao et al. 2003; Stoecklin et al. 2004; Cao & Lin 2009), it is perhaps unsurprising 
that TTP is found phosphorylated to a remarkable extent in vivo and in vitro. At least 14 
sites of phosphorylation exist in mice (Cao et al. 2006; Cao et al. 2014) and most correspond 
with a human counterpart. 
 
With regards to serine 52 & 178, the TTP protein persists in a constant equilibrium between 
the unphosphoryltaed (active) and phosphorylated (inactive) form. Basally, TTP is mostly 
unphosphorylated and expressed at low levels in the nucleus. In response to pro-
inflammatory stimuli and MAPK signalling, TTP undergoes rapid NFκB-dependent 
transcriptional up-regulation and P38-dependent mRNA and protein stabilisation. 
Moreover, studies in Mk2-/- mice and transient transfection of mutant forms of TTP into a 
macrophage cell line suggest that the inactivating ser-52 and ser-178 (Ser-60 and Ser-186 in 
humans) phosphorylation is critical to protecting TTP from proteasomal degradation (Rigby 
et al. 2005). A mutant form of murine TTP, in which the MK2 specific phosphorylation sites 
Ser-52 and Ser-178 are replaced by un-phosphorylatable alanine residues, has recently been 
investigated. Mice homozygous for the mutant form of TTP are healthy and fertile and show 
a strongly attenuated response to endotoxin. In addition, the mutation had little to no effect 
on acquired immunity in Zfp36aa/aa mice inoculated with S. typhimurium. Surprisingly, 
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heterozygous mutants show equally as potent TTP-mediated mRNA destabilisation and 
inhibition of pro-inflammatory cytokine expression (unpublished data - manuscript in 
review), highlighting the dominant nature of this mutation. Although potently effective 
however, the “TTP-AA” mutant is highly unstable and constitutively degraded by the 
proteasome, as is the active, Ser52/178 unphosphorylated protein.  Shifting the 
phosphorylation equilibrium of murine TTP Ser-52/-178 towards a constitutively active state 
successfully augmented the mRNA destabilising and anti-inflammatory capacities of TTP 
without inducing any observed adverse effects. Critically, manipulation of the TTP Ser-
60/186 in humans could be useful for the treatment of immune pathology. 
 
1.12.4 The role of TTP in inflammation 
The role of TTP in inflammation was originally established by studies in knockout mice 
(Taylor, Carballo et al. 1996), which initially appeared normal but soon developed a severe 
complex inflammatory syndrome including cachexia, dermatitis, destructive arthritis, 
myeloid hyperplasia and autoimmunity (Taylor et al. 1995). Treatment of young TTP-
deficient mice with antibodies to TNFα prevented development of essentially all aspects of 
the phenotype and so the syndrome observed was put down to the overexpression of TNFα, 
owing to an absence of TTP (Taylor, Carballo et al. 1996). Mice subject to myeloid-specific 
disruption of Zfp36 on the other hand are hypersensitive to low-dose LPS challenge but do 
not develop a spontaneous inflammatory syndrome and are otherwise phenotypically 
normal and fertile (Qiu et al. 2012). These data might suggest that the temporal and 
qualitative control of TNFα mRNA decay by TTP in myeloid cells is required for the re-
instalment rather than maintenance of immune homeostasis (Kratochvill et al. 2011). 
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Subsequent confirmation about the role of TNFα in TTP-deficiency syndrome pathogenesis 
was made when TTP-/- mice lacking functional TNFRs appeared normal (Carballo, Cao et al. 
2001). In concurrence, transgenic mice overexpressing TNFα were shown to develop an 
analogous phenotype to the TTP knockout mice (Keffer, Probert et al. 1991). Carballo et al 
(1997) demonstrated that macrophages derived from TTP-/- mice exhibited increased 
stabilisation of TNFα mRNA when compared to wild type animals. It was suggested that TTP 
had a crucial negative feedback role in restraining TNFα synthesis and stability during the 
immune response (Carballo, Lai et al. 1998). Kontoyiannis et al. (1999) then showed that 
deletion of the TTP binding region from the TNFα 3' UTR caused inflammatory arthritis. 
Further study revealed that TTP was able to bind directly to the TNFα 3’ UTR ARE and induce 
destabilisation of the mRNA transcript (Carballo, Lai et al. 1998; Lai, Carballo et al. 1999; 
Smoak and Cidlowski 2006).  
Critically, as a form of positive feedback, TNFα enhances pro-inflammatory mRNA stability 
through MAPKs and activation and inhibition of stabilising and degrading mRNA binding 
proteins respectively. Responsible for the myeloid hyperplasia phenotype of TTP knockout 
mice, GM-CSF is another target of TTP that has been instrumental to uncovering the 
mechanisms of ARE-containing mRNA decay (Carballo et al. 2000). By introducing the GM-
CSF AT-rich sequence to the 3’UTR of rabbit β-globin mRNA, Shaw and Kamen demonstrated 
the ability of AREs to confer instability of otherwise stable transcripts (Shaw & Kamen 1986). 
Furthermore, TTP deficiency was responsible for the greatly enhanced half-life of GM-CSF 
message in TTP knockout versus wild type bone marrow derived stromal cells (BMSCs) 
treated with TNFα and actinomycin D. In the same study, northern blot analysis confirmed 
that TTP deficiency prevents the initial deadenylation of transcript, rather than facilitating 
stabilisation (Carballo et al. 2000).  
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Knockdown studies conducted by Tiedje et al. (2012) showed that an absence of TTP 
resulted in increased association of TNFα mRNA with the polysome. On the other hand, 
removal of HuR reduced TNFα transcript localisation within translational processing 
fractions. The dynamic of this competition is strongly shifted in favour of HuR in the 
presence of active p38 MAPK/ MK2, even with TTP concentrations four-times that of HuR. In 
fact, whilst MK2 greatly reduces the affinity of TTP for a synthetic ARE, HuR remains 
unaffected (Tiedje et al. 2012). Interestingly the TTP/HuR double knockdown phenotype 
paralleled that of the HuR single knockdown; whereby TNFα transcripts were excluded from 
and reduced in polysomal and monosomal cytoplasmic fractions. These results suggest that 
not only is HuR required for the translational processing of TNFα and putatively a number of 
other pro-inflammatory mRNAs but also is a constitutive activator of TNFα protein 
expression (Tiedje et al. 2012).  
 
A number of therapeutically invaluable inflammatory agents have been shown to induce TTP 
expression. Glucocorticoids have been used for management of chronic inflammatory 
syndromes for decades. However in truth, their exact mechanism of action is incompletely 
understood (Clark & Belvisi 2012; Newton 2013). Glucocorticoids have, however been 
shown to increase the expression of TTP at the level of mRNA and protein in A549 cells, 
pulmonary bronchial epithelial cells and MEFs (Smoak & Cidlowski 2006; Ishmael et al. 
2008). Glucocorticoid-mediated up-regulation of TTP has a strong anti-inflammatory 
outcome. Ishmael et al. (2008) observed a striking reduction in the antagonistic effects of 
glucocorticoid on the TNFα-response in Zfp36 -/- MEFs. The post-transcriptional effects of 
glucocorticoids are well documented (Stellato 2004). Indeed, glucocorticoids have been 
shown to increase rates of decay for numerous inflammatory cytokines and chemokines. In 
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addition, the absence of TTP in MEFs reduced GC-mediated gene expression by up to 85% 
and therefore TTP may also influence anti-inflammatory transcriptional regulation by 
glucocorticoids (Ishmael et al. 2008). Glucocorticoids also strongly induce the expression of 
DUSP1, downstream of which lies the un-phosphorylation and activation of TTP protein 
(Kassel et al. 2001; Lasa et al. 2002; Issa et al. 2007; King, Holden, et al. 2009a; Holden et al. 
2010; Abraham & Clark 2006). The anti-inflammatory effects of glucocorticoids are 
augmented by supplementation of Long-acting β2-Adrenoceptor agonists. Numerous 
agonists of cAMP signalling pathways have powerful anti-inflammatory consequences and 
are often used for the treatment of asthma and conditions of chronic airway inflammation. 
Several of these cAMP-activating compounds have been shown to positively regulate TTP 
expression as a critical mechanism of their function. In addition to these two striking 
examples, a number of other anti-inflammatory acting agents have the capacity to up 
regulate the expression or activation of TTP or both. The question is, how this achieved and 
how depended are is the anti-inflammatory effects dependent on TTP expression. 
 
NFκB is a key factor of inflammatory signalling, positively regulated by TNFα and hence 
inhibited by TTP. Additional to its AREBP properties, TTP also regulates inflammatory signal 
transduction in the nucleus. Nuclear translocation of the NFκB catalytic subunit p65 is 
enhanced in TTP knockout MEFs and knockdown HUVECs (Schichl et al. 2009). The same 
study showed that number of non-ARE genes were upregulated in TTP deficient cells. The 
TTP-p65 association was echoed by Liang’s study, which also identified TTP-mediated 
suppression of NFκB at the corepressor level via an interaction with HDAC-1, -3 and -7 in 
vivo. TTP-dependent inhibition of an NFκB reporter was partly abrogated when cells were 
treated with HDAC inhibitors or HDAC siRNAs. Consistent with this finding, chromatin 
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immunoprecipitation after LPS treatment of TTP deficient cells showed a decreased 
accumulation of HDAC1 as well as an increase in CBP at the MCP-1 promoter (Liang et al. 
2009). Together these findings coincide with previous suggestions that TTP may have 
inhibitory effects on pro-inflammatory gene expression at the transcriptional level by 
negatively regulating NFκB mediated gene expression (Carballo et al. 1998). 
 
1.12.5 The role of TTP in cancer 
Central to early events in tumourogenesis is the overexpression of factors that promote cell 
growth, inflammation and angiogenesis; often accompanied by an under-expression of 
genes orchestrating cellular senescence. As a putative tumour suppressor, TTP is evidently 
down regulated in a number of cancerous tissues and cell lines and in a number of cases, 
expression level restoration has anti-oncogenic effects. Hyperphosphorylation of TTP by 
MAPK p38/MK2 in malignant glioma may contribute to the aberrant stabilising effects of 
HuR and the observed overexpression of VEGF and IL8. Reestablishment of TTP expression 
and its ARE-mediated effects on VEGF and IL-8 mRNA inhibited disease progression in 
gliomal cells. Aberrant HuR-dependent stabilisation of VEGF has also been detected in 
colorectal cancer, alongside increased COX-2 production.  Substrates of TTP, VEGF and COX-
2 cause tumour vascularisation and cell proliferation; restoration of TTP abrogates these 
effects.  
Hypermethylation of a single CpG in the Zfp36 promoter smad-binding sequence causes TTP 
down-regulation in hepatocellular carcinoma (HCC). CMyC is a TTP target that is upregulated 
in HCC. By reactivating TTP biosynthesis, DNA methylation inhibitor 5azadeoxycitidine 
inhibits tumourogenesis caused by cMyC up-regulation. 
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Cervical cancer is attributed to the oncogenic actions of HPV oncogenes E6/7, which inhibit 
the tumour suppressive functions of master cell regulator p53 and pRB. In non-carcinogenic 
cervical tissue TTP is abundant at the level of mRNA and protein; however cancerous 
cervical biopsies and cell lines are deficient in TTP. The E6AP message is AU-rich; up-
regulation of TTP destabilises E6 RNA, prevents p53 ubiquitination and inhibits hTERT and 
leads to cellular senescence in HPV18-HeLa cells. TTP has also been shown to sensitise HeLa 
to proapoptotic stimuli such as TNF and staurosporine. 
The reduced synthesis of TTP observed in breast cancers is often an indicator of high tumour 
grade and a poor prognostic outcome. An inverse relationship between MiR29a and TTP 
may be key to breast cancer pathogenesis since increased MiR29a supressed TTP expression 
malignant cell lines. The anti-oncogenic effects of TTP re-expression in these cells 
subsequently reduced metastasis and proliferation. A number of ARE-mRNAs are stabilised 
in breast cancer identifying them as novel targets of TTP. Also deficient in lung, ovary, 
prostate and thyroid tissues, TTP has clear tumour suppressive effects and a lot more 
research is becoming focused on these novel properties of TTP. 
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1.13 Project aims 
This project is concerned with the regulation of negative feedback genes by pro- and anti- 
inflammatory pathways. We are interested in how these two opposing systems converge 
and cooperatively resolve inflammation. We will investigate the involvement of NFκB in the 
induction of three anti-inflammatory feedback node genes (FNGs). Further to this we would 
like to characterise the expression of these genes in response to a number of anti-
inflammatory agents. I want to identify how pro-inflammatory stimuli and anti-
inflammatory agents cooperate to control the expression and activity of DUSP1, A20 and 
TTP. 
 
1.13.1 Endogenous mRNA and protein expression of FNGs in response to pro-
inflammatory stimuli and anti-inflammatory agonists 
DUSP1, TNFAIP3 and ZFP36 are rapidly and transiently up-regulated in response to pro-
inflammatory agonists such as LPS and IL1. However the extent of NFκB involvement in 
these mechanisms however is not well characterised. Furthermore, for the purpose of this 
study, where we aim to elucidate some of the cooperative mechanisms between pro-
inflammatory up-regulation of anti-inflammatory genes it will be necessary to have a clear 
understanding of NFκB mediated induction of these genes.  
Initially, I will investigate the LPS-induced expression profile of all three FNGs in primary 
human and murine derived macrophages and RAW cells. Following this, I will utilise 
MLN4924, a powerful and specific inhibitor of NFκB-mediated nuclear processes, to explore 
the involvement of NFκB in the induction of cytokine and FNG expression. Additionally, I will 
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focus attention on the mechanisms pro-inflammatory mediated up-regulation of Zfp36, with 
the aim of identifying important and novel regulatory regions and enhancer sequences.  
In order to begin to understand how pro-inflammatory and anti-inflammatory mechanisms 
converge, I will characterise cytokine and feedback node gene expression in several cell lines 
and primary macrophages of human and murine origin in response to a pro-inflammatory 
stimulus alone (IL-1/LPS), the anti-inflammatory agent alone and a combination of both. The 
effects of pro-inflammatory and/or anti-inflammatory stimulation at the mRNA level will be 
quantified by real-time quantitative PCR (QPCR) whereas the effects at the level of protein 
will be quantified by western blot or enzyme linked immunosorbent assay (ELISA). With the 
intention of elucidating the importance of DUSP1 as a central regulator of anti-inflammatory 
mechanisms, I will carry out parallel experiments in Dusp1-/- macrophages. 
 
1.13.2 Elucidating the transcriptional regulation of Zfp36; novel regulatory 
elements and transcription factor binding sites 
The rest of the study will focus on transcriptional regulation of Zfp36. 
I will identify and characterise putative Zfp36 regulatory elements capable of mediating 
transcriptional responses to antiinflammatory stimuli and LPS or IL1 in macrophage 
epithelial cell lines respectively. Initially, I will do this by transcriptional reporter assay. The 
regions involved in gene regulation often show evolutionary conservation, DNAseI 
hypersensitivity, or histone (H3K4) methylation and much of this information is accessible 
via public genome browsers like UCSC. I will select a number of putative regulatory 
sequences from the TTP locus and individually clone them upstream of a minimal promoter 
      75
and luciferase reporter gene. Responses of these constructs to IL-1/LPS or anti-inflammatory 
stimuli will be tested following transient transfection into HeLa or RAW264.7 cells.  
This method is a valuable tool for identifying putative enhancer sequences. However 
describes the function of only a few transcription factor binding sites in isolation and does 
not reflect the true interaction of multiple responsive regions that are likely to surround a 
highly inducible gene such as Zfp36. In reality, it is likely that enhancer sequences act in 
concert as opposed to individually and in addition Lai et al 1998 showed that the intron is 
essential for full serum inducibility of Zfp36. Therefore, as a tool to investigate 
transcriptional responsiveness of the entire Zfp36 gene locus, I will synthesise a Zfp36 
mimic-gene, based on the Zfp36 locus but containing a luciferase cDNA in place of the two 
endogenous Zfp36 exons. I will measure the response of this mimic gene to LPS and, or an 
anti-inflammatory stimulus.  If strong transcriptional responses are shown and given the 
time and materials, I will carry out further deletion and mutation analysis of this construct 
so as to identify important transcription factor binding sites. 
Chromatin immunoprecipitation (ChIP) will be performed to identify sites of DNA-
transcription factor (RNAPII, NFkB, and GR) association with the Zfp36 sequence in primary 
macrophages and RAW cells treated with LPS & anti-inflammatory stimuli. I will use 
systematic approach to identifying important sites of protein-DNA interaction by designing 
primers that span the entire Zfp36 locus. 
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2.0 MATERIALS AND METHODS 
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2.1 Materials 
2.1.1 Cytokines and inflammatory Stimulants 
 
The cytokines and other signalling proteins used in this study are listed in Table 2.1. 
Table 2.1 Recombinant Cytokines 
Cytokine/ 
Signalling molecule 
 
Application 
 
Concentration 
 
Source 
M-CSF Cell culture 100ng/ml Genetics Inst. MA, 
USA 
GM-CSF Cell culture 100ng/ml PeproTech EC UK 
IL-10 Cell stimulation 10ng/ml Schering-Plough, 
USA 
TNFα Cell stimulation/ 
ELISA 
 PeproTech EC UK 
IL-1 Cell stimulation 1ng/ml PeproTech EC UK 
IFNγ Cell stimulation 10ng/ml R&D Systems UK 
TGFβ  Cell stimulation 10ng/ml PeproTech EC LTD. 
UK 
PGE2  Cell stimulation 10ng/ml Torcis Bioscience UK 
LPS (E. Coli) Cell stimulation 10ng/ml Sigma, Dorset UK 
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2.1.2 Antibodies 
 
2.1.2.1 Antibodies used for western blotting 
 
The antibodies used for western blotting are detailed in Table 2.2. 
Table 2.2 Antibodies used for western blot analyses 
Specificity Species Dilution Source 
α-Tubulin H Mouse 1:5000 Sigma, Dorset, UK 
β-actin M, H Mouse 1:5000  
Sac-21, M Rabbit 1:1000  
H-120, M, H Mouse 1:1000  
RelA, M, H Rabbit 1:1000  
TNFAIP3 M, H Mouse 1:1000 Cell Signalling,  USA 
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2.1.2.2 Antibodies used for chromatin immunoprecipitation 
The antibodies used for ChIP and their dilutions are shown in table 2.3. 
Table 2.3 Antibodies used for ChIP 
Specificity Concentration Source Species 
RNAPII  
(sc-9001-X) 
2mg/ml Santa Cruz 
biotechnology, USA 
Rabbit 
RNAPII CTD 
phospho-ser2 
(ab5095) 
1mg/ml Abcam, Cambridge, 
UK 
Rabbit 
ChIP isotype control 
(ab46540-1) 
1mg/ml Abcam, Cambridge, 
UK 
Rabbit 
RelA (p65)  
(ab7970-1) 
2mg/ml Abcam, Cambridge, 
UK 
Rabbit 
GR (H-300)  
(sc-8992) 
2mg/ml Santa Cruz 
biotechnology, USA 
Rabbit 
PU.1    
 
2.1.3 Inhibitors 
Complete mini protease inhibitor tablets were purchased from Roche Applied Science as 
well as PhosSTOP phosphotase inhibitors both were used according to manufacturers’ 
instructions. 
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2.1.4 PCR Primers 
2.1.4.1 Taqman primers 
All assay-on-demand premixed TaqMan probe master mixes were purchased form Applies 
Biosystems, Warrinton UK. 
Table 2.4 TaqMan probes used for q-PCR analysis of mRNA and cDNA 
Gene Catalogue number Species 
Gapdh/ GAPDH Mm99999915_g1/ 
Hs99999905_m1 
Mouse/Human 
Tnfα/ TNFα Mm99999068_m1/ 
Hs00174128_m1 
Mouse/Human 
Zfp36/ ZFP36 Mm00457144_m1/ 
Hs00185658_m1 
Mouse/Human 
Dusp1/ DUSP1 Mm00457274_g1/ 
Hs00610256_g1 
Mouse/Human 
Tnfaip3/ TNFAIP3 Mm00437121_m1/ 
Hs00234713_m1 
Mouse/Human 
Med29 Mm00786410_s1/ 
Hs00378316_m1 
Mouse/Human 
PlekHg2 Mm00507178_m1/ 
Hs00293943_m1 
Mouse/Human 
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2.1.4.2 Custom designed oligonucleptide primers 
The oligonucleptide primers used in this study are listed in the following tables. They we all 
purchased from MWG, Germany.  
Table 2.5 Oligonucleotide primers used for SYBER green q-PCR of cDNA. 
Name Sequence Species 
ActB For/ActB Rev CGGCATCGTCACCAACTG 
AACATGATCTGGGTCATCTTCTC 
Human 
B2M For/B2M Rev GTATGCCTGCCGTGTGAAC 
AAAGCAAGCAAGCAGAATTTGG 
Human 
hGAPDH_F1/hGAPDH_R1 GTCAGCCGCATCTTCTTTTGC 
AATCCGTTGACTCCGACCTTCC 
Human 
hIFNβ1_F1/hIFNβ1_R1 TGGCACAACAGGTAGTAGGC 
AGTGGAGAAGCACAACAGGAG 
Human 
hIL-10_F1/hIL-10_R1 GCCTAACATGCTTCGAGATC 
TGATGTCTGGGTCTTGGTTC 
Human 
hMPK1_F1/hMKP1_R1 ACAACCACAAGGCAGACATCA 
CAGTGGACAAACACCCTTCCT 
Human 
hRELA_F1/hRELA_R1 GCTATCAGTCAGCGCATCCA 
TCCCCACGCTGCTCTTCTAT 
Human 
hSTAT3_F1/hSTAT3_R1 GTCGCAGCCGAGGGAACAA 
CCATTGGGCCATCCTGCTAAAA 
Human 
TBP For/TBP Rev TGCCCGAAACGCCGAATATAATC 
GTCTGGACTGTTCTTCACTCTTGG 
Human 
hTNFα_F1/hTNFα_R1 CCCCAGGGACCTCTCTCTAAT 
TCTCTCAGCTCCACGCCATT 
Human 
hTNFAIP3_F1/hTNFAIP3_R1 CCCTTGGAAGCACCATGTTTG 
GGTTGGGATGCTGACACTCC 
Human 
hZFP36_F1/hZFP36_R1 TCCACAACCCTAGCGAAGAC 
GAGAAGGCAGAGGGTGACAG 
Human 
mGapdh_f1/mGapdh_r1 CATCATCTCCGCCCCTTCTG 
CATCACGCCACAGCTTTCC 
Mouse 
mIfnβ1_f1/mIfnβ1_r1 AGTTTCTGGTAAGTCTTC 
TGC AGA GTT ACA CTG CC 
Mouse 
mMkp1_f1/mMkp1_r1 ACAACCACAAGGCAGACATCA 
CAATGAACAAACACTCTCCCT 
Mouse 
mRelA_f1/mRelA_r1 GCTTCTGGGCCTTATGTGG 
GTC TGG GCA GAG GTC AGC C 
Mouse 
mTnfα_f1/mTnfα_r1 TTCTATGGCCCAGACCCTCA 
ACAAGGTACAACCCATCGGC 
Mouse 
mTnfaip3_f1/mTnfaip3_r1 CAGGCCGCCGAAAGACG 
TCACAGCTTTCCGCATATTGCT 
Mouse 
mZfp36_f1/mZfp36_r1 TGGATCTCTCTGCCATCTACG 
ATTCGGTTCCTCCGTGGTC 
Mouse 
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Table 2.6 Oligonucleotide primers used for amplification of Zfp36 sequences  
Name Species Sequence Location 
mZfp36_ECR2 F1 mouse   
mZfp36_ECR2 R1    
mZfp36_ECR3 F1 mouse GCGCTCGAGGGATCTAG  
mZfp36_ECR3 R1  GCGCTCGAGCACACGTG  
hZfp36_ECR3 F1 human GCGCTCGAGGATCCAGG  
hZFP36_ECR3 R1  GCGCTCGAGCACACGTG  
mZfp36_ECR4 F1 mouse GCGCTCGAGTGGGGGTT  
mZfp36_ECR4 R1  GCGCTCGAGGGATTTGT  
hZFP36_ECR4 F1 human GCGCTCGAGTGGGGGTA  
hZFP36_ECR4 R1  GCGCTCGAGGGATTTGG  
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Table 2.7 Oligonucleotide primers used for Chromatin Immunoprecipitation. 
Name Sequence Location (UCSC format) Species 
Zfp36_1F1/ Zfp36_1R1 ACAGGAACCACCTGTTTTGC 
CATCAAAGCCCAGATCACCT 
>chr7:29171741+29171915 175bp Mouse 
Zfp36_2F1/ Zfp36_2R1 TAACCCAGGCATTTTGGTTC 
TGAGCCCTTTAGACCTTCCTC 
>chr7:29171369+29171527 159bp Mouse 
Zfp36_3F1/ Zfp36_3R1 CCGGCTATGGAGTGAGAGAC 
TCCCAGAGACTGTGGAGACC 
>chr7:29170657+29170884 228bp Mouse 
Zfp36_4F1/ Zfp36_4R1 GCTGCGGTTTGTTAGTAGCC 
TGTGGTTCTTTCCCCTACCC 
>chr7:29170177+29170347 171bp Mouse 
Zfp36_5F1/ Zfp36_5R1 TGAATGAAGGCTTGGCTTTT 
CTTCTGGCTCCCAAGTCCTA 
>chr7:29169657+29169828 172bp Mouse 
Zfp36_6F1/ Zfp36_6R1 AGCTACCTCAACAGCCCAGA 
TTTCACAAGCCCACACCATA 
>chr7:29169059+29169290 232bp Mouse 
Zfp36_7F1/ Zfp36_7R1 AGTGTGGGGTCCCTAGTGTG 
GGTCTTCTGGACACACAGCA 
>chr7:29168570+29168788 219bp Mouse 
Zfp36_8F1/ Zfp36_8R1 GACTTGCACACACTGGCATC 
ATGACCAAGTGCCACAAACA 
>chr7:29168133+29168338 206bp Mouse 
Zfp36_9F1/ Zfp36_9R1 CCGTGGGATCTGTGCTAAGT 
ACTGTCAGGAACAGGCAACC 
>chr7:29167817+29167984 168bp Mouse 
Zfp36_10F1/Zfp36_10R1 GGAATCCCCTCTGGAATGAC 
GTCCCTGCTTGTTTTTCTGG 
>chr7:29167065+29167262 198bp Mouse 
Zfp36_11F1/Zfp36_11R1 TGCCTGGTATTGGGCTACTC 
CCACTGGACAAGGAAAGGAA 
>chr7:29166596+29166801 206bp Mouse 
Zfp36_12F1/Zfp36_12R1 GAACTTGCGATCCTCCAGTC 
TCCCTACCTCGATACGCAAC 
>chr7:29165851+29166047 197bp Mouse 
Zfp36_13F1/Zfp36_13R1 CATGCAAAATGTGCCTGAAC 
CCTCAGTCTCTGCCCTTGTC 
>chr7:29164406+29164607 202bp Mouse 
Zfp36_14F1/Zfp36_14R1 CAAACTCCAGGGAGAACCTG 
GGAGTCCTAGAGGCCCAAAG 
>chr7:29163644+29163802 159bp Mouse 
Zfp36_15F1/Zfp36_15R1 GTGGCAGAGTTCCGTTTTGT 
CTGAGCTGTCACCCTCACCT 
>chr7:29163117+29163307 191bp Mouse 
Zfp36_16F1/Zfp36_16R1 CTCTATCAAGTCCGCCCAAG 
GTAAGGGGTGCTCTGGTCCT 
>chr7:29161385+29161611 227bp Mouse 
Zfp36_17F1/Zfp36_17R1 TGGCTTTGGCTATTTGCTTT 
CCCTCTGCAACTCTGGTCTC 
>chr7:29162039+29162204 166bp Mouse 
Zfp36_18F1/Zfp36_18R1 TTGTGGAAGAGACCCGATTC 
CTTGGGCGGACTTGATAGAG 
>chr7:29161230+29161404 175bp Mouse 
Zfp36_19F1/Zfp36_19R1 TCGCGTCCTTTTTCCTTGTA 
GATATGAACCCTCCCGGTTT 
>chr7:29160789+29161033 245bp Mouse 
Zfp36_20F1/Zfp36_20R1 AGCCCCCGAGAGACTTTTTA 
TGGGTGAGGGAAACAAACTC 
>chr7:29160213+29160373 161bp Mouse 
Zfp36_21F1/Zfp36_21R1 GCTAGACCAGGGTTTTGCAG 
GCCAGACTGAGTTCCAGGAC 
>chr7:29159754+29159972 219bp Mouse 
Zfp36_22F1/Zfp36_22R1 GTGGAGCAGGTGAGAAGAGG 
TCATCGAAAGCCCACCTTAC 
>chr7:29159169+29159332 164bp Mouse 
Zfp36_23F1/Zfp36_23R1 CCCAGACTGGCCTAAACTCC 
GGCCAAACACCCATACACAT 
>chr7:29158739+29158895 157bp Mouse 
Zfp36_25F1/Zfp36_25R1 TCAATCAAATGTTTTGGCTTGT 
CCAGTACTAGGGAGGCAGAGG 
>chr7:29158186+29158335 150bp Mouse 
hZFP36_1F1/hZFP36_1R1 GCCTTCTCACAGGAAACTGG 
GTCATGTGTACCCGGTTGTG 
>chr19:39893046+39893195 149bp Human 
hZFP36_2F1/hZFP36_2R1 CGTCATTCCAGAGGGGATT 
TCGATCAGATCCAGGAGACC 
>chr19:39893554+39893712 158bp Human 
hZFP36_3F1/hZFP36_3R1 CAGCAGATGGGAGAGAGGAG 
CGCAGCTTAAAGGATTGAGG 
>chr19:39894260+39894439 179bp Human 
hZFP36_4F1/hZFP36_4R1 GCAGCCTGCAAGAATGAACT 
ATCAAAGGGTCGCCCTAAGT 
>chr19:39894807+39894964 157bp Human 
hZFP36_5F1/hZFP36_5R1 CAGCTTGGTGATTTGGAGGT  
CTGAGACTTCAGCCCCAGAG 
>chr19:39897732+39897942 210bp Human 
hZFP36_6F1/hZFP36_6R1 ATATCCGGGGAGGACAAGAG  
AGGAACCCAGAGTTGGAGGT 
>chr19:39898081+39898238 157bp Human 
hZFP36_7F1/hZFP36_7R1 CGCGGTCTAGAGACAGGAAT  
TCTGGTGACCTCACCTGGTC 
>chr19:39900067+39900227 160bp Human 
hZFP36_8F1/hZFP36_8R1 CGCGTCTTCAGACCATACAA  
GGTGAGGGTAGGGAAAGGAG 
>chr19:39900769+39900967 198bp Human 
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2.1.5 Solutions 
2.1.5.1 General buffers 
Phosphate buffered saline (PBS) 4.3 mM Na2HPO4 
     1.4 mM KH2CO3 
     1.4 mM KCl 
     137 mM NaCl 
     pH 7.2 
 
Tris buffered saline (TBS)  20 mM 
     137 mM NaCl 
     pH 8.0 
 
Triton lysis buffer   1% (v/v) Triton X100 
10 mM Tris HCl pH 7.6 
150 mM NaCl 
1 mM EDTA 
0.1 mM Na3VO4 
5 mM NaF 
1 x protease inhibitor cocktail 
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 Western blotting reagents 
 
Lysis buffer (protein) 
SDS-PAGE running buffer   25 mM Tris-base 
192 mM Glycine 
0.1% (w/v) SDS 
 
5 X protein gel sample buffer  250 mM Tris HCL pH 8 
(laemmli buffer)   10% (w/v) SDS 
50% (v/v) Glycerol 
12.5% (v/v) β-mercaptoethanol 
 
Blocking buffer    TBS/Tween-20 (0.1%) 
5% (w/v) Marvel skimmed milk powder 
 
 
      86
2.1.5.3 ELISA reagents  
2.1.5.4 ChIP solutions 
 
Lysis buffer 1 (LB 1)   50 mM Hepes-KOH pH 7.5 
 - Cell membrane lysis   140 mM NaCl 
     1 mM EDTA 
50% Glycerol 
10% NP40* 
10% Triton X-100* 
ddH20 
 
Lysis buffer 2 (LB2)   10 mM Tris HCL pH 8 
- Detergent removal   200 mM NaCl 
     1 mM EDTA  
     0.5 mM EGTA 
     ddH2O 
 
Lysis buffer 3 (LB3)   10 mM Tris HCL pH8 
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-Nucleic disruption   100 mM NaCl 
     1 mM EDTA 
     0.5 mM EGTA 
     0.1% Na-deoxycholate*  
     0.5% N-Lauroylsarcosine* 
ddH2O 
 
RIPA buffer    50 mM Hepes-KOH pH 7.6 
     500 mM LiCl 
     1 mM EDTA 
     1% NP40* 
     10% N-Deoxycholate*  
ddH2O 
*add after autoclave 
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2.1.6 Molecular Biology Reagents 
2.1.6.1 Molecular biology solutions 
Lennox L broth base (LB)    20g LB, Invitrogen Paisley UK 
1L dH2O 
(Autoclave before use) 
 
Lennox L agar     32g LB agar, Invitrogen Paisley UK 
1L dH2O 
(Autoclave and add antibiotics once cool before 
pouring plates) 
 
Ampicillin       100mg/ml, Sigma Poole UK 
 
Kanamycin      50mg/ml 
 
DNA Hyperladders     5μl loaded per lane Bioline London UK 
 
Ethidium Bromide     Final concentration 0.1μg/ml 
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2.1.6.2 Bacterial strains 
One Shot® TOP10 Chemically Competent E. coli  
Genotype: DH5α; F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK–, mK+) 
phoA supE44 λ– thi-1 gyrA96 relA1  
 
2.1.6.3 Cloning and reporter vectors 
The vectors used in this study, for the cloning of Zfp36 enhancer sequences and luciferase 
reporter construction are listed in table 2.10 
Table 2.8 Vectors 
Vector Application Antibiotic resistance Details 
pCR®-Blunt 
(Invitrogen) 
Cloning Kanamycin Blunt end ligation 
pGL3-P  
(Promega) 
Luciferase reporter Ampicillin Luc+ SV40 minP 
pGL4.1 
(Promega) 
Luciferase reporter Ampicillin Luc2 no promoter 
pGL4.28 
(Promega) 
Luciferase reporter Ampicillin Luc2CP minP Hygro 
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2.1.7 Cell Culture Reagents 
2.1.7.1 Cell lines 
The cell lines used in this study are described briefly in Table 2.10 
Table 2.9 Cell lines 
Cell line Species Details Application 
RAW264.7 Mouse leukaemic  
macrophage-like 
Endogenous mRNA/ 
protein expression; 
reporter assays; 
ChIP. 
HeLa Human Henrietta Lacks  
epithelial carcinoma 
Endogenous mRNA/ 
protein expression; 
reporter assays. 
A549 Human Lung adenocarcinoma Endogenous mRNA/ 
protein expression. 
293/TLR4-MD2-CD14 Human Fibroblast Zfp36 mini gene 
reporter assay. 
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2.1.7.2 Media and supplements 
Media and supplements were sourced from Sigma (Dorset, UK) Including: Dulbecco’s 
modified Eagle’s medium (DMEM) (with L-glutamine and L-glucose); Roswell park memorial 
institute (RPMI) 1640 culture medium; heat inactivated foetal calf serum (HIFCS); penicillin 
(100U/ml)/ streptomycin (100ug/ml) mixture; trypsin-EDTA; and cell dissociation solution. 
Optimem-1 with glutamax was obtained from Invitrogen (Paisley, UK). 
Cell culture was performed using Corning/ Falcon plastic and disposable scrapers were 
purchased from Greiner BioOne Stonehouse UK. 
 
2.1.8 Western blot reagents 
SDS-PAGE and western blot procedures were carried out using the Bio-Rad Trans-Blot® 
Turbo™ Transfer System and therefore Mini-PROTEAN® Precast Gels and Trans-Blot® 
Turbo™ PVDF Transfer Packs were also purchased from Bio-Rad. 
A full-range molecular weight rainbow marker from Amersham Biosciences (UK) and 10 x 
SDS-PAGE running buffer, acquired from ** were used for electrophoresis. 
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2.2 Methods 
 
2.2.1 Tissue Culture 
All cell cultures were maintained at 37˚C; 5% CO2; and 95% humidity. 
 
2.2.1.1 Maintenance of cell lines 
All cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing 
2mM L-glutamine and 4.5g/L L-glucose and supplemented with 10% heat inactivated Foetal 
calf serum (FCS). Blasticidin and ** were also added to the medium for culture of HEK-293 
cells. Being adhesive cell lines, RAW264.7 cells were detached by scraping whereas HeLa 
and A549 cell lines were lifted by trypsin-EDTA incubation for 10 min at 37°C. Cells were 
passaged at 80% confluency and used for experiments until passage 15-20. 
Cryopreservation of cell lines was in a solution of 10% dimethylsuphoxide (DMSO) and 
HIFCS. Freezing serum/cell aliquots were frozen initially to -70˚C before being transferred to 
liquid nitrogen for storage at -198˚C. For cell thawing, a 37°C water-bath was used and the 
DMSO removed by washing with the appropriate culture media before seeding the cells at 
high density in medium sized flasks for overnight recovery. 
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2.2.1.2 Isolation of bone marrow derived macrophages BMDMs 
Generated from mammalian bone marrow, BMDM are commonly used in immunology 
research. Following extraction, day 1 undifferentiated bone monocytes are cultured in 
lineage specific growth factor for 3 to 5 days.  
Murine primary macrophages were isolated from the bone marrow of the femur and tibia. 
Severed mouse legs were sterilised with ethanol and all of the skin and tissue removed by 
scalpel. The bone must be cleaned carefully without breaking or scratching to avoid 
contamination of the marrow. The meniscuses were removed and the ends of the bones 
cut, to expose the marrow. The cut bones were then placed in 150µl tubes pierced at the 
bottom, within 1.5ml microcentrifuge tubes and centrifuged at 5000g for 4 minutes. The 
bone marrow collected was then resuspended in, per mouse, 50 ml of RPMI; 10% HIFCS; 1% 
Pen/Strep and 100ng/ml of M-CSF and seeded onto 5 X 10cm tissue culture dishes. 
Inoculation of the culture media with M-CSF directs an M2-macrophage differentiation. 
After 5 days the macrophages were mature and adherent and ready to seed for 
experimentation. For removal, cells were lifted by dissociation solution, scraped, washed 
and reseeded at an appropriate density in RPMI containing 5%HIFCS and 1%Pen/Strep. 
2.2.1.3 Isolation and separation of peripheral blood monocytes (PBMCs) 
Human monocyte derived macrophages represent a human model for studying 
immunological signalling pathways. Furthermore, medium supplementation with either GM-
CSF or M-CSF allows isolation of M1 or M2 macrophage populations, respectively. 
PBMCs were isolated from single donor plateletpheresis residues. The heparinised residues 
were diluted with an equal volume of HBSS media and layered over an equal volume of 
Ficoll-Hypaque lymphoprep in sterile 50ml tubes and centrifuged at 3500 g for 20 minutes, 
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with no brake. After centrifugation the PBMC-containing interface layer was isolated, 
washed 3 X in HBSS and resuspended in 20 ml 10% HIFCS/RPMI media. 20 X 106 cells/ml 
were layered on an equal volume of Percoll solution before centrifugation at 400 g from 30 
minutes minimum acceleration and no brake. The monocyte-fraction or interphase was 
collected, washed by centrifugation at 3000 g for 5 minutes, resuspended in RPMI and 
plated at a density of 20 x 106 per 10cm tissue culture dish. Cells were left to adhere for 1 
hour contaminating cells remain in suspension and were removed by washing. RPMI media 
was replaced with 5%HIFCS, 1%Pen/Strap and 50ng/ml of GM-CSF or 100ng/ml M-CSF to 
direct M1- or M2- type macrophage differentiation respectively. Cells were left to 
differentiate for 3 to 5 days. Once mature, cells were then washed, gently lifted with cell 
dissociation solution, scraped and resuspended in appropriate media for experimentation. 
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2.2.2 Molecular biology methods 
2.2.2.1 Preparation of total RNA from cells 
Total RNA was extracted from primary cells and cell lines alike using the Qiagen RNeasy 
extraction kit. Briefly, 1x106 cells were placed on ice and washed with PBS, lysed in the 
provided buffer containing 10µg/ml β-mercaptoethanol and further homogenised using 
shredder columns, also provided by Qiagen UK.  
Homogenised lysates were then applied to a second column to which the total RNA bound 
and impurities washed away. Total RNA was on-column DNase treated before elution in 
RNase free dH2O and stored at -80˚C. The quantity and quality of RNA was measured using 
a nanodrop. 
2.2.2.2 Reverse transcription of total RNA to cDNA 
Reverse transcription of total RNA was performed at 25˚C for 5 minutes followed by 42˚C for 
30 minutes and 5 minutes at 85˚C. The iScript™ cDNA Synthesis Kit was purchased from Bio-
Rad UK. The 5μl total reaction mixture was as follows: 
RNA template (100fg - 1μg)   2.5μl 
iScript reverse transcriptase   0.25μl 
5X iScript reaction mix  1μl 
Nuclease-free water    1.25μl 
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2.2.2.3 Real-time PCR 
Quantitative PCR (qPCR) is a method of quantifying gene expression at the mRNA level by 
measuring the incorporation of a TaqMan fluorogenic probe or SYBR green-fluorescent dye. 
As the fluorescence intercalates with dsDNA during amplification a signal, directly 
proportional to the amount of DNA, is produced and detected using the qPCR instrument. 
The threshold cycle (Ct) is the term used for the number of PCR cycles necessary for the 
fluorescence associated with the reaction to be greater than baseline. All readings are 
normalised to a housekeeping gene, like GAPDH that is constitutively expressed, unrelated 
to the gene(s) of interest and not altered by any conditions of the experiment. The method 
for calculating relative abundances are described in figure 2.1  
TaqMan probes were used alongside LightCycler® 480 Probes Master whilst customised 
oligonucleotides were combined with Takara SYBR®Premix Ex Taq™ in the following 
reactions: 
Table 2.10 Real-time PCR reaction components 
Reaction component LightCycler® 480 Probes 
Master 
Takara SYBR®Premix Ex 
Taq™ 
cDNA 2.5µl 2.4 µl 
Master mix (5 X) 2µl (2 X) 3µl 
Probe 0.01µl - 
Forward primer - 0.1µl 
Reverse primer - 0.1µl 
H2O 5.49µl 0.4µl 
Total                      10µl             6µl  
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Figure 2.1 The Ct comparative method for Real-Time PCR 
Above is a schematic of the typical Real-Time PCR profile. The calculation for measuring the 
relative amount of DNA is referred to as the comparative Ct, or ∆∆Ct method. The ∆Ct is the 
difference between the average threshold cycles for the housekeeping gene and the gene of 
interest. Whereas, ∆∆Ct provides an arbitrary constant to which other values from the test-
group are normalised.  
    ∆∆Ct = ∆Ct sample - ∆Ct reference 
The ∆Ct sample refers to, for example an unstimulated, control (F in the schematic) value 
normalised to the housekeeping gene whereas ∆Ct reference corresponds to the value of a 
treated sample (E) being measured: 
F - C = ∆CtF  
E – B = ∆CtE      
In order to ascertain the fold difference between sample mRNA contents the 2-∆∆Ct value is 
used. The target can thus be normalised to the endogenous reference and to a relative 
calibrator included in the experiment, usually an un-stimulated control, for which the 2-∆∆Ct 
value equals 1: 
∆CtD - ∆CtD = ∆∆CtD    2
-∆∆CtD = 1 
∆CtE - ∆CtD = ∆∆CtE    2
-∆∆CtE = x 
∆CtF - ∆CtD = ∆∆CtF    2
-∆∆CtF = y 
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2.2.2.4 Real-time primary transcript PCR 
Transcriptional effects on genes can be measured by comparing the populations of primary 
and mature transcript at a given time. By designing oligonucleotide primers across the 
intron-exon boundary of a gene such as Zfp36 or Tnfα, the level of primary transcript i.e. 
unspliced and unprocessed mRNA, can be measured. 
Bone marrow derived murine macrophages were plated at a density of 1x 106 cells/ml. RNA 
was extracted from the cells,  purified and DNase treated as described in section 2.2.2.1. 
Complementary DNA was synthesised from RNA as in section 2.2.2.2, including a control 
reaction for each sample that included all of the same components except the reverse 
transcriptase. Primary transcript directed oligonucleotides are designed such that they will 
also amplify trace amounts of contaminating genomic DNA. Thus by excluding the reverse 
transcriptase from the cDNA synthesis reaction, one can control for any interfering genomic 
DNA contamination. 
To make a valid comparison, real-time PCR of the respective mature mRNA transcript was 
measured simultaneously. As is standard, PCR of a housekeeping gene was also 
simultaneously carried out and all samples were measured in triplicate.  
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2.2.2.5 Polymerase chain reaction 
Targeted amplification of DNA by PCR was performed using Thermus aquaticus (Taq) DNA 
polymerase and made-to order oligonucleotides described in Table 2.6, unless otherwise 
stated. Generally, a total reaction volume of 50µl was combined of the following: 
 DNA template    0.5μg 
10 X PCR buffer    5μl 
MgSO4 (20 mM)    1.5μl 
dNTPs (1mM)     1μl 
Forward primer (100 pmol/μl)  1μl 
Reverse primer (100 pmol/μl)  1μl 
Taq DNA polymerase    0.5μl 
dH2O      x μl (make up to volume) 
 
Typically, the thermocycler lid temperature was set to 95˚C to prevent sample-lid 
condensation. Initial denaturation at 95˚C for 5 minutes proceeded 30 cycles of: 
denaturation at 95˚C for 30 seconds; 1 minute annealing at 55˚C; and 1 minute at 72˚C for 
elongation. The final 10 minute elongation step was performed at 72˚C before an infinite 
hold at 4˚C. 
PCR products were resolved by agarose gel electrophoresis. Using 1 x Tris-borate EDTA (TBE) 
and agarose from *Ambion gels were made up to the appropriate percentage for the 
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fragment sizes to be analysed Table 2.11. Products used for cloning were mixed with 10% 
(v/v) SYBR Green in addition to 10% (v/v) DNA loading buffer before loading. After 
electrophoresis (approximately 120V for 45 minutes), a dark reader transilluminator was 
used to visualise the DNA fragments. 
Table 2.11 Recommended % agarose for optimum resolution of linear DNA 
fragments 
Fragment size % (w/v) Agarose/ TBE 
1000 – 30,000 bp 0.5 % 
800 – 12,000 bp 0.7 % 
500 – 10,000 bp 1.0 % 
400 – 7,000 bp 1.2 % 
200 – 3,000 bp 1.5 % 
50 – 2,000 bp 2.0 % 
 
2.2.2.6 DNA fragment purification from a preparative agarose gel 
Fragments of DNA separated by electrophoresis were retrieved by extraction from the 
preparative gel, using Qiagen gel extraction kit, according to manufacturer’s instructions. 
The fragment of interest was cut from the gel using a scalpel, weighed and three volumes of 
buffer QG added before incubation at 55°C to dissolve the gel completely. The resulting 
yellow solution was then applied to a QIAquick spin column and spun for 30 seconds at 
10,000 g, this step was repeated for any remaining gel-mix and the flow-through discarded 
each time. An additional 500µl of buffer QG was added and the column spun, again for 30 
seconds at 10,000 g. The columns were then washed with 750µl of buffer PE and 
centrifuged. To remove any residual ethanol, columns were placed in new collection tubes 
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and spun for 2 minutes at 18000 g. DNA was recovered by addition of 30µl of elution buffer 
and centrifugation for 2 minutes at 10,000 g. DNA was stored at 4°C until use. An analytical 
gel was used to verify the product size. 
2.2.2.7 Restriction endonuclease digestion of DNA 
The restriction enzymes and corresponding buffers used in this study were obtained from 
New England Biolabs, Hitchin UK or Promega Madison USA. Enzymes were, generally, used 
in a 20μl reaction volume with the following components: 
DNA    2μg 
NEB 10 X buffer  2μl 
BSA    2mg 
Enzyme   1µl 
H2O    x µl (make up to volume) 
The reaction was incubated at 37°C for a standard time of 3 hours, unless otherwise 
specified by the manufacturer’s instructions. Restriction fragments were resolved for 
cloning or analysis by preparative or analytical agarose gel electrophoresis respectively. 
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2.2.2.8 De-phosphorylation of DNA ends 
Once linearised by the appropriate restriction endonuclease(s), dephosphorylation of DNA 
termini is necessary to prevent vector recircularisation in the absence of insert. Shrimp 
alkaline phosphatase (SAP) was purchased from promega, Madison USA, and the reaction 
set up as follows: 
DNA    2µg 
SAP    2µl 
10 X SAP buffer  1µl 
H2O    x µl (make up to 20µl volume) 
The reaction was incubated at 37°C for up to 30 min and heat inactivated at 65°C for a 
further 15 min. DNA was generally purified after SAP treatment using the Qiagen Gel and 
PCR clean up system.  
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2.2.2.9 Polishing of cohesive DNA termini 
Pyrococcus furiosis (Pfu) polymerase calalyses the incorporation of free nucleotides onto 
ssDNA in a 3’ to 5’ direction (polymerase activity) and exhibits a 3’ to 5’ exonuclease activity. 
DNA 5’ overhangs are therefore filled in while 3’ overhangs are polished (care must be taken 
when cloning fragments in frame); the outcome of both is blunt ended DNA fragments. The 
enzyme and buffers were purchased from Promega (Madison USA) while the dNTP’s were 
from Invitrogen (USA). The reaction below was incubated at 72°C for 30 min and placed on 
ice: 
DNA    20µl 
10 X buffer  5µl 
10 mM dNTP  4µl 
Pfu polymerase 4µl 
dH2O   21µl 
 
2.2.2.10 Precipitation of DNA using sodium acetate and ethanol 
3 volumes of ice-cols 100% ethanol and ¼ volume of 3M sodium acetate pH 5.2 was added 
to the solution of DNA. The sample was kept on ice or at -20°C for 1 hour and then 
centrifuged at 18, 000 g for 1 minutes and the supernatant was aspirated, taking care not to 
dislodge the fragile DNA pellet. The pellet was washed with 500µl of 70% ice-cold ethanol, 
dried and resuspended in either dH2O or the required buffer. 
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2.2.2.11 Ligation of DNA 
Ligation of DNA termini was carried out at 16°C overnight, in the following reaction: 
Insert DNA   2µl 
Vector DNA   1 µl 
10 x T4 DNA ligase buffer 1µl 
T4 DNA ligase   1µl 
H2O    5µl 
 
In addition, reactions containing either vector or insert DNA alone were carried out to 
control for contamination by circularised DNA plasmid DNA that can cause high background 
levels of colonies on transformation plates. The T4 DNA ligase and accompanying buffer 
were purchased from New England Biolabs (Hitchin UK). 
2.2.2.12 Transformation of chemically competent E.Coli 
One Shot® TOP10 Chemically Competent E. coli were purchased from Invitrogen (USA). For 
transformation, 1-4µl of ligation product was added to a 50µl aliquot of chemically 
competent bacteria. The mixture was incubated on ice for 30 minutes before heat shock at 
42°C for 45 seconds and transferred immediately back onto ice for 2 minutes. Cells were 
then incubated for 30 minutes at 37°C in 500µl of SOC medium, to allow recovery and the 
expression of antibiotic resistance. Pre-dried and warmed LB agar plates containing the 
appropriate antibiotic were inoculated with 200µl of transformation product, inverted and 
stored overnight at 37°C. Colonies were picked for LB suspension culture the next day. 
      105
2.2.2.13 Miniprep isolation of plasmid DNA from E.Coli 
Purification of DNA from transformed plates was performed using kits from Qiagen. The 
technique is performed on columns with a silica matrix and uses approximately 1.5ml of LB 
broth culture. The technique is based on the alkaline lysis method of plasmid DNA 
purification. Plasmid DNA was eluted in 50µl of dH2O and yielded approximately 0.2µg/µl of 
DNA.  
2.2.2.14 Maxiprep isolation of plasmid DNA from E.Coli 
Purification of endotoxin free DNA from 100ml LB broth bacteria cultures was performed 
using kits purchased from Qiagen. The procedure is scaled up method based on the 
miniprep procedure. The kit contains a buffer used for the removal of bacterial endotoxin. 
The preparation yielded approximately 0.6 – 1.0 µg/µl plasmid DNA. 
2.2.2.15 Preparation of bacterial glycerol stocks 
To prepare glycerol stocks, 20ml of LB bacterial culture was centrifuged at 3000 g for 10 
min, most of the media was removed, leaving 2ml on the pellet. The bacteria were 
resuspended in the remaining media and split between two cryovials, each containing 0.5ml 
glycerol. The bacterial/glycerol cultures were mixed thoroughly and snap frozen in liquid 
nitrogen and stored at -70°C. 
To grow bacteria from stocks, the glycerol was partly defrosted on dry ice. The defrosted 
top layer was scraped off and mixed with 200µl of LB and incubated over-night on a plate 
containing the appropriate antibiotic. Small/large scale preparation was carried out, as 
required. 
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2.2.3 Cloning of Zfp36 ECR luciferase reporters 
The evolutionary conserved regions (ECRs) for luciferase reporter constructs were amplified 
by PCR from human and murine template DNA (Promega) using the primers detailed in 
Table 2.6. An XhoI site was designed into both the forward and reverse primers as part of 
the cloning strategy. The PCR product was cloned into the pCR™-Blunt vector purchased 
from Invitrogen. 
Following miniprep purification (2.2.2.14), double restriction digests were carried out to 
identify positive clones and ensure the correct orientation of inserts. Maxipreps were 
prepared (2.2.2.15) for the appropriate clones. Zfp36 fragments were recovered from pCR®-
Blunt via restriction enzyme digestion (2.2.2.6) with XhoI and confirmed by agarose gel 
electrophoresis and sequencing. Inserts were subcloned, via XhoI into Luciferase containing 
minimal-promoter vectors, pgl3P and pGL4 (Promega) upstream of the reporter sequence.  
2.2.4 Zfp36 mimic gene construction 
The Zfp36 mimic gene, Zfp-Luc was generated as follows. Upstream (Chr) and downstream 
(Chr) sequences were amplified from murine genomic DNA using primers described in table 
2.6. In addition the Luc2CP secuence for replacement of the Zfp36 Exon II was amplified 
from the pGL4.28 vector purchased from Promega, using the primers detailed in table 2.6. 
The endogenous first exon of Zfp36 was replaced with an 18bp luc2cp sequence derived 
from directly upstream of the luc2cp region amplified from pGL4.28 in house. The last two 
base pairs in the ‘synthetic’ luc2cp were complementary to the first of the ‘amplified’ luc2cp 
and formed a splice-able motif. Firstly, the endogenous upstream (US) region of Zfp36 was 
cloned into the PEX-lucZfp36 containing vector. In the next step, the PEX-Zfp36US-lucZfp36 
containing vector was ligated to the luc2cp fragment amplified from pGL4.28 to produce 
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PEX-Zfp36US-lucZfp36-Luc. Finally, the endogenous downstream (DS) region of Zfp36 was 
ligated as appropriate to form the final mimic gene PEX-Zfp36US-lucZfp36-Luc-Zfp36DS or 
“Zfp-luc”. 
 
2.2.4 Transient transfection of immortal cell lines 
Transfection is the process of delivering nucleic acids into eukaryotic cells by non-viral 
methods and is used to study gene function and protein expression in the context of a cell. 
Transfection was used in this study to transiently introduce reporter constructs to cell lines 
for Zfp36 promoter analysis.  
The transfection protocol specifics for each cell type/ reagent used are outlined in Table 
2.12. Generally, cells were seeded in 6 well plates, as appropriate to achieve 40-60% 
confluency the next day.  
Table 2.12 Transfection of immortal cell lines 
Cell type Cell density Reagent Incubation 
RAW264.7 1.5 X 106/ 3ml FuGene 5-10 min RT 
HeLa 2 X 105/ 3ml Superfect 10-15 min 4°C 
HEK 5 X 105/ 3ml FuGene 5-10 min RT 
 
The transfection mixtures were made up as detailed below in Table 2.13 and incubated 
according to the provided instructions, allowing DNA complexes to form. 
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Table 2.13 Transfection mixture components (per well of a 6 well plate) 
 FuGene Superfect 
DNA 3µg 1µg 
Transfection reagent 11µl 5µl 
Serum free media x µl (make up to volume) x µl (make up to volume) 
Total      150µl     105µl 
Superfect transfection reagent requires that cells be washed twice in PBS and 500µl of 
serum free media (SFM) replaced before treatment with 105µl of transfection mix per well. 
The FuGene transfection mix is sufficient to transfect cells in 3ml of complete media and 
thus 150µl can be added straight to the well. Transfection was carried out for 3 hours under 
general tissue culture conditions. After transfection, cells washed with warm PBS, 
supplemented with 3ml complete media and left to recover for 24 hours before 
experimentation. 
2.2.5 Primary cell transfection of RelA siRNA 
Human primary macrophages were derived from plateletpheresis residues by culturing the 
cells with macrophage-colony stimulating factor as described in 2.2.1.3. Human primary 
macrophages were plated in 10cm plates (1010 cells per plate) in RPMI 1640 for 24 hours 
and transfected for 48 hours with siRNA (Thermo Fisher Scientific) targeted to RelA (200 
nM) or a double stranded non-targeting siRNA control using Dharmafect 1 as a transfection 
reagent in OPTIMEM medium. 
2.2.6 Luciferase reporter assay 
The Dual-Luciferase® Reporter Assay System (Promega) was used to quantify reporter 
luminescence. Following treatment, cells were washed with PBS and harvested with 200µl 
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of passive lysis buffer (Promega), scraped and transferred to 1.5ml microcentrifuge tubes. 
Cells were subjected to active lysis by incubation on dry ice and 2 X freeze thaw cycles. 
Lysates were centrifuged for 1 min at 18,000 g at 4°C and 20µl of each cleared lysate loaded 
onto an opaque 96-well luminometer plate (Costar). Luciferase Assay Reagent II was added 
to each sample and the Firefly luminescence measured. Once quantified, this reaction was 
quenched and the Renilla luciferase reaction initiated simultaneously by addition of Stop & 
Glo® Reagent. 
 
2.2.7 Sodium dodecyl sulphate poly acrylamide gel electrophoresis (SDS-PAGE) 
SDS page allows separation of proteins by their individual molecular weights. SDS is an 
amphipathis molecule that coats the denatured protein in a uniform charge; thus negating 
the individual charges that would alter the electrophoretic mobility of the proteins. 
For protein isolation, 1x106 cells/ml were treated with 60-70µl ice-cold protein lysis buffer 
containing, as appropriate phosphatase/ protease inhibitors and incubated on ice for 10 
min. Cells were harvested by scraping and transferred to a cold shredder column (Qiagen) 
for homogenisation by centrifuge; 5 minutes, 18000 g at 4°C. At this stage a protein assay 
(Bio-Rad) was performed to ensure an equal amount of protein is loaded for each sample. 
Protein extracts were then mixed with an appropriate volume of 5 x SDS-PAGE sample 
buffer and boiled for 5 min at 95°C to denature the proteins. Proteins were then loaded on 
pre-cast gels purchased from Bio-Rad and run alongside a full-range molecular weight 
rainbow marker at approximately 120V for 90 min. 
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2.2.8 Western blotting 
Proteins separated by SDS-PAGE may be transferred from gel to a membrane which allows 
for protein identification by antibodies. The antibodies used for western blotting are 
described in Table 2.1.  
2.2.8.1 Protein transfer 
Pre-assembled polyvinylidene difluoride (PVDF) membranes were bought from Bio-Rad. 
Assembled in the Trans-blot turbo system-cassette, the gel was placed directly onto the 
activated PVDF membrane, between the bottom and top layers of the transfer membrane 
sandwich. The complete cassette was then transferred to the Trans-blot Turbo and a voltage 
of 150mV applied for 7 minutes. 
2.2.8.2 Immunoblotting 
The membrane was blocked in 5% (w/v) dried milk powder in TBS/0.2% Tween-20 for 1 
hour. The primary antibody was diluted as appropriate (Table 2.1) in blocking solution and 
applied to the membrane overnight at 4°C. After washing, the membrane was incubated 
with secondary-HRP conjugated antibody for 1 hour prior to addition of the detection 
reagent, ECL (chemiluminescent substrate). The membrane blots were then visualised on 
the chemidoc. For re-probing with a different antibody, membranes were treated with 
stripping buffer (Bio-Rad), washed in TBS/0.2% Tween-20 and the immunoblotting 
procedure repeated. 
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2.2.9 Enzyme linked immunosorbent assay (ELISA)  
The concentration of cytokines was measured by sandwich ELISA. All of the ELISA kits were 
purchased from BD biosciences (San Diego CA). ELISA plates were obtained from Nunc 
(Roskilde Denmark). Between each step, plates were washed three times with 1 x PBS 
Tween (0.01%) wash buffer. The capture antibody was diluted in assay diluent and 50µl 
used to coat each well of the 96 well plate and left over night at 4°C. The wells were washed 
and blocked in 100µl of diluent for 1 hour at room temperature. After washing, 50µl of 
appropriately diluted sample(s) was added to the plate, alongside a serial dilution of 
recombinant protein standards and incubated at room temperature from 2 hours. The plate 
was washed and 50µl of appropriate secondary biotinylated antibody was diluted, added to 
the wells and incubated for 1 hour. 100µl of strepavidin-HRP conjugate was added to the 
washed wells and after a further incubation for 1 hour the samples were developed using 
the TMB peroxidase substrate systems. TMB peroxidase substrate and peroxidase substrate 
solution were purchased from KPL Inc. (Maryland USA). The reaction was stopped with 
H2SO4 and the absorbance read at 450nm. 
 
2.2.10 Chromatin Immunoprecipitation 
Chromatin immunoprecipitation is a powerful genomics tool that allows the analysis of 
interactions between endogenous transcription factors and their promoters. The cells are 
subjected to formaldehyde crosslinking to freeze DNA and protein interactions in place, 
therefore taking a ‘snapshot’ of the genome-associated chromatin representing the 
conditions of the experiment. The nuclei are then isolated and sonicated to allow shearing 
of the chromatin, fragmenting the genome into small sequences of ~500 bp. The DNA 
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binding protein of interest is then immunopricipitated with specific antibodies and the 
associated DNA bound. After several washing procedures, the immune complexes are 
eluted and reverse crosslinked using heat. The DNA may then be purified and subject to 
real-time PCR using primers directed at various positions to assess the extent of protein 
recruitment. Antibodies used here are described in Table 2.3 and primers used for real-time 
PCE analysis are detailed in Table 2.7 Figure 2.3 is a schematic of the ChIP procedure. 
2.2.10.1 Preparation of nuclear extracts 
Primary cell cultures were seeded at a density of 10x106 cells/ml whereas cell lines were 
seeded at 7x106 cells/ml in 10cm tissue culture dishes and treated the following day, as 
appropriate. Cells were crosslinked with 1% (final concentration) formaldehyde for 10 
minutes at room temperature. Fixed cells were then quenched with 125Mm (final 
concentration) Tris pH 7.5 and washed with ice-cold PBS. An additional three washes with 
ice-cold PBE removed formaldehyde. Cells were detached from the plate by scraping into 
PBS containing protease inhibitor cocktail (Roche), transferred to 1.5ml Eppendorf 
(Cambridge UK) Lobind tubes and recovered by centrifugation; 5 000 g for 5 minutes at 4°C. 
Once recovered and the supernatant discarded, pellets were resuspended in cell membrane 
lysis buffer 1 (LB1) and incubated on ice for 10 minutes before 2 min centrifugation at 5000 
g. Cell detergents were removed and nuclei recovered by incubation with lysis buffer 2 (LB2) 
for 10 minutes at room temperature and subsequent centrifugation for 2 min at 5000 g. 
Pellets were resuspended in nuclear lysis buffer 3 (LB3). 
2.2.10.2 Sonication 
Isolated chromatin was sonicated using conditions optimised for each cell type (6 x 12 sec or 
8 x 12 sec for primary macrophages or RAW 254.7 respectively at 20% amplitude). To ensure 
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that DNA was sheared to a suitable size, a 50µl aliquot was removed from each sample and 
analysed for electrophoresis as a standard practice, for quality control. The sonicate was 
reverse crosslinked at 65°C overnight and the DNA precipitated by phenol chloroform 
extraction and ethanol precipitation. The samples were resuspended in 30µl of H2O, 10µl of 
which was loaded into a 1% agarose gel and run at 120v until sufficiently resolved to 
ascertain the DNA fragment size. The desired fragmentation was 200-500 base pairs; if 
concurrent, 10% triton was added to samples for storage at -80°C before 
immunoprecipitation. 
2.2.10.3 Immunoprecipitation 
Immunoprecipitation was carried out at 4°C, using magnetic capture by Dynabeads® Protein 
G (Invitrogen). Beads were washed 3 X in freshly made ice-cold, block solution (1 X PBS with 
0.5% BSA, filtered). The appropriate antibody and isotype control were diluted as 
appropriate (Table 2.3) in the blocking solution and left rotating overnight at 4°C. Antibody 
removed and beads washed with blocking buffer, 100µl of lysate and 400µl of block were 
added to the beads and incubated overnight at 4°C. 
Samples were spun at 18, 000 g for 1 minute, captured and 200µl of supernatant was kept 
for input DNA. The remaining magnetic bead-associated Immunoprecipitate was 
subsequently washed 5x 3 minutes in RIPA buffer plus protease inhibitor, followed by one 
wash in 1ml TE + 50mM NaCl. Beads were spun at 3000 g for 3 minutes and resuspended, 
gently, in 200µl of elution buffer (2% SDS in TE) then left at 65°C for 15 minutes, 
resuspending every 2 minutes. After spinning down and application to the magnetic bead 
separator, the elute was transferred to new tubes and reverse cross-linked over-night at 
65°C. 
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2.2.10.4 DNA purification 
Immunoprecipitated complexes and input fractions were purified using the QIAquick PCR 
purification kit (Qiagen) as per the manufacturer’s instructions. DNA was eluted with 200µl 
of ddH2O in Eppendorf Lobind tubes and stored at -20°C until used for real-time PCR analysis 
(Section 2.2.2.3). 
 
2.2.10 Statistics 
GraphPad Prism software (Version 5.03) was used for statistical analysis. Unpaired, two-
tailed Student’s t-test was applied for comparison of two groups. For analysis of multiple 
groups, ANOVA was used with Bonferroni correction for multiple comparisons. The 
following marks are used throughout: *,p<0.05; **,p<0.01;***,p<0.005 
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Figure 2.3 Schematic of Chromatin Immunoprecipitation procedure.   
This figure has been adapted from Massie and Mills (2008). (A) Cells are treated with 
formaldehyde which cross-links chromatin/DNA/protein interaction. (B) The cells are 
lysed and the nuclei isolated. (C) The nuclear fraction is sonicated to shear chromatin and 
genomic DNA. (D) Immunoprecipitation of chromatin associated with the antibody of 
interest is carried out using magnetic capture of Dynabeads® with Protein G. The 
associated DNA is isolated (E) and purified (F) for real-time PCR analysis. 
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3.0 THE ROLE OF NF-κB IN LPS-INDUCED EXPRESSION OF FEEDBACK 
NODE GENES 
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3.1 Introduction 
LPS is a potent microbial initiator of inflammation and in macrophages stimulates signalling 
by TLRs; ultimately leading to the activation of MAPKs and transcription factors like NFkB 
and AP1 (Bowie & O’Neill 2000). Nuclear factor κB consists of homo/heterodimers of the Rel 
family, which includes p50, p52, cRel, p65 (RelA) and RelB. Activation of NFκB complex 
proteins results in the rapid and transient production of inflammatory mediators due to the 
simultaneous synthesis of anti-inflammatory proteins that negatively feedback on pro-
inflammatory agonists (Hayden & Ghosh 2014). A number of factors are involved in 
controlling this delicate balance between an effective immune reaction and the protection 
of host tissues. Canonical NFκB signaling is under regulatory control at a number of different 
molecular levels (Ruland 2011). In unstimulated cells, NFκB proteins are sequestered in the 
cytoplasm associated with inhibitors of κB proteins; IκBα, IκBβ, IκBγ and IκBε. Upon LPS 
stimulation IκBs become phosphorylated, ubiquitinated and targeted for degradation, thus 
resulting in activation and nuclear translocation of NFκB (Rao et al. 2010). Ubiquitination of 
the IκBs is directed by an E3-ligase complex comprised of multiple proteins including cullin-
1, S-phase ligase-1 and Fbox (Soucy et al. 2010) and collectively termed cullin-RING (really 
interesting new gene) ligase-1. Activity of this complex is enhanced by the attachment of 
neuronal precursor cell expressed developmentally down-regulated -8 (Nedd8); that is, 
neddylation of cullin-1 (Watson et al. 2011; Read et al. 2000). Neddylation is catalyzed by 
Nedd8-activating enzyme (NAE). MLN4924 is a small molecule inhibitor of NAE and 
therefore causes cells to accumulate cullin-ring substrates including IκBs, leading to 
sustained sequestration of NFκB in the cytoplasm (Chang et al. 2012). Furthermore, 
MLN4924 has been shown to decrease phosphorylation and degradation of IκBs and 
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therefore nuclear accumulation of NFκB as well as directly reducing the expression of 
several target genes (Milhollen et al. 2010; Swords et al. 2010).  
Additionally, deubiquitinases act upstream of IκB kinases (IKKs), so as to block activation of 
NFκB signalling (Ruland 2011). A20 is one such protein, directly induced by NFκB with dual 
ubiquitin-editing functions that promote the removal of K63- and addition of K48- 
polyubiquitin chains to RIP1; subsequently targeting it for proteasomal decay (J. C. Lee et al. 
2000; Wertz, O’Rourke, Zhang, et al. 2004). A number of genome wide association studies 
have linked polymorphisms within the TNFAIP3 locus; that encodes the A20 gene, with 
susceptibility to various inflammatory and autoimmune diseases including SLE, Type 2 
Diabetes, Sjogren syndrome, coronary artery disease, RA and IBD (Catrysse et al. 2014). 
Perhaps pertaining to the pathological potential of its aberrant activity, A20 may also target 
other components of the NF-kB signalling cascade including TRAF6 (Boone et al. 2004), IKKγ 
(Mauro et al. 2006), RIP2 (Hitotsumatsu et al. 2008) and MALT1 (Düwel et al. 2009). 
Additionally, A20 interacts with components of the DISC complex (Jin et al. 2009) and is a 
key regulator of apoptosis in a number of cell types (Bellail et al. 2012). Amongst numerous 
targets of NFκB, anti-inflammatory factors such as A20 feedback negatively upon the 
inflammatory signalling pathways as a means of restraint. In response to MAPK signalling 
the anti-inflammatory protein DUSP1 becomes active through phosphorylation, what’s 
more DUSP1 transcript is up-regulated by NFκB. Through inhibition of MAPK signalling, 
DUSP1 leads to the timely dissociation of inflammatory signalling complexes including those 
that promote IKK activation and NFκB translocation to the nucleus (Winsauer & de Martin 
2007). An important function of DUSP1 is to modulate the phosphorylation of Tristetraprolin 
(TTP), an additional NFκB/AP1 directly-responsive gene.  The primary function of TTP is 
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widely considered to be the posttranscriptional down-regulation of gene expression. 
Therein lies a large proportion of its ability to quench the inflammatory response by 
targeting injurious cytokines for degradation. However a number of studies have highlighted 
the potential for TTP to directly inhibit NFκB signalling through interaction with p65, HDAC 
recruitment and suppression of NFκB dependent promoters (Zhang et al. 2013; Schichl et al. 
2009; Liang et al. 2009).  
The aim of this chapter was to investigate the mRNA expression profiles of DUSP1, TTP and 
A20 in response to LPS and the pharmacological inhibitor of NFκB MLN4924. With a 
particular focus on TTP, the objective was to identify the molecular mechanisms underlying 
LPS-mediated gene expression of feedback node genes.   
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3.2 Results 
3.2.1 LPS-induced synthesis of Tnfα mRNA is inhibited by MLN4924 
 
As a primary target of NFκB, we expect the potent inflammatory mediator TNFα to be 
rapidly and transiently up-regulated by LPS simulation in myeloid cells. 
Primary human macrophages were isolated from peripheral blood monocytes whereas 
murine primary cells were derived from bone marrow; both cell types required M-CSF for 
polarisation. After 5 days of maturation, primary cells were seeded at a density of 
1x106cells/ml in 12 well plates whereas RAW264.7 macrophages were seeded at 
5x105cells/ml in 6 well plates. The next day, cells were left untreated, stimulated with LPS or 
LPS and MLN4924 simultaneously for 1, 2, 4 or 8 hours. At the appropriate time point, cells 
were harvested for mRNA and subject to QPCR with probes specifically designed for TNFα.  
LPS strongly and rapidly induced expression of TNFα mRNA in all cell types (Figure 3.1). 
TNFα is a primary response gene (PRG) and under active transcription as early as 15 minutes 
post LPS-stimulation (Smallie et al. 2010). The expression was highest after 1 hour LPS 
stimulation and although slowly diminishing, remained elevated above basal levels until 
after the last time point at 8 hours. In the same experiments, cells were treated with LPS in 
combination with NFκB antagonist MLN4924. In response to MLN, the level of LPS-induced 
TNFα mRNA was strongly reduced, by approximately 90% in primary human and RAW 
macrophages and 50% in primary murine macrophages. Significant inhibition was observed 
in primary macrophages at 1 (p<0.001) and 2 (p<0.001) hours of incubation and from 1 to 8 
hours (p<0.001) of stimulation in RAW264.7 cells. The observed significant inhibition of 
TNFα transcription by MLN4924 was an expected outcome and signified efficient inhibition 
of NFκB signaling in each cell type, using the novel pharmacological inhibitor MLN4924.  
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Figure 3.1 TNFα is inhibited by MLN4924 in primary macrophages and RAW cells 
(A) Preliminary titrations of MLN4924 carried out in BMM seeded at a density of 
1x106cells/ml in 12-well plates. For measurements of mRNA, whole cell lysates were 
harvested in RNA lysis buffer containing β-mercaptoethanol. Supernatant was collected 
and diluted accordingly for protein quantification by ELISA. MLN was effective at 
inhibiting LPS-induced TNFα at the level of mRNA expression (i) and protein secretion (ii) 
at each dose tested and an optimal concentration of 100nM was chosen for future 
experiments. (B) Primary macrophages and RAW cells were seeded at a density of 
1x106cells/ml and 5x105cells/ml respectively and either left un-stimulated, treated with 
LPS (10ng/ml) or LPS and MLN4924 (100nM) for the times indicated. Data show the mean 
+/- SEM for three and four separate experiments in primary and RAW macrophages 
respectively. Each QPCR was carried out in triplicate. *** p< 0.001  
Black bars = MLN (100nM); White bars = LPS (10ng/ml); Red bars = MLN + LPS 
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3.2.2 Chemical inhibition of NFκB enhances LPS-induced Dusp1 mRNA expression 
 
Using the material obtained from experiments in 3.1, the mRNA expression profile of Dusp1 
was observed over a period of 8 hours. Expressed at almost undetectable levels in un-
stimulated macrophages, Dusp1 precipitously responds to LPS, in a dose dependent manner 
(data not shown). In accordance with literature, Dusp1 mRNA was up-regulated by the 1 
hour time point in response to LPS-activation, in all cell types (Figure 3.2). Over a period of 8 
hours the transcript expression profile of Dusp1 gradually resolved back down to basal levels. 
These data confirm the responsiveness of Dusp1 to inflammatory activation in an immediate 
early manner. The transcription of Dusp1 is regulated by a number of factors and 
accordingly the promoter region contains a large number of transcription factor binding 
motifs. NFκB has a central role in the succinct activation of gene transcription in response to 
TLR activation. Indeed, at least two conserved NFκB consensus motifs are located within 
2.2kb upstream of the human DUSP1 promoter with exact sequence matches ~2.5kb 
uspstream of the murine Dusp1 promoter (J. Wang et al. 2010; Huang & Tan 2012). 
Furthermore J Wang et al. (2010) showed that mutation of these sites within a Dusp1-
promoter driven reporter strongly attenuated luciferase expression. Interestingly however, 
the addition of NFκB inhibitor MLN4924 (1nM) in fact significantly (p<0.001) enhanced and 
extended the amount of LPS-induced Dusp1 mRNA in all cell types. Cooperativity between 
LPS and the NFκB inhibitor was three times the inducing effect of LPS alone on Dusp1 gene 
expression at 2 and 4 hours in human primary macrophages. The same effect was not quite 
as striking in murine cells but was sustained over 4 and 8 hours in primary and RAW 
macrophages respectively. NFκB is a critical downstream effector of TLR and MAPK 
signalling, as is DUSP1 protein. It is generally conceived that functional κB elements within 
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the Dusp1 promoter are primarily responsible for its up-regulation during inflammation. 
Chemical inhibition of MAPKs from ERK, p38 and JNK families was unable to effectively 
inhibit Dusp1 gene expression (J. Wang et al. 2010), whereas inhibition of NFκB or indeed 
mutation of promoter proximally located NFκB motifs abrogated Dusp1 transcription in 
response to LPS. (King, Holden, et al. 2009a). The promoter of Dusp1 contains numerous cis-
acting motifs and therefore it is possible that in these experiments, the absence of nuclear 
components of NFκB facilitates binding of an orchestra of factors that may influence 
transcription more efficiently than in the presence of NFκB. 
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Figure 3.2 The effects of MLN on FNG transcript expression. 
In parallel with Chapter 3.2.1 (Figure 3.1) the relative level of FNG mRNA expression was quantified by 
QPCR in macrophages un-stimulated, treated, with MLN (100nM) (black bars) activated with LPS (10ng/ml) 
(white bars) or LPS  + MLN simultaneously (red bars) for the times indicated. Data represent the mean ± 
SEM for three and four separate experiments in primary and RAW macrophages respectively. *** p< 0.001 
**p<0.01 *p<0.05.  
(A)  Expression of DUSP1 mRNA is significantly enhanced by MLN in primary macrophages and RAW cells. 
(B) LPS-induced ZFP36 (TTP) mRNA expression is partly dependent on nuclear NFκB 
(C) LPS-induction of Tnfaip3 mRNA is strongly inhibited by MLN4924 
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3.2.3 LPS-induced ZFP36 mRNA expression is partly dependent on nuclear NFκB 
The expression of Zfp36 mRNA was also quantified in macrophages stimulated with LPS, 
MLN or both in combination.  
Zfp36 is an immediate early gene induced by LPS and TTP protein primarily acts post-
transcriptionally to destabilise pro-inflammatory mRNAs. TTP has a multitude of targets, 
most notably TNFα. In addition, TTP also has direct negative effects on NFκB target gene 
transcription (Liang et al. 2009). Therefore as a classical negative regulator, TTP inhibits the 
pathways from which it was activated. The transcriptional regulation of TTP is not well 
understood.  In order to characterise the Zfp36 response to LPS, mRNA was quantified by 
QPCR. Typically, in the absence of inflammatory stimulus, macrophages expressed very low 
levels of Zfp36 mRNA. A small number of studies have suggested that Zfp36 transcription is 
dependent on NFκB (Lai et al. 1998; Jalonen et al. 2005; King, Kaur, et al. 2009; Chen et al. 
2013). Carayol et al showed that IKK/NFκB signalling has a dominant role in the LPS-
mediated early response in monocytic cells. Indeed, DUSP1 was included in their microarray 
as one of the immediate early genes dependent on NFκB activation and inhibited by a 
dominant negative mutant version of the IKKγ complex (Carayol & Wang 2006). However 
TTP was not identified as NFκB-dependent by the same microarray, contrary to previously 
discussed studies. Since the activation of NFκB requires an inflammatory agonist, it would 
corroborate that Zfp36 is not actively transcribed in resting cells. Correspondingly, LPS 
rapidly induces Zfp36 transcript within 60 minutes in a dose-dependent manner (data not 
shown). Further to this, LPS treated mRNA preparations from previously described 
experiments (Chapter3.2.1) were subject to QPCR (Figure 3.2(B)). Zfp36 mRNA was 
increased significantly (p<0.001) by LPS as early as 30 minutes (not shown) and reached a 
maximal level at 1 hour in macrophages. As a primary response gene, Zfp36 transcription is 
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initiated almost instantaneously following TLR activation. It is this mechanism that causes 
the peak of mRNA expression as early as 1-hour post LPS treatment. Thereafter, expression 
levels moderated before peaking again at 4 hours of incubation with LPS. At the four-hour 
time point Zfp36 responds similarly to a secondary response gene and it could be that 
distinct mechanisms underlie this wave of transcript up-regulation. In fact, Sauer et al (2006) 
have shown that interferons strongly induce TTP via signaling through STAT1 and co-
stimulation of p38 MAPK. Furthermore, the same study identified that IFN-driven up-
regulation of the TTP protein reduced the expression of numerous LPS-induced pro-
inflammatory genes including TNFα and IL6 (Ines Sauer et al. 2006). Following 8 hours of 
treatment, Zfp36 mRNA remained elevated above the resting level. The rapid up regulation 
of immediate early genes like Zfp36 often requires NFκB. Conversely, secondary response 
genes are often under the control of alternative transcription regulators. In order to 
determine the role of NFκB in the biosynthesis of TTP, mRNA from cells treated with LPS and 
MLN4924 was probed for Zfp36 transcript by QPCR. In primary human macrophages 
MLN4924 almost abolished LPS-induced Zfp36, reducing transcript expression by over 70% 
at 1 and 2 hours and 90% at 4 and 8 hours post co-treatment. The effect of MLN4924 on 
Zfp36 mRNA in murine macrophages however, was more complex. In primary and RAW 
murine macrophages, MLN4924 was inhibitory to LPS-dependent mRNA up-regulation by 
roughly 20% and 50% at 1 hour. After 2 and 4 hours of co-stimulation, MLN had no 
significant effect on the LPS-mediated increase in mRNA in either murine cell types. At the 
8-hour time point MLN once again significantly lowered Zfp36 mRNA in murine 
macrophages.   
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3.2.4 LPS-induction of TNFAIP3 requires NFκB  
Another significant negative feedback regulator, A20 is transcribed directly downstream of 
TLR-signalling and subsequently targets the essential canonical NFκB activators RIP1 and 
TRAF6 for proteasomal degradation. Here we examined the LPS-induced mRNA expression 
profile of A20 in human and murine primary macrophages and RAW cells treated as 
previously described (Chapter 3.2.1). Within 1 hour of LPS activation, macrophages strongly 
expressed Tnfaip3 mRNA. The pattern of expression was transient and gradually decreased 
in primary macrophages. In contrast to primary macrophages, RAW264.7 cells expressed 
Tnfaip3 in a biphasic manner, with peaks at 1 and 4 h after an LPS stimulus. The addition of 
MLN4924 resulted in a dramatic inhibition of LPS-driven Tnfaip3 mRNA synthesis, 
particularly in primary human (~90%) and RAW macrophages (~80%). The LPS effect on gene 
expression was also significantly inhibited in murine primary macrophages, although to a 
lesser extent (~70%). These results suggest that NFκB is the principal transcription factor 
involved in A20 biosynthesis in response to LPS. Indeed, two highly conserved consensus 
binding sites for NFκB have been identified within the TNFAIP3 promoter (Altonsy et al. 
2014). However it has been documented that Tnfaip3 may selectively escape transcriptional 
inhibition by the nuclear factor GR, which is known to obstruct NFκB-driven pro-
inflammatory gene expression (Caldenhoven et al. 1995; Altonsy et al. 2014).  
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3.2.5 The effect of MLN on LPS-induction of Tnfα, Zfp36 and Tnfaip3 mRNA 
expression in Dusp1-/- macrophages 
DUSP1 is key in modulating the inflammatory response and critically required for the timely 
inactivation of MAPK signalling. The effects of excessive MAPK p38 activation are 
highlighted in mice null for Dusp1; where the consequent build-up of phosphorylated TTP 
results in increased pro-inflammatory mRNA stability. In Dusp1-/- macrophages, TNFα is 
elevated at the posttranscriptional level when compared to WT macrophages but not at the 
level of gene expression. Overexpression of inflammatory cytokines driven by increased 
mRNA stability in mice null for Dusp1 subsequently leads to severe hypotension and 
multiple organ failure due to an increased susceptibility to endotoxic shock (Zhao et al. 
2006; Salojin et al. 2006).  
In parallel with time-course experiments in WT primary murine macrophages, cells were 
also isolated from the bone marrow of age and sex matched Dusp1-/- knock out mice and 
treated with LPS, MLN or both as appropriate. Cells were harvested for mRNA, which was 
used as a template for QPCR of TNFα, A20 and TTP. The ΔCt values for Dusp1-/- mRNA data 
were normalised against that of the WT unstimulated and therefore graphs in Figure 3.3 
represent fold increase in mRNA compared to WT basal expression levels. 
3.2.5.1 MLN-mediated inhibition of LPS-induced Tnfα synthesis is reduced in Dusp1-
/- macrophages 
Murine Dusp1 -/- macrophages expressed basal levels of TNFα far in excess of the negligible 
amount observed in WT cells. Consequently, on activation with LPS, TNFα transcript levels 
were dramatically augmented in knock out cells; at 1 hour reaching approximately 600 times 
the quantity observed in WTs. On addition of MLN, LPS-induced TNFα mRNA expression in 
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the knock out cells was reduced with significance at the 1-hour time point albeit to a far 
lesser extent than in WT macrophages. Thereafter MLN was not significantly inhibitory to 
TNFα production in response to LPS. One explanation for the reduced effectiveness of MLN 
in Dusp1-/- macrophages could be an increase in stability of the TNFα transcript due to 
enhanced p38 activity and TTP phosphorylation. In Fact, a number of cytokines and 
chemokines are overexpressed in mice null for Dusp1. Additionally, results from our group 
show that the rate of transcription of TNFα is not dissimilar between Dusp1-/- and WT 
macrophages.  
3.2.5.2 The inhibitory effects of MLN on Tnfaip3 mRNA expression are lost in Dusp1-
/- macrophages  
LPS-activated Dusp1-/- macrophages expressed elevated Tnfaip3 mRNA, up to 800 times the 
levels observed in WT cells, due to excessive stimulation of this heavily NFκB-responsive 
gene. Co-stimulation of these cells with LPS and MLN simultaneously reduced Tnfaip3 
transcript quantities at the 1-hour time point but, rather unexpectedly, amplified expression 
after 2 hours of incubation. Thereafter MLN had no effect on the level of LPS-induced 
Tnfaip3 message. The Tnfaip3 locus contains two upstream NFκB binding motifs and is a 
direct target of NFκB mediated transcription (Lai et al. 2013). Therefore we observe its 
enhanced expression as a result of inflammatory signalling; a response that is augmented in 
Dusp1 knockout cells where p38 signalling is protracted. Unexpected however, is the 
reduced effectiveness of MLN inhibition in these cells, along with the significant 
augmentation of Tnfaip3 gene expression after 2 hours of co-stimulation. The Tnfaip3 
transcript has two highly conserved adenine-uridine rich motifs, TTATTTATT and TTATTTATA 
motif; both of which are appropriate TTP binding sequences. Just as the stability of pro-
inflammatory TNFα and CXCL1 message is elevated in Dusp1-/-, it could be that reduced TTP 
      131
activity is also responsible for an increase in Tnfaip3 transcript levels. Additionally, Tnfaip3 
contains a highly p38 dependent C/EBPβ binding motif within its promoter (Litvak et al. 
2009; Lai et al. 2013). It is possible that enhanced p38 MAPK activation due to a lack of 
Dusp1 facilitates the binding of transcription factors, other than NFκB that regulate Tnfaip3 
transcript up-regulation. 
3.2.5.3 MLN treatment induced Zfp36 transcript expression in DUSP1-/- 
macrophages 
Again, Zfp36 was more strongly induced in the knockout but not to the same extent as Tnfα 
or Tnfaip3. TTP is a potent anti-inflammatory protein capable of destabilising multiple 
mRNAs. Furthermore, the effectiveness of TTP depends on the equilibrium between active 
and inactive configurations, rather than on transcriptional up-regulation. Activated cells that 
lack Dusp1 accumulate TTP in its inactive state due to extended p38 activity. Thus the 
natural dissipation of the inflammatory response and the cellular equilibrium that favours 
the active form of TTP, is retarded in Dusp1-/- macrophages.  
When stimulated with MLN alone, Dusp1-/- macrophages showed a small and unexpected 
increase in Zfp36 transcript level. Dusp1-/- macrophages display a higher basal level of 
cytokine expression due to increased mRNA stability and although could account for this 
slight increase in Zfp36 message mice null for DUSP1 are normal under basal conditions and 
only show a hyperresponsive reaction under immune challenge. Other than this 
phenomenon, the patterns of Zfp36 expression are broadly similar between WT and KO 
cells, with the exception that MLN enhances expression at 4 hours in KO. 
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Figure 3.3 Quantification of Tnfα, Tnfaip3 and Zfp36 transcript expression in WT and 
Dusp1-/- macrophages treated with LPS and MLN 
In parallel with WT experiments, macrophages were harvested and matured from age and 
sex matched Dusp1-/- mice and treated with LPS, MLN or both as appropriate. Cells were 
harvested for mRNA, of which Tnfα, Tnfaip3 and Zfp36 were quantified by QPCR. The ΔCt 
values for Dusp1-/- mRNA data were normalised against that of the WT unstimulated and 
therefore graphs represent fold increase in mRNA compared to WT basal expression levels. . 
*** p< 0.001 **p<0.01 *p<0.05 
Black bars = MLN (100nM); White bars = LPS (10ng/ml); Red bars = MLN + LPS 
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3.2.6 Design of reporter constructs containing upstream conserved regions of the 
human and murine Zfp36 locus 
In order to identify and characterise novel regulatory sites at the Zfp36 locus and their 
responsiveness to various inducers of transcription, reporter constructs were assembled 
containing evolutionarily conserved regions (ECRs) of the murine and human Zfp36/ZFP36 
locus. By cloning putative regulatory and enhancer regions upstream of a reporter 
sequence, it is possible to assess the ability of these regions to respond transcriptionally in 
vitro to a number of stimuli. This is a conventional genetic approach to establishing the 
biological relevance of DNA segments. However in order to elucidate sequence function it is 
important to use complimentary information from a number of different methods designed 
to identify regions of interest at specific gene loci. Evolutionary conservation of non-coding 
regions is often a marker of elements involved in the control of gene expression. 
Phylogenetic foot-printing is an approach that uses sequence conservation to identify 
putative regulatory elements. Figure 3.4 is a VISTA plot of the Zfp36 locus detailing 
conservation between mouse, human, rat and chimp for sequences coding exons, UTR’s and 
non-coding nucleotides. At the top of the figure is a cartoon of the Zfp36 gene structure, 
which is highly conserved between mouse and human. Although powerful, evolutionary 
mechanisms of identifying non-coding functional elements are limited. For example, 
transcription factor binding sites are mostly short sequences and often highly degenerate, 
making them hard to identify and align. Some biological gene categories are subject to rapid 
evolutionary turnover, even amongst closely related species. The immune-regulatory genes 
are identified within this example and therefore the absence of sequence conservation 
between species regarding this functional group should not be interpreted as evidence for 
lack of function. Nor does an evolutionary approach to sequence detection allude to the 
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molecular mechanisms under selection, the relevant cell types or the physiological 
processes involved. Further complimentary to the two aforementioned techniques are 
biochemical methods of identification which provide information about both the molecular 
function of underling DNA elements and the cell types in which they act and therefore offer 
a launching point from which to study human disease (Kellis et al. 2014). 
Genome-wide analyses of chromatin structure can provide helpful clues to the location of 
regulatory elements. DNAse I hypersensitivity assays are a method of detection which takes 
advantage of the compromised chromatin structure surrounding transcription regulatory 
sites. Hypersensitive sites are regions of open chromatin conformation, which frees up the 
DNA to enhance the binding of transcription facilitators. Moreover, transcription factor 
binding displaces histone octamers, further increasing the sensitivity of these loci. 
Hypersensitive sites can either indicate transient remodelling of chromatin as in the case of 
transcriptional induction, or stable epigenetic inheritance of programmed changes to a locus 
during differentiation (Pipkin 2006). DNase I hypersensitive sites can be identified across the 
genome by high-throughput sequencing of the ends generated by limited digestion of 
genomic DNA (Song et al. 2011; Boyle et al. 2011). Some DNAse I hypersensitivity and 
evolutionarily conserved site maps are now publicly accessible via the University of 
California Santa Cruz (UCSC) genome browser. 
The small pink peak of highly conserved sequence directly upstream of the TTP transcription 
start site indicates the promoter region, which is rich in multiple transcription factor binding 
motifs including κB, AP1, SP1, TAK and ERG1. Studies of Zfp36 transcriptional regulation 
have previously tended to focus on this small but critical region of conservation (Chen et al. 
2013; Ogawa et al. 2003; I Sauer et al. 2006; Gaba et al. 2012). Although Lai et al. (1998) 
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have investigated serum inducibility of the Zfp36 intronic region, whilst Florkowska et al. 
(2012)have inspected the sequence further upstream and identified Elk-1 transcription 
factor binding. Still, there are a number of more distal loci that are also well preserved, 
which we have termed ECR1 (in the Med29 3’UTR; not shown) ECR2, ECR3 and ECR4. Of 
particular importance, given the role of NFκB in the transcription of TTP, ECR4 contains a 
small number of both perfectly and imperfectly conserved κB consensus sequence 
gggRNNYYcc (Carayol et al. 2006; King, Kaur, et al. 2009; Chen et al. 2013). These three 
regions were amplified from human and mouse genomic DNA (Figure 3.4) and cloned 
upstream of luciferase-containing pGL3P (SV40 promoter) and PGL4.26 (minimal promoter). 
ECR3 and ECR4 were amplified both singularly and juxtaposed to explore potential 
cooperativety between the sequences. 
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3.2.7 Three 5’ putative TTP regulatory elements respond transcriptionally to LPS 
and one conserved region contains a functional NFκB element 
Previously, studies have focused on the role of a 2kb upstream promoter region of TTP in 
LPS-mediated transcriptional regulation. In order to further explore NFκB-mediated ZFP36 
expression, three putative regulatory sequences identified by evolutionary conservation 
were analysed for their ability to induce gene transcription and luciferase activity. Human 
and Murine TTP 5’ ECR-driven luciferase plasmids were transfected into HeLa and RAW cells 
respectively and cells were stimulated with IL1 or LPS for 8 hours. In addition to the 
appropriate human (Hs) ECR constructs, HeLa cells were, in parallel, transfected with 
positive (containing (κB)3-) or negative; (empty) pGL3P control vectors. The HeLa positive 
control vector contains six repeats of an NFκB motif ((κB)3-) cloned upstream of the 
luciferase sequence in the same minimal promoter containing vector used for the 
experimental constructs, pGL3P. Similarly, the RAW cell positive control vector contains the 
NFκB-responsive 5’ and 3’ un-translated sequences of Tnfα. This ensures that NFκB 
signalling is functional in the transfected system. The negative control is the ‘empty’ pGL3P 
vector and allows any background luciferase induction mediated by the minimal promoter 
sequence to be accounted for. 
As can be seen in figure 3.5, the positive controls for each RAW264.7 (A) and HeLa (B) cells 
strongly induce luciferase expression and therefore the respective signalling pathways of 
the transfected cells remain intact. Using a positive control, we can confirm the 
experimental effects of chemical inhibition, for example by MLN are true. On the other 
hand, the empty pGL3P vector containing cells do not respond significantly to LPS 
stimulation as expected. 
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Figure 3.5 shows that the murine and human ECRs respond to pro-inflammatory agonists 
LPS and IL1α respectively by stimulating luciferase transcription and translation. A number 
of consistencies were identified between species. The longest conserved sequence 
containing ECR3-4 was the most responsive and brought about the largest induction of 
luciferase in both cell types, followed by ECR4, ECR3 and ECR2. Generally, the human 
constructs appear to induce a stronger luciferase response however could be an artefact of 
numerous factors including stimulus type and cell type. The effects of NFκB inhibiting 
compound MLN on luciferase induction by each ECR were also consistent between species. 
The luciferase activity driven by ECR4 was blocked in both human and murine cells by MLN. 
This effect was also observed in ECR3-4. ECR4 contains a putative NFκB binding element 
located between base pairs −1859 and −1850 (Chen Jiang 2013) of the murine Zfp36 locus. 
This putative element is likely responsible for the observed inhibition of transcriptional 
activity by MLN. Neither ECR2 nor ECR3 contain identified NFκB binding motifs and 
accordingly in RAW cells neither reporter was affected by MLN. However HsECR 3 was 
negatively affected by MLN whereas HsECR2 was positively affected.  
These functional studies suggest that the expression of TTP could be induced by NFκB 
signalling through an NFκB-binding site within ECR4 in macrophages and epithelial cells. 
Additionally, it may also outline sequence and/or functional differences between human 
and murine conserved regions. It should be noted that transfection of naked plasmid DNA 
does not mimic native chromatin environment and therefore the relative activity of 
constructs can often be marginal when compared to the induction of endogenous mRNA 
and protein. However in this study, transcriptional responses in both cell types are quite 
robust and not too dissimilar to the endogenous induction profile of Zfp36.   
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Figure 3.5 Human and murine Zfp36 ECRs respond to transcriptional regulation by IL-1 
and LPS respectively and ECR4 is sensitive to inhibition by MLN 
(A) RAW264.7 and (B) HeLa cells were transiently transfected with luciferase reporter 
constructs. The following day, cells were left un-stimulated (black bars); RAW cells 
activated with 10ng/ml LPS (white bars) and HeLa cells with 1ng/ml IL1α (white-striped 
bars); 1nM MLN4924 (red bars) or in combination (red bars for RAW and red striped bars 
for HeLa) for an optimum of 8 hours. Following passive lysis, luciferase assays were 
performed. Data are expressed as mean ± SEM for three separate experiments. Cartoon 
(C) represents murine evolutionary conservation against a human-base genome and the 
ECRs 2-4, which were cloned for the reporter constructs above are represented here in 
red (blue is conservation of the Zfp36 coding sequence). . *** p< 0.001 **p<0.01 *p<0.05 
 
      140
3.2.8 Optimisation of ChIP in murine bone marrow derived macrophages 
Due to the fact that MLN was able to reduce the LPS-response of Zfp36 upstream ECR-
containing constructs and the limitations of using reporter assays to investigate endogenous 
gene-regulation, the next step was to identify NFκB interactions with the TTP locus in vivo. 
Chromatin immunoprecipitation is a powerful technique for identification of protein-DNA 
interaction in vivo. In combination with RNAi technology, ChIP is an invaluable tool for 
studying mechanisms of gene regulation (Li et al. 2006). Furthermore, the application of 
RNAPII ChIP can be used as a means to identify functional regions of chromatin involved in 
the regulation of transcription (Sandoval et al. 2004). This will prove useful in determining 
the mechanisms underlying the LPS-driven biphasic expression of Zfp36 mRNA observed in 
this chapter (Figure 3.2) as well as previously (Tchen et al. 2004; Chen et al. 2013). A 
schematic of the ChIP procedure can be found in Chapter 2.2.9. Formaldehyde is initially 
used to fix the cells, freezing the architecture of the genome and ensuring that protein-DNA 
complexes are preserved. Transcription factors bound to their cognate sequences within the 
DNA can therefore be detected within the context of chromatin. Crosslinked chromatin is 
then subjected to sonication in order to shear or fragment the DNA, solubilising the 
chromatin in preparation for immunoprecipitation. Specific antibodies are used to complex 
target proteins, together with their fragments of DNA and thus enrich for DNA associated 
with the protein of interest. The crosslinks between the protein/DNA complexes are 
reversed, the DNA isolated and subject to PCR in order to detect specific target sequences. 
ChIP can therefore be used to identify regions of the genome where transcription factors or 
protein modifications are located (Massie & Mills 2008). We initially decided to probe for 
RNA polymerase II, to distinguish functional regulatory regions of the Zfp36 locus in 
response to LPS-stimulation.  
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In order to design primers for the murine Zfp36 gene region, the sequence pertaining to the 
target region was retrieved from UCSC Genome Browser. Primers were constructed to 
amplify targets of approximately 100-200bp based, generally 500bp apart. Oligonucleotide 
sequences were calculated to contain a similar GC content and have a predicted annealing 
temperature of 60°C. Each set of primers was initially tested for sequence specificity by 
RTPCR of input DNA isolated from the ChIP procedure, followed by melt curve analysis and 
agarose gel electrophoresis. Figure 3.7 details the location of each designed primer pair 
(black rectangles) in correlation to the murine Zfp36 locus. Additionally, arrows mark the 
location of important genomic regions as well as the previously discussed ECRs. Upstream of 
Zfp36 lies Med29; downstream is Plekhg2, both of which are non LPS-responsive as is 
evident from Figure 3.6, an experiment in which mRNA transcript was quantified for both 
genes in response to macrophage stimulation with LPS for the times indicated. ECRs 1 and 5 
are associated with PU1; a marker of accessible chromatin in myeloid cells. Our hypothesis 
states that the entire gene region of Zfp36 is transcriptionally active and for these reasons, 
primer pairs were designed across the locus and surrounding ECR1/5 which encroach on the 
3’UTR and 5’UTR of Med29 and Plekhg2 respectively (Figures 3.5C and 3.7). 
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Figure 3.7 Design and sequence location of oligonucleotide primers targeting the 
mouse Zfp36 locus 
Primers (Chapter 2.1.4.2) were designed to target the mouse Zfp36 locus (chr7:28371243 
- 28386589) for use in ChIP analyses in RAW264.7 and primary bone marrow derived 
macrophages. Oligonucleotides were spaced approximately 500bp apart, each pair 
generating amplicons of roughly 300bp. 
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Figure 3.6 Upstream Med29 and downstream Plekhg2 transcripts are not LPS-induced 
in primary murine macrophages 
Putative Zfp36-regulatory elements located within the Med29 3’UTR and Plekhg2 5’UTR  
have been proposed and ChIP with RNAPII revealed an enrichment for these sites in 
response to LPS. In order to identify whether these effects were due to up-regulation of 
either Zfp36 flanking gene, QPCR was carried out for Med29 and Plekhg2 on LPS-
stimulation time courses. In parallel with previously described mRNA quantification 
experiments, the two Zfp36 flanking genes were measured for their response to 
induction by LPS 10ng/ml (red bars) over an 8 hour period.  
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Figure 3.8 ChIP primer analysis and optimisation of chromatin sonication conditions for 
shearing myeloid cell chromatin 
(A) Melt curve analysis of products generated during RT PCR. (B) RTPCR run profile 
showing input DNA and immunoprecipitated (IP) unstimulated, LPS treated and isotype 
control DNA. Input samples represent DNA not enriched by IP protein, contain more DNA 
and therefore are amplified at lower cycle numbers. Samples IP with IgG represent 
experimental noise and are used as a control for background and are unaffected by 
treatment conditions. Those samples IP for protein of interest (In this case RNAPII) 
change in cycle number for treatment conditions, reflecting the associated alterations in 
RNAPII enrichment at the locus. (C) Chromatin sonication optimisation. Cells were fixed 
with formaldehyde and chromatin isolated as described for ChIP (Chapter 2; Section). 
Chromatin was subject to an increasing number of sonication pulses in order to 
determine the appropriate number to use for ChIP. Following sonication, formaldehyde 
crosslinks were reversed by heat (65˚C) overnight. Total DNA was isolated before analysis 
using agarose gel electrophoresis.  
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As shown in Figure 3.8, the approach to primer design resulted in successful primer pairs for 
the amplification of specific target sequences.  
The sonication of formaldehyde fixed chromatin is an important part of ChIP and involves 
shearing of the genome into fragments that are, in this case mostly 400-500bp in length. 
This ensures accurate resolution can be obtained to determine the position on the genome 
where the protein of interest is located. To achieve the appropriate level of genomic 
fragmentation, sonication was optimised for each cell type. Increasing amounts of 12 
second pulses were applied to chromatin isolated from RAW264.7 and primary bone 
marrow derived macrophages. Total DNA was then isolated from these preparations and 
analysed by gel electrophoresis in order to visualise DNA fragment size (Figure 3.8). With an 
increasing number of pulses, shearing efficiency is enhanced and product size becomes 
smaller and more uniform. In this case, the optimum number of pulses for RAW cells and 
macrophages is 9 and 7 times respectively due to the mode of spread between 300-700bp. 
Based on these conditions, a ChIP experiment was performed on 10 million RAW264.7 
macrophages seeded overnight. The next day, cells were left un-stimulated, stimulated with 
LPS or LPS+MLN4924 for 1, 2 and 4 hours. Primers designed to the locus of Zfp36 were used 
to enrich DNA immunoprecipitated with antibodies specific for NFκB subunit RelA (p65), 
RNA polymerase II (RNAPII) or an immunoglobulin isotype control (IgG). The isotype control 
did not increase and remained constant, indicating the specificity of the RelA and RNAPII 
antibodies. The values for isotype control under each condition were used as a baseline to 
which the percent input quantities were normalised.  
Run profiles of the real-time PCR for this experiment are shown in Figure 3.8 and show 
specific enrichment of the Zfp36 locus DNA bound to RNAPII. The input DNA amplified at a 
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lower cycle number due to its relative abundance and represents DNA not enriched by the 
specific antibodies. Melt curve analysis was used to confirm that the PCR primers designed 
for this locus resulted in a specific amplification product. An aliquot of each chromatin 
sample used was checked for sonication efficiency. 
 
3.2.9 Analysis of Zfp36 chromatin involvement in RAW264.7 macrophage 
response to LPS; RNAPII ChIP 
Once optimised, chromatin immunoprecipitation could be used to characterise the 
underlying mechanisms of LPS-mediated Zfp36 expression through identification of protein-
DNA interactions in vivo.  
Figure 3.9 Shows ChIP of the TTP locus with an antibody specific for RNAPII in RAW cells that 
were stimulated for 1 hour with LPS or left untreated. Panel (A) depicts regions of the Zfp36 
locus (x axis) found to be enriched for RNAPII under resting conditions and when stimulated 
with LPS. Enrichment is calculated by normalisation of the per cent input values to the 
isotype control antibody, which essentially yields the amount of RNAPII accumulation at 
each primer position in relation to the background DNA-antibody association. TTP is a 
primary response gene (Schott et al. 2014)and even under basal conditions is associated 
with a relaxed chromatin configuration, which encourages the protein-DNA interactions that 
facilitate rapid gene transcription. Promoter proximal pausing is one such mechanism 
whereby RNAPII associates with the promoter sequence of PRGs and is held in a state of 
transcription initiation whilst elongation is inhibited, awaiting an appropriate activation 
signal (Hargreaves et al. 2009). Figure 3.9 shows a clear accumulation of RNAPII within the 
promoter region (x-axis p14) and much further upstream of Zfp36. Corresponding to p10-12, 
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the ECRs investigated previously (Chapter 3.2.7) are enriched for RNAPII in the absence of 
stimulus, which implicates them as putative transcription enhancer sequences. Enhancers 
facilitate gene transcription under varied and specific conditions of activation through 
increasing DNA-associations with co-activators, which might be proximal or distal to the 
gene region. Chromatin looping is an efficient mechanism whereby distal regulatory regions 
are brought into proximity with the target gene sequence.  
For each ChIP, two control regions of the TNFα locus were probed by QPCR in parallel with 
Zfp36 target sequences. RNAPII accumulation at these two TNFα regulatory regions was 
considered before continuing with QPCR using experimental target primers. 
Panel (B) of Figure 3.9 shows the RNAPII fold enrichment across the locus, which is 
calculated by normalising the LPS-stimulated values for each primer pair to the equivalent 
un-stimulated figure. The greatest increase in RNAPII association with the Zfp36 locus on 
stimulation with LPS happens within the coding region and downstream of the gene, 
illustrating the 5’ – 3’ movement of RNAPII as it transcribes the DNA. RNAPII proximal to the 
3’UTR has already transcribed a molecule of mRNA whereas RNAPII in the gene region will 
be in the process of transcription.  
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Figure 3.9 Enrichment of RNAPII at the Zfp36 locus in RAW264.7 murine macrophage cells left 
unstimulated or treated with LPS 
RAW cells were seeded at a density of 7x105 /ml overnight before being left unstimulated or 
treated with LPS (10ng/ml) for 1 hour. Subsequently, cells were subjected to ChIP with antibodies 
specific for RNAPII and an isotype control (IgG) before QPCR using oligonucleotides designed 
against the murine TTP locus (Figure 3.7). (A) Shows regions of the TTP locus enriched for RNAPII 
in unstimulated and LPS-treated cells, normalised to the percent input values of the isotype 
control. (B) Highlights the fold increase in sequence enriched for RNAPII on administration of LPS. 
Plotted are the mean values ± SEM of four separate experiments, for each of which QPCR was 
carried out in triplicate. (C) Cartoon schematic representing the murine Zfp36 gene locus 
including primer tracks in black (numbered 1-27) and ECRs as red triangles. Light and dark blue 
bars represent un-treated and LPS-stimulated cells respectively. 
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3.2.10 Association of RNAPII with the Zfp36 locus in primary murine macrophages 
at 1, 2 and 4 hours of LPS stimulation 
Further to RAW264.7 cells, ChIP was also carried out in primary murine BMM harvested at 
1, 2 and 4 hours post-LPS treatment as well as for unstimulated cells. This was to address 
the mechanism behind the biphasic expression profile of TTP mRNA in response to LPS. In 
response to LPS, Zfp36 transcription is rapidly up-regulated and reaches maximum after 1 
hour post-stimulation. Secondary to this, after an initial depression in LPS-mediated mRNA 
at 2 hours there is a succeeding increase in TTP transcript levels at 4 hours incubation in 
myeloid cells. ChIP of the Zfp36 locus using an RNAPII specific antibody allowed 
measurement of the abundance of transcription-facilitating machinery for each time point. 
Enrichment for RNAPII is shown for each time point in Figure 3.10. Again, we observe a large 
amount of RNAPII paused upstream of the TTP promoter in unstimulated cells. In cells 
treated with LPS, this association shifted in a 5’-3’ direction and indicates active 
transcription of Zfp36. At one hour, the 5’-3’ transition of RNAPII was smooth and 
enrichment was maximal at the most 3’ end of TTP, which indicates that a large number of 
transcripts have already been produced in this time frame. At two hours the majority of 
RNAPII had dissociated from the coding region of Zfp36 and re-associated in the upstream 
region, although coding sequence accumulation was still above basal levels. Similar to the 
one hour time point, at four hours once again RNAPII efficiently traffics along the DNA in a 
5’-3’ manner and accumulates towards the end of the 3’UTR. Thus the RNAPII ChIP in BMM 
concurs with the LPS-induced transcription profile of endogenous mRNA expression as 
depicted in Figure 3.3. 
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Figure 3.10 Enrichment of RNAPII at the Zfp36 locus in murine bone marrow derived macrophages 
Primary murine BMM were seeded at a density of 1x106 /ml overnight before being left unstimulated or treated 
with LPS (10ng/ml) for the times indicated ((A) = unstimulated, (B) = 1h LPS, (C) = 2h LPS, (D) = 4h LPS). 
Subsequently, cells were subjected to ChIP with antibodies specific for RNAPII and an isotype control (IgG) before 
QPCR using oligonucleotides designed against the murine TTP locus (Figure 3.7). Plotted are the mean values for 
triplicate QPCRs of one experiment that is representative of three similar results. Cartoons below each figure 
represent the location of each primer pair denoted on the x-axis, with respect to the gene regions of Zfp36 and 
Med29 (upstream) and Plekhg2 (downstream). Figure (E) Shows data from all measured time points (light blue = 
unstimulated; turquoise = 1h LPS; dark blue = 2h LPS; Indigo = 4h LPS) in one graphical representation for 
comparison and below (F), is a schematic of the Zfp36 locus including primer locations, gene boundaries and 
evolutionarily conserved regions of interest. 
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3.2.11 Analysis of NFκB recruitment to the Zfp36 gene locus in RAW274.7 murine 
macrophages using RelA ChIP 
Supplementary aliquots of chromatin isolated from RAW cells (Chapter 3.2.9) were 
precipitated with antibodies specific for RelA; the major subunit of NFκB.  
Panel (A) of figure 3.11 represents the regions of DNA, denoted by primer pairs (x axis) that 
were enriched for RelA antibody associations in vivo; under resting conditions (pale yellow) 
and when stimulated with LPS (orange). As described previously, in resting conditions, NFκB 
is mostly inactive and sequestered in the cytoplasm by IκB proteins. For that reason, RelA 
does not immunoprecipitate with regions of the Zfp36 locus in unstimulated cells (Figure 
3.12A). However, following stimulation with LPS, NFκB is permitted to translocate to the 
nucleus and bind to DNA. Since the basal level of RelA recruitment to the Zfp36 locus is 
negligible, the values for fold enrichment are most representative of the mechanistic action 
during cell stimulation. Zfp36-proximal sequences enriched for by RelA ChIP are focused 
around ECR4 (primer pair 12), the promoter and within the intron, where known NFκB are 
recognised to reside. Additionally however, these data highlight a number of putative RelA- 
binding motifs upstream of Zfp36 in ECRs 1 (primer pair 2), 2 (primer pairs 7-8) and 3 
(primer pairs 10-11). Furthermore, we observe RelA associations downstream of Zfp36 
(primer pairs 25-26), within the PlekHg2 5’UTR where ECR5 is located. As aforementioned 
(Chapter 3.2.9) Chromatin looping is one mechanism which increased transcription potential 
by bringing enhancer regions into proximity with the promoter. Distal protein-DNA 
associations identified by Chromatin Immunoprecipitation can occasionally be a direct result 
of looping, whereby a protein bound to its cognate site might associate with a looped 
sequence through tethering.  
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Figure 3.11 Enrichment of RelA at the Zfp36 locus in RAW264.7 murine macrophage cells left 
unstimulated or treated with LPS 
The same experiment as Figure 3.10. RAW cells were seeded at a density of 7x105 /ml overnight 
before being left unstimulated or treated with LPS (10ng/ml) for 1 hour. Subsequently, cells were 
subjected to ChIP with antibodies specific for RelA and an isotype control (IgG) before QPCR using 
oligonucleotides designed against the murine TTP locus (Figure 3.8). Whie bars =  unstilulated 
Orange bars = 1 hour LPS treated. (A) Shows regions of the TTP locus enriched for RNAPII in 
unstimulated and LPS-treated cells, normalised to the percent input values of the isotype control. 
(B) Highlights the fold increase in sequence enriched for RelA on administration of LPS. Plotted 
are the mean values ± SEM of three separate experiments, for each of which QPCR was carried 
out in triplicate. (C) Cartoon schematic representing the murine Zfp36 gene locus including 
primer tracks in black (numbered 1-27) and ECRs as red triangles. 
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Tethered or looped DNA may then be enriched for by an antibody to the protein of interest 
indirectly. This could be the case for a number of the Zfp36 promoter distal RelA 
associations. Equally, these associations might be genuine directly bound sequences 
containing imperfect or context-dependent κB sites. 
 
3.2.11.2 NFκB is associated with the Zfp36 locus at the 1-hour time point but not 
thereafter 
NFκB is activated early and negatively regulated in a rapid manner. It is clear from 
endogenous mRNA studies in which MLN only partially blocked LPS-mediated TTP 
transcription that there are other activators of Zfp36 gene expression. We hypothesized that 
the second wave of TTP expression was not mediated by NFκB.  
In the same experiment as previously described (Chapter 3.2.10), aliquots of chromatin 
prepared from BMMs untreated or stimulated with LPS for 1, 2 and 4 hours were probed for 
antibody specific for RelA (p65), a major subunit of NFκB. NFκB is not present in the cell 
nucleus of unstimulated cells, therefore in Figure 3.12 the data are shown as fold 
enrichment for RelA compared to the unstimulated chromatin. The greatest accumulation of 
RelA appears within the gene region. A number of κB motifs have previously been identified 
within the TTP promoter (Lai et al. 1995; Chen et al. 2013)and intron (Lai et al. 1998). 
Additionally, ECR4 is a functional element of the TTP locus and contains a putative NFκB 
binding site. We observed an accumulation of RelA at all of these positions and additionally 
in the locus 3’ of Med29, distally upstream of TTP; a similar location to the observed 
accumulation of RNAPII. At the 2 hour time point the majority of RelA has dissociated from 
the locus and increasingly so at the 4 hour time point. RNAPII data from the same 
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experiment shows that RNAPII remains associated with the Zfp36 locus at 2 and 4 hours 
following LPS stimulation (Figure 3.11); a similar observation as that for endogenous mRNA 
(Figure 3.3). This would suggest that other transcription factors and coactivators of 
transcription are involved in the up-regulation of TTP synthesis at these later time points. 
Given that NFκB signaling is inhibited by TTP (Liang, lei 2009), it is perhaps unsurprising that 
transcription initiation of early NFκB-driven feedback node genes later require induction by 
alternative, readily available factors.   
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Figure 3.12 Enrichment of RelA at the Zfp36 locus in murine bone marrow derived 
macrophages 
Primary murine BMM were seeded at a density of 1x106 /ml overnight before being left 
unstimulated or treated with LPS (10ng/ml) for the times indicated ((A) = 1h LPS (B) = 2h 
LPS, (C) = 4h LPS. Subsequently, cells were subjected to ChIP with antibodies specific for 
RelA and an isotype control (IgG) before QPCR using oligonucleotides designed against 
the murine TTP locus (Figure 3.8). The fold induction is calculated as a normalisation of 
LPS-stimulated to unstimulated values for RelA antibody. Plotted are the mean values for 
triplicate QPCRs of one experiment that is representative of two similar results. 
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3.2.12 ChIP of the human ZFP36 locus and RelA knockdown by siRNA 
3.2.12.1 
Further to the work on pharmacological inhibition of NFĸB, primary human macrophages 
were subject to transfection with siRNA directed against human RelA in order to determine 
the effects on TTP transcription rate and RNAPII association. 
Primary human macrophages were isolated as described in chapter 2.2.1.3 and on the third 
day transfected with RelA siRNA or scrambled oligonucleotide as a control. Transfection 
mixture was removed after 2 hours and cells allowed to recover for 48 hours before being 
subject to LPS activation or left un-stimulated.  
As in 3.2.8, the ChIP procedure was optimised for human primary macrophages and QPCR 
primers were designed against specific regions of interest along the ZFP36 locus (Figure 
3.14). The focus of the human ChIP centred around 8 specific DNA regions of interest. This 
decision was partially based on time constraints, given that human cells were available only 
occasionally and therefore experimental timescales were lengthy. In addition and relatedly, 
the recovery of macrophage material was reduced in human cells when compared to 
murine primary macrophages and cell lines. Therefore it was not possible to recapture 
enough human DNA to carry out the amount of QPCR required to cover the human ZFP36 
locus in its entirety. The western blot in Figure 3.15(A) shows an approximate 80% 
knockdown in cells transfected with RelA siRNA versus scrambled oligonucleotide. In 
macrophages treated with a scrambled control siRNA, I detected strong association of RelA 
with ECR4, which contains putative NF-kB binding sites. There was also apparent association 
of RelA with ECR3, but not with the human ZFP36 intron, consistent with a previous report 
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(Chen 2013). Treatment of macrophages with siRNA directed against RelA virtually ablated 
all of these ChIP signals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      158
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fi
gu
re
 3
.1
3 
D
es
ig
n
 a
n
d
 s
e
q
u
en
ce
 l
o
ca
ti
o
n
 o
f 
o
lig
o
n
u
cl
eo
ti
d
e 
p
ri
m
er
s 
ta
rg
et
in
g 
sp
ec
if
ic
 
co
n
se
rv
ed
 r
eg
io
n
s 
o
f 
th
e 
h
u
m
an
 Z
fp
36
 lo
cu
s 
(A
) 
P
ri
m
er
s 
w
er
e 
d
es
ig
n
ed
 t
o
 t
ar
ge
t 
se
q
u
en
ce
s 
o
f 
in
te
re
st
 a
t 
th
e 
h
u
m
an
 Z
fp
3
6 
lo
cu
s,
 
in
cl
u
d
in
g 
EC
R
3 
(c
h
r1
9:
3
98
9
30
4
6
-3
98
9
31
9
5 
an
d
 
ch
r1
9:
3
98
9
35
5
4
-3
98
9
37
1
2
),
 
EC
R
4
 
(c
h
r1
9:
3
98
9
42
6
0
-3
98
9
44
3
9 
an
d
 
ch
r1
9:
3
98
9
4
80
7
-3
98
94
9
64
),
 
th
e 
in
tr
o
n
 
re
gi
o
n
 
(c
h
r1
9:
3
98
9
77
3
2
-3
98
9
79
4
2 
an
d
 c
h
r1
9:
39
89
8
08
1
-3
98
98
2
38
),
 3
’ 
U
TR
 (
ch
r1
9
:3
9
90
0
06
7
-
39
90
02
2
7
) 
an
d
 
a 
d
o
w
n
st
re
am
 
re
gi
o
n
 
(c
h
r1
9:
3
99
00
76
9
-3
9
90
0
96
7
).
 
Ea
ch
 
p
ri
m
er
 
p
ai
r 
am
p
lif
ie
d
 a
 s
in
gl
e 
p
ro
d
u
ct
 o
f 
ap
p
ro
xi
m
at
el
y 
10
0
-2
00
b
p
. 
(B
) 
C
h
ro
m
at
in
 s
o
n
ic
at
io
n
 w
as
 
o
p
ti
m
is
ed
 f
o
r 
h
u
m
an
 m
o
n
o
cy
te
 d
e
ri
ve
d
 m
ac
ro
p
h
ag
es
. 
Si
x 
p
u
ls
es
 o
f 
12
 s
ec
o
n
d
s 
w
er
e
 
fo
u
n
d
 t
o
 b
e 
o
p
ti
m
al
 f
o
r 
sh
ea
ri
n
g 
ch
ro
m
at
in
 in
to
 f
ra
gm
en
ts
 a
p
p
ro
xi
m
at
el
y 
20
0b
p
 -
 1
0
0b
p
 
in
 le
n
gt
h
. 
  
      159
 
 
 
 
 
 
 
 
(A) 
 
 
 
 
 
 
 
(B) 
 
 
 
 
 
 
 
 
 
Figure 3.14 Knockdown of RelA & ChIP of the ZFP36 locus in human primary 
macrophages 
Primary human macrophages were seeded at a density of 10x106. After 3 days, cells were 
transfected with either RelA siRNA or scrambled oligonucleotide. After transfection, cells 
were allowed to recover for two days before being stimulated with LPS and undergoing 
ChIP with antibody specific for RelA. In parallel, cells were harvested for RelA protein 
detection. (A) Western blot showing 80% RelA knockdown in primary human 
macrophages treated with RelA siRNA and scrambled oligonucleotide in the presence (1 
hour) and absence of LPS. DNA was then subjected to QPCR using primers directed at 
regions of interest within the Zfp36 locus (Figure 3.12). (B) Confirmation of RelA knock 
down in ChIP experiments. RelA was not recovered from siRNA treated cells. Data shows 
mean values from QPCR in triplicate of a ChIP experiment from one donor. Black bars 
represent knockdown of RelA (siRNA) whereas red bars show scrambled control siRNA. 
ECR = evolutionarily conserved region; INT = intron; DS = downstream region. 
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3.3 Discussion 
In this chapter, I have shown that although NFκB signalling plays a substantial role in the 
transcriptional regulation of FNGs in response to LPS, it is not indispensable. Whereas TNFα 
and A20 mRNA levels were significantly inhibited by MLN4924, The combination treatment 
had a cooperative effect on DUSP1 transcript expression. This effect could be due to the 
association of additional immune-related transcription factors with cis-acting elements at 
the DUSP1 locus that might become more readily available in the absence of NFκB. DUSP-1 
can be induced by a myriad of extracellular stimuli, including growth factors and serum 
(Keyse 2000; Noguchi et al. 1993; Li et al. 2001). Accordingly, the DUSP1 promoter contains 
a large number of regulatory sequences and transcription factor binding motifs, including 
cMyc, cJun, cFos, Elk1 and ATF2 (Brunet et al. 1999; Davis 1995; Treisman 1996). Equally, it 
is possible that a negative regulator of Dusp1 gene expression is induced by LPS in a strongly 
NFκB dependent manner. Noticeably, the stimulatory effect of MLN is stronger after 1 hour 
of incubation, which might allude to de novo protein synthesis of a DUSP1 inhibitor.  It 
should be remarked, that MLN might have off-target effects that are not yet understood.  
Despite previous studies highlighting the importance of NFκB in the transcriptional up-
regulation of Zfp36, the inhibitory effect of MLN on LPS-induced Zfp36 mRNA expression 
was underwhelming in WT macrophages. Furthermore, in Dusp1-/- cells the inhibitory effect 
of MLN was lost entirely. These data indicate that additional transcription factors are 
involved in the control of Zfp36 up-regulation in response to pro-inflammatory stimuli and 
that prolonged MAPK activation may enhance the effect of trans-acting factors other than 
NFκB.  
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Previously, κB sites have been identified 5’ of Zfp36 in the region encapsulated by ECR4 and 
additionally within the Zfp36 intron. Concomitantly, the murine ECR4 was the only element 
to show sensitivity to inhibition by MLN, whereas MmECR3-4, which contains the same 
sequence juxtaposed with MmECR3 was unresponsive to MLN. It would appear that the 
functional sequences within MmECR3 are able to overcome inhibition of MmECR4 by MLN. 
However, HsECR3-4 was significantly inhibited by MLN, therefore it is evident that there are 
differences in the regulation of Zfp36 functional elements between the two species. These 
differences may be responsible for the transcriptional dependency on NFκB in humans that 
is not observed in murine macrophages treated with LPS and MLN. Indeed, Zfp36 mRNA 
levels were inhibited to a higher degree in human macrophages when compared to murine 
cells. 
The use of chromatin immunoprecipitation revealed a number of previously unidentified 
RelA - DNA associations. Aside from the recognised κB motifs at loci corresponding to 
primer pairs 12-13 (ECR4), 14 (promoter region) and 15-16 (Intron), enriched DNA was 
recovered using primer pairs 2-3 (ECR1), 7-8 (ECR2), 21-22 and 26 (ECR5). According to 
online databases, conserved regions 1 and 5 each contain imperfect κB consensus 
sequences and binding motifs for PU.1 – a myeloid marker of accessible chromatin domains. 
LPS induced enhancers are often bound to PU.1 and exhibit mono methylation of H3 lysine 4 
(HSK4me1), which facilitates local histone depletion (Heintzman et al., 2007; Smale 2010). 
These two regions at either end of the Zfp36 locus are therefore susceptible to enhancer 
activation and recruitment of inducible transcription factors including NFκB and, amongst 
others the IRF family of transcription activators following LPS stimulation. Subsequent 
binding of transcription co-activators and p300/ CBP protein complexes then allows 
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communication with promoter elements through looping and therefore enhances the 
frequency and efficiency of transcriptional elongation and transcript processing (Carey & 
Gentleman 2009; Medzhitov & Horng 2009; Smale 2010; Ghisletti et al. 2010; De Santa et al. 
2010). 
Often the presence or absence of a transcription factor cognate motif is neither sufficient 
nor necessary to configure binding or indeed activate, or repress transcription. Under varied 
conditions, sequences of DNA may be differentially responsive to a number of factors 
depending on protein associations induced by alternative stimuli, in different cell types, 
tissues and time frames depending on the milieu and absent or available effectors. 
Therefore most DNA sequences and putative binding motifs are context dependent and 
although well conserved, may not exhibit the expected consensus sequence. For example 
differential phosphorylation of p65 (RelA) is relevant to the capacity of NFκB to induce, or 
inhibit, transcription (Huang et al. 2011; Hochrainer et al. 2013). Post-translational 
modification of any of the 12 phosphorylation sites on RelA can enhance associations with 
cAMP-response element binding protein (Ser246/311) (Duran et al. 2003; Zhong et al. 
1998)), HDAC1 (Thr435/505, Ser547) (O’Shea & Perkins 2010; Rocha et al. 2005) and alter 
associations with basal components of transcription machinery (Ser529/538) (Buss et al. 
2004; Wang et al. 2000). These interactions influence NFκB binding or tethering to 
sequences of DNA that may or may not encode a recognised κB site therefore adding to the 
specificity of transcriptional control. Of course, DNA looping to achieve promoter-enhancer 
juxtaposition could also account for apparent RelA associations with distal loci. 
It is clear that other factors have the ability to bind the Zfp36 locus and induce transcription 
in response to LPS and other immune-related agonists. In fact a number of transcription 
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factor binding sites have been identified by computer analysis in mouse (DuBois et al. 1990; 
Lai et al. 1995), human (Heximer & Forsdyke 1993; Lai et al. 1995; Smoak & Cidlowski 2006), 
rat (Kaneda et al. 2000) and bovine (Lai et al. 1995)  promoter and intron sequences (Lai 
1998). Consensus sequences of AP2, SP1 and TPE1 have been identified directly 5’ of the 
Zfp36 transcription start site as well as in the intron and have a confirmed role in serum 
inducibility of the TTP transcript. IL4 has been shown to stimulate TTP expression through 
signal transducer and activator of transcription 6 (STAT6) in mice (Suzuki et al. 2003) 
whereas TGFβ has been shown to up-regulate TTP expression through smad3 and smad4 
(Ogawa et al. 2003) located in the promoter region (Smoak & Cidlowski 2006). A 
glucocorticoid-like response element has also been suggested to reside in the mouse TTP 
promoter (DuBois et al. 1990) as well as a hexameric glucocorticoid response element 
sequence in the human TTP 5’ flanking region (Smoak & Cidlowski 2006). A functional GAS 
element that binds STAT1 has also been reported to mediate increases in TTP expression 
with interferon and p38 co-stimulatory stress signals (I Sauer et al. 2006). Figure 3.15, 
below, is a representation of current knowledge pertaining to the binding sites for 
numerous transcription factors which have been investigated as putative up-regulators of 
Zfp36. 
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Figure 3.15 Zfp36 locus transcription factor binding motifs 
The Zfp36 locus is small and compacted. However numerous agents have been suggested 
to induce Zfp36 transcription. The above schematic illustrates our current knowledge of 
functional transcription factor binding motifs within the Zfp36 locus. Also depicted are 
the evolutionary conserved regions discussed and used throughout this study, in relation 
to transcription factor binding sequences. ECR1 and ECR5 map directly onto two regions 
of significant DNAse hypersensitivity and are associated with PU.1, a transcriptional 
activator associated with macrophage activation and typically marks sites of accessible 
chromatin i.e. rapid response genes in macrophages. 
EGR1,
SP1,
TPE1,
GRE,
GAS,  
PU.1 AP2   PU.1
GRE ELK1                     SP1, GRE
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4.0 THE ANTI-INFLAMMATORY EFFECTS OF DEXAMETHASONE 
SELECTIVELY SPARE FEEDBACK NODE GENE EXPRESSION 
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4.1 Introduction 
Glucocoricoids represent the most effective anti-inflammatory treatment for chronic 
inflammatory diseases (Newton 2013). However the mechanisms by which glucocorticoids 
mediate their anti-inflammatory actions remain incompletely understood. A number of 
studies focused on identifying these mechanisms have sometimes uncovered contradictory 
findings and accommodated much debated schools of thought.  
The feedback node genes DUSP1, ZFP36 and TNFAIP3 are induced by pro-inflammatory 
stimuli in macrophages and act negatively on their respective pathways of activation. Prior 
to this study, Lasa et al (Lasa et al. 2002) identified the cooperative up-regulation of DUSP1 
mRNA in HeLa cells co-stimulated with the pro-inflammatory cytokine IL1α and the anti-
inflammatory synthetic glucocorticoid dexamethasone (DEX). Further to this, studies in 
Dusp1-/- mice revealed that the expression of Dusp1 contributes to the anti-inflammatory 
effects of glucocorticoids (Abraham et al. 2006). 
Tristetraprolin is a negative feedback regulator downstream of the MAPK p38 pathway and 
surprisingly, is also up-regulated by DEX treatment in A549 human alveolar epithelial cells 
(Smoak & Cidlowski 2006). This finding was contradictory to that of Jalonen et al. (2005), 
who showed that DEX inhibited tristetraprolin both at the level of mRNA and protein in a 
macrophage-like cell line. A handful of other groups have also highlighted inconsistencies 
regarding the effects of glucocorticoid on the regulation of Zfp36.  
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For example, when administered alone DEX was shown to induce TTP in A549 cells (King, 
Kaur, et al. 2009). However, in the same study and contradictory to Smoak & Cidlowski 
(2006), DEX inhibited TTP induction by the inflammatory cytokine IL1β (King, Kaur, et al. 
2009). More recently, Brahma et al. (2012) revealed that glucocorticoid strongly induced 
TTP in adipocytes both alone and in combination with an inflammatory stimuli. The 
observed inconsistencies might be explained by the differential regulation of TTP according 
to cell type, stimulus and species.  
With a strong transcriptional dependency on NFκB (Chapter 3) and a powerful ability to 
inhibit canonical NFκB signalling, A20 is a classic negative feedback regulator. However, only 
recently it has been reported that NFκB-mediated gene transcription at this locus may 
escape inhibition by GR (Altonsy et al. 2014). 
The aim of this research chapter was to characterise FNG expression in response to the 
glucocorticoid dexamethasone in both resting and activated cells. In addition and drawing 
the focus to regulation of TTP expression, I investigated transcriptionally active sequences of 
the Zfp36 locus and their response to stimulation with DEX and LPS. 
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4.2 Results 
4.2.1 Dexamethasone inhibits pro-inflammatory gene mRNA production in 
macrophages  
Initially, the kinetics and magnitude of dexamethasone’s effect on the inflammatory 
mediators TNFα, IL1α and IL6 was measured by QPCR in primary human monocyte and 
murine bone marrow derived and RAW264.7 macrophages. Figure 4.1 shows that TNFα and 
IL1α primary response genes (PRG) were rapidly and transiently induced upon stimulation 
with LPS. Forming part of the secondary response, IL6 mRNA levels were up-regulated at the 
2 hour time point and increased until 8 hours in primary macrophages, whereas expression 
was extended in RAW264.7 macrophage-like cell line. In resting macrophages, DEX alone 
had a small inhibitory effect on the expression of each pro-inflammatory mRNA. 
Dexamethasone was able to significantly inhibit LPS-induced expression of all pro-
inflammatory mRNAs measured and at each time point as previously reported (Abraham et 
al. 2006). Glucocorticoids employ diverse inhibitory mechanisms and have transcriptional 
and posttranscriptional effects on gene expression. Thus GCs facilitate efficient down-
regulation of PRGs and SRGs alike. Early inhibition of mRNA expression is often indicative of 
transcription inhibition, whereas late inhibition may signify post-transcriptional mechanisms 
of down-regulation (Hargreaves et al. 2009). 
These data are consistent with similar studies and verify the anti-inflammatory outcome of 
dexamethasone treatment in these cell types.  
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Figure 4.1 Dexamethasone inhibits mRNA expression of several pro-inflammatory genes in 
macrophages 
Primary human and mouse macrophages and RAW264.6 macrophage-like cells were left untreated, 
stimulated with LPS (10ng/ml) (black bars), dexamethasone (100nM) (white bars) or LPS + DEX in 
combination (green bars) for 0, 1, 2, 4 and 8 hours. Total RNA was isolated and used as a template for 
cDNA synthesis and quantitative PCR of TNFα, IL1α and IL6 gene expression, performed in triplicate. 
Mean values are shown with standard error and are representative of three separate experiments. 
Statistical significance was assessed using two-way ANOVA, *** (p < 0.001). 
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4.2.2 Dexamethasone and LPS cooperatively regulate Dusp1 mRNA production 
Consistent with studies previously conducted, the ability of dexamethasone to induce 
DUSP1 in HeLa and A549 cell lines (Joanny et al. 2012; Lasa et al. 2002) was preserved in 
primary human and mouse macrophages and RAW264.7 macrophage-like cell line as well as 
HeLa and A549 epithelial cell lines.  
Dexamethasone treatment alone was able to induce DUSP1 at the level of mRNA in human 
epithelial cell lines approximately 5 fold, over an incubation period of 1 to 8 hours (Figure 
4.2). This effect was stronger and more transient in the myeloid lineages; with an 8-fold 
induction at 1 hour in both human and mouse primary macrophages and 5 fold at 1 hour in 
the RAW264.7 macrophage cell line. Further to this, co-stimulation with biologically 
effective doses of LPS (10ng/ml) and DEX (100nM) significantly enhanced and extended 
Dusp1 mRNA expression in macrophages. The synergistic induction was twice the 
magnitude of LPS alone and an effect more than additive of each agonist individually. A 
similar expression pattern was observed under co-treatment with IL-1α (1ng/ml) and DEX in 
the epithelial cell lines however the cooperative effect was not striking and may reflect the 
additive effect of IL-1α and DEX (Figure 4.2).  
The up-regulation of Dusp1/DUSP1 by glucocorticoids has previously been recognised 
(Abraham et al. 2006; Johansson-Haque et al. 2008; Tchen et al. 2010; Shipp et al. 2010; 
Joanny et al. 2012). Additionally, studies have shown that the anti-inflammatory potencies 
of glucocorticoids are partly dependent on the expression of Dusp1 (Abraham et al. 2006; 
Lasa et al. 2002; Weinstein et al. 2011). Here, we observed the cooperative up-regulation of 
Dusp1 by pro-inflammatory stimuli and the anti-inflammatory synthetic glucocorticoid DEX. 
The Dusp1 locus contains a number of NFκB-like binding motifs as well as GR binding 
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sequences. Proximal GR association is generally considered to inhibit NFκB driven 
transcription through protein-protein interaction. However the expression of Dusp1 in 
response to pro-inflammatory stimuli not only escaped GR-mediated inhibition but was 
significantly enhanced and extended by DEX treatment. 
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Figure 4.2 Dexamethasone and LPS cooperatively regulate DUSP1 mRNA production.  
Cells were left untreated, stimulated with LPS 10ng/ml (white bars) or IL1 1ng/ml 
(Striped bars), dexamethasone 100nM (black bars) or LPS/IL1 + DEX (dark/light green 
bars) in combination for 0, 1, 2, 4 and 8 hours. Total RNA was isolated and used as a 
template for cDNA synthesis and real time QPCR gene expression assay for DUSP1, 
performed in triplicate. Data shows mean values ± SEM. Significance was assessed with 
Two-way ANOVA. Top and bottom level statistical marks indicate significance between 
LPS/LPS+DEX and DEX/LPS respectively *(p < 0.05), **(p < 0.01), ***(p < 0.001). 
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4.2.3 Dexamethasone and LPS cooperatively regulate Zfp36 mRNA and protein 
expression  
 
Regulation of gene transcription by glucocorticoids is a key but non-exclusive mechanism of 
their anti-inflammatory action. Indeed, glucocorticoids modulate gene expression by 
multiple mechanisms and a large proportion of glucocorticoid target genes are post-
transcriptionally regulated. Transcriptional mechanisms are intricately coupled to 
posttranscriptional modification of gene expression at the level of mRNA transport, decay 
and translation and therefore a critical influence on the timing and magnitude of cellular 
responses (Brook et al. 2000; Stellato 2004). Posttranscriptional control of gene expression 
in inflammation is central to maintaining rapid protein output from primary response genes. 
Glucocorticoids have extensively been shown to act on tyrosine kinase pathways, which are 
key immunomodulatory ‘switches’. The ERK pathway is strongly inhibited by glucocorticoid 
up-regulation of DUSP1 in murine mast cells and human osteoblasts (Kassel et al. 2001; 
Engelbrecht et al. 2003). In addition, glucocorticoid induced leucine zipper (GILZ) blocks 
phosphorylation of Raf1 and subsequent activation of MKK1/2 and ERK in T-cells (Ayroldi et 
al. 2002) but not in macrophages (Fernandes et al. 1999). In macrophages GCs are 
documented to inhibit JNK and, perhaps most relevant to posttranscriptional regulation in 
macrophages, MAPK p38 (Swantek et al. 1997; Kontoyiannis et al. 1999). Activated 
macrophages treated with inhibitors of p38 exhibit a sharp decrease in the mRNA of several 
genes including IL1, VEGF, TNFα, IL6, IL8 and COX2; all of which are post-transcriptionally 
inhibited by glucocorticoids (Schwiebert et al. 1996; Amano et al. 1993; Tobler et al. 1992; 
Swantek et al. 1997; Lasa et al. 2001; Gille et al. 2001). 
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As aforementioned, the up-regulation of DUSP1 by glucocorticoids and subsequent 
inhibition of MAPK signalling in macrophages may account for the mRNA destabilising 
effects of glucocorticoids. However this mechanism remains largely unclear.  
Downstream of MAPK p38, TTP is inactivated by MK2-mediated phosphorylation of two 
specific and highly conserved serine residues. However Zfp36 gene expression also lies 
downstream of inflammatory signalling and p38 MAPK -activation of numerous transcription 
factors including SP1, AP1, and NFκB (Chapter 3) to name just a few. Smoak and Cidlowski 
reported glucocorticoid-mediated up-regulation of tristetraprolin mRNA in the A549 human 
pulmonary alveolar cell line and in rat tissues, proposing a novel mechanism for 
glucocorticoid action. Our hypothesis was that, as with Dusp1, dexamethasone would 
‘superinduce’ TTP mRNA when in combination with a pro-inflammatory stimulus; that is, LPS 
in myeloid cells and IL1α in epithelial cell lines.  
Basally, TTP was expressed at very low levels, both in terms of mRNA and protein. In 
response to DEX treatment, Zfp36 mRNA was transiently increased in the epithelial lineages 
(Figure 4.3). This effect was strongest in A549 cells, where we observed a 5 fold DEX-
dependent increase in TTP RNA at the 1 hour time point, which had doubled to 10 fold by 4 
hours of incubation preceding a decline after 8 hours. Gene induction in the HeLa cells 
followed a similar pattern and peaked with a 5-6 fold increase in Zfp36 RNA expression at 4 
hours post DEX treatment. However, DEX alone had very little effect on TTP mRNA levels in 
the myeloid cells.  
Pro-inflammatory stimuli (LPS or IL-1) alone induced Zfp36 gene expression strongly and 
significantly in all cell types. At 1 hour in human cells, LPS-induced Zfp36 was between 10 
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and 15 fold over basal levels. In murine cells, TTP induction was marginally stronger and 
between 20 to 30 times resting levels after 1 hour. 
In combination with LPS, DEX was able to synergistically increase Zfp36 mRNA synthesis to 
magnitudes that were significant at 1 and 4 hours in macrophages. Maximal induction of the 
Zfp36 message with co-stimulation was up to 60 fold over basal levels in bone marrow 
derived primary murine macrophages. The murine derived myeloid cells showed the 
greatest synergistic effect where DEX treatment at least doubled the LPS induction of TTP 
mRNA at 1 hour and at 4 hours in RAW cells. After 4 hours, the effects of LPS or DEX 
treatment were little to non-existent in human macrophages. However simultaneous 
treatment increased ZFP36 mRNA levels 5 fold more than LPS or DEX alone. The RNA 
expression profile of TTP at four hours of inflammatory stimulation is particularly 
interesting. The effects of DEX on LPS-induced Zfp36 expression in the epithelial cells 
reflected a similar pattern to the myeloid cells at 1 and 2 hours in A549 cells and at 1 hour in 
HeLa cells. However it is less clear after the 1-hour mark whether some of the LPS plus DEX 
effects on ZFP36 up-regulation are additive, rather than a result of the two agonists acting 
synergistically. 
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Figure 4.3 Dexamethasone and LPS cooperatively regulate Zfp36 mRNA expression 
Cells were left untreated, macropghages and epithelial cells were stimulated with LPS 
(10ng/ml) (white bars) or IL1 (white striped bars) respectively, dexamethasone (100nM) 
(black bars) or LPS/IL1 + DEX in combination (dark/light green bars) for 0, 1, 2, 4 and 8 
hours. (A) Total RNA was isolated and used as a template for cDNA synthesis and RT PCR 
gene expression assay for Zfp36, performed in triplicate. Data shows mean values ± SEM 
of four separate experiments. Significance was assessed with Two-way ANOVA *(p < 
0.05), **(p < 0.01), ***(p < 0.001).  
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4.2.4 Dexamethasone and LPS cooperatively regulate Tnfaip3 mRNA production 
Another target of pro-inflammatory agonists, A20 (TNFAIP3) has recently been described to 
escape GR-mediated inhibition in airway epithelial cells co-stimulated with dexamethasone 
and TNFα (Altonsy et al. 2014; Rao et al. 2011). In this study, we showed the same effect in 
the A549 pulmonary alveolar cell line and primary human and murine macrophages co-
treated with an inflammatory stimulus plus DEX.  
LPS induction of Tnfaip3 was greatest in murine cells; transcripts were detected at levels 
170 and 100 times that of resting level in BMM and RAW respectively. LPS induction of 
TNFAIP3 was more modest in human cells with a 50 fold induction observed at 1 hour in 
human macrophages and an approximately 80 fold in human epithelial cells. Treatment with 
dexamethasone alone was able to induce Tnfaip3 2 fold in macrophages and up to 6 fold in 
human epithelial cell lines.  One hour of co-treatment significantly and cooperatively 
augmented Tnfaip3 gene induction in macrophages and A549 cells. DEX also cooperatively 
enhanced the LPS effect at 2 hours in RAW murine macrophage-like cells. However, 
thereafter DEX had no significant augmenting effect on LPS induced Tnfaip3 expression. In 
fact at two hours post co-stimulation, DEX was significantly inhibitory to Tnfaip3 
transcription in HeLa cells and at 2, 4 and 8 hours in BMMs. A20 gene expression was rapidly 
induced by pro-inflammatory stimuli and was shown to be strongly dependent on NF-kB 
(Chapter 3). This response constitutes a negative feedback loop that helps to determine the 
kinetics of NF-kB activation. It is possible that dexamethasone inhibits A20 expression at late 
time points indirectly, by altering the characteristics of the NF-kB - A20 negative feedback 
loop. 
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However, we did not observe DEX inhibition of TNFAIP3 in every cell type. Additionally, 
TNFAIP3 is a PRG, therefore late-stage inhibition after de novo protein synthesis should not 
restrict the early function of A20. These data indicate that, in addition to DUSP1 and Zfp36, 
Tnfaip3 is a feedback node gene that mostly escapes GR-mediated inhibition of 
inflammatory signalling-responsive genes. 
 
 
Figure 4.4 Dexamethasone and LPS cooperatively regulate Tnfaip3 mRNA production  
Cells were left untreated, macrophages and epithelial cells stimulated with LPS 
(10ng/ml) (white bars) or IL1 (1ng/ml) (white striped bars) respectively, 
dexamethasone (100nM) or LPS/IL1 + DEX in combination (dark/ light green bars) for 
0, 1, 2, 4 and 8 hours. Total RNA was isolated and used as a template for cDNA 
synthesis and RT PCR gene expression assay for Tnfaip3, performed in triplicate. Data 
shows mean values ± SEM. Significance was assessed with Two-way ANOVA *(p < 
0.05), **(p < 0.01), ***(p < 0.001). 
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4.2.5 Cooperative up-regulation of Zfp36 mRNA by LPS and DEX requires DUSP1 
In order to highlight the anti-inflammatory effects of glucocorticoids, previously we used 
QPCR to quantify Tnfα mRNA under conditions of LPS, DEX or LPS+DEX. The down-regulation 
of numerous pro-inflammatory factors by glucocorticoids and their therapeutic potential is 
in part, dependent on the expression of DUSP1 (Abraham et al. 2006; Tchen et al. 2010; 
Joanny et al. 2012). Studies using Dusp1-/- mice or DUSP1 knock down have illustrated its 
importance in glucocorticoid-mediated transcriptional inhibition. Additionally, a number of 
pro-inflammatory genes up-regulated by p38-dependent mRNA stabilisation are inhibited by 
glucocorticoids via posttranscriptional mechanisms (Abraham et al. 2006). These mRNAs, 
including Tnfα, Cox2, Il1α/β and Cxcl1 are encoded by labile transcripts and require 
continuous activation of the p38 pathway for expression (Abraham & Clark 2006).  
Both MAPK p38 and downstream effector MK2 post-translationally modify and inactivate 
TTP, preventing destabilisation of pro-inflammatory transcripts (Marchese et al. 2010; 
Clement et al. 2011; Stoecklin et al. 2008; Ronkina et al. 2010; Tchen et al. 2004; Brook et al. 
2006; Tudor et al. 2009). In Dusp1-/- cells p38 MAPK activity is significantly enhanced, 
meaning that TTP remains phosphorylated and inactive. Furthermore, p38 MAPK is 
insensitive to inhibition by DEX in Dusp1-/- cells suggesting that Dusp1 plays a role in 
glucocorticoid anti-inflammatory function (Clark et al. 2003; Abraham et al. 2006; Abraham 
& Clark 2006). As we currently understand, one function of DUSP1 is to limit p38 signalling 
and release TTP from its inactive state. 
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In order to identify whether the cooperative regulation of TTP by pro-inflammatory stimuli 
and DEX is a mechanism dependent on DUSP1, experiments were carried out as previously 
and compared WT and Dusp1-/- BMM Zfp36 gene expression in response to DEX. 
In parallel to previous time courses, age- and sex- matched wild type (Dusp1+/+) and Dusp1-
/- murine BMMs were stimulated over a period of 0-8 hours with either DEX, LPS or 
LPS+DEX. Cells were harvested for RNA and subject to QPCR.  
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Figure 4.5 Synergistic induction of Zfp36 mRNA by LPS and dexamethasone requires 
DSUP1 
Primary macrophages were derived from the bone marrow of wild type (WT) and Mkp1-
/- mice and cultured in GM-CSF for 5 days before seeding at a density of 10^6 cells/ ml in 
12 well plates. Cells were left untreated, stimulated with LPS (10ng/ml), dexamethasone 
(100nM) or LPS + DEX in combination for 0, 1, 2, 4 and 8 hours. Total RNA was isolated 
and used as a template for cDNA synthesis and quantitative PCR of Zfp36 gene 
expression, performed in triplicate. Data shows mean values of three independent 
experiments for each WT and Mkp1-/- primary macrophages ± SEM. Significance was 
assessed with Two-way ANOVA *(p < 0.05), **(p < 0.01), ***(p < 0.001). 
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The mechanisms dictating the normal expression of TTP are numerous, interrelated and 
therefore complex. Firstly, TTP binds to its own 3’UTR and subsequently regulates its own 
expression by mRNA destabilisation which couples its expression further to the activity of 
MAPK p38. Therefore, the initial gene induction of Zfp36 requires NFκB-mediated 
transcriptional activation and p38 mediated mRNA stabilisation. Hence in wild type cells, as 
p38 activity declines TTP becomes active and destabilises its own mRNA accounting for the 
transient expression of Zfp36 observed in WT BMMs (Figure 4.6). Additionally, in WT cells, 
DEX cooperated with LPS to activate Zfp36 transcription but also induced Dusp1 gene 
expression to inactivate p38 and enforce the off phase of the TTP. This effect is illustrated by 
a strong early peak of expression at 1 hour followed by a rapid decline thereafter.  
In Dusp1-/- macrophages the initial transcriptional activation of Zfp36 was enhanced by a 
minimum of two fold compared to WT, however DEX was unable to increase this expression 
further (Figure 4.6). In addition, the sustained elevation of LPS mediated Zfp36 transcript 
expression in Dusp1-/- illustrates disruption to the off phase of TTP expression.  
Unpublished data from our group showed that prolonged activation of p38 in these cells 
means that Zfp36 mRNA remains stable, rather than becoming unstable and therefore 
accumulates. Indeed, results from the Clark group (currently unpublished data) have shown 
that increased stability of a set of pro-inflammatory cytokines and chemokines due to 
disruption of MAPK signalling in Dusp1-/- macrophages is entirely dependent on TTP 
phosphorylation.  
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Figure 4.6 Complex mechanisms dictating expression of TTP 
The inactivation of TTP by specific phosphorylation (Ser52/178 in mouse) is a downstream 
mechanism of p38 and MK2 (A), reversible by PP2A and the removal of p38 signalling. When 
active, TTP binds to AREs in its own 3’UTR (B) and promotes mRNA decay, furthermore 
coupling its expression to the actions of p38 MAPK. Transcriptionally, Zfp36 is under the 
control of numerous transcription factors including NFκB (C). Therefore activation of both 
NFκB and p38 MAPK is required to raise the strong initial phase of TTP synthesis. DUSP1 
blocks the p38 pathway and therefore facilitates not only TTP activation but also instability. 
DEX augments the effects of DUSP1 and has transcriptional effects on Zfp36, yet in doing so 
increases TTP protein and mRNA instability. 
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4.2.6 Synergistic regulation of Zfp36 reporter constructs by pro-inflammatory 
stimuli and dexamethasone LPS and dexamethasone  
Using the reporter constructs detailed in Chapter 3, our aim was to identify the potential of 
DEX to regulate transcription via functional ECRs 2, 3 and 4.  
HeLa cells were transfected with the appropriate experimental constructs and 
correspondingly with (κB)3- or pGL3P (empty)- luciferase vectors. Containing six tandem 
NFκB binding motifs, the (κB)3- containing luciferase reporter acts as a control ensuring 
inflammatory signalling remains in-tact in the transfected cells. Additionally, transfection of 
the rudimentary pGL3P vector is a control for potential background transcription of 
luciferase via the minimal promoter sequence. As previously described in Chapter 3, all of 
the constructs mounted a transcriptional response to stimulation with IL1α in HeLa cells  
(Figure 4.6). DEX alone increased luciferase activity in cells transfected with the HsECR3-4 
expression vector but had no effect on transcription of the other constructs. The 
combination of IL1α and DEX augmented the expression of luciferase in HsECR3 and 
HsECR3-4 containing cells in a cooperative manner. On the other hand however, the 
transcriptional response of HsECR4 to IL1α was inhibited by treatment with DEX.  
Similarly, RAW264.7 cells were transfected with the appropriate murine sequence (Mm) 
ECRs; 2; 3; 4; and 3-4. In this case the positive control expression vector contained a Tnfα 5’ 
(TNF5’) sequence. In response to LPS, all of the constructs were able to induce transcription 
and increased luciferase activity. Comparable to experiments in HeLa cells, DEX alone 
induced transcriptional activity of MmECR3-4 and additionally MmECR2 in RAW cells. 
Whereas co-stimulation enhanced the luciferase response additively in MmECR2, MmECR3-
4 responded synergistically to DEX and LPS. In contrast to the HsECR3, the murine sequence 
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showed inhibited LPS-induced transcriptional activity when stimulated with DEX in 
combination, as did MmECR4.  
In summary, we observed a number of consistencies between species and cell type. The 
ECR4 responded negatively to DEX, whereas ECR3-4 responded positively to DEX treatment 
and ECR3 showed relatively little response to DEX which was slightly positive in HeLa or 
negative RAW cells and therefore might be dependent on species or cell type. Sequence 
similarity between human and mouse within these regions is in the region of 70-79%. In 
both mammals, the ECR4 contains four overlapping sequences akin to κB-like binding 
motifs, whereas ECR3 contains one such motif and a putative GR sequence and ECR2 
contains a GR motif. These data would suggest that cooperative regulation of transcription 
at the TTP locus requires the proximal binding of GR and NFκB in a way that does not 
facilitate transrepression. That is, NFkB sequences in isolation are subject to inhibition by 
GR, presumably through transrepression. However a number of recent studies have 
highlighted the complexity of GR and NFκB cross-talk (Joanny et al. 2012; Lannan et al. 2012; 
King et al. 2013) and when found in proximity, these two nuclear factors have been shown 
to work in concert to multiplicatively augment gene expression (Rao et al. 2011; Uhlenhaut 
et al. 2013). Coactivation of GR and NFκB has been the topic of recent studies exploring 
altered binding site repertoires in response to treatment with either agonist or both. Indeed 
crosstalk between glucocorticoids and pro-inflammatory stimuli may result in the loss or 
gain of GR-binding sites and their association with p65 (NFκB) in a mutually dependent 
manner (Rao et al. 2011). Furthermore we have identified these ECRs as putative GR, as well 
as NFκB binding sequences. 
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Here we have used transient transfection of luciferase reporter constructs as a tool to 
identify sequences responsive to GR, NFκB and the two in combination. However, it must be 
remarked that the actions of both GR and NFκB depended on epigenetic regulation, 
chromatin context, the recruitment of cofactors and associations with distal and proximal 
DNA sequence; none of which can be accounted for in this system (Uhlenhaut et al. 2013; 
Rao et al. 2011). 
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Figure 4.7 Dexamethasone and LPS co-induction of a luciferase reporter construct 
containing evolutionarily conserved regions of the Murine and Human Zfp36 locus 
(A) RAW264.7 and (B) HeLa cells were transiently transfected with luciferase reporter 
constructs. The following day cells were left unstimulated, activated with (A) LPS 
10ng/ml (white bars) or (B) IL1α 1ng/ml (striped bars), dexamethasone 100nM (black 
bars) or mutually (dark green = LPS+dex striped green = IL1+dex) for an optimum of 6 
hours. Following passive lysis, luciferase assays were performed. Data are expressed as 
mean ± SEM for four and three separate experiments in RAW264.6 and HeLa cells 
respectively. 
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4.2.7 Dexamethasone has no significant effect on LPS-induction of a Zfp36 mini-
gene reporter. 
In general, genes that are responsive to a wide variety of different agonists often have 
multiple, discrete and independent enhancers dispersed over large distances in the genome. 
Examples are Pepck, Rank and Ifng. However the Zfp36 locus is relatively small, with only 6 
and 5 kb separating it from its nearest 5' and 3' neighbours (Med29 and Plekhg2, 
respectively). The whole mouse Zfp36 locus occupies only 13.6 kb. The hypothesis states 
that important cis-acting elements involved in coordinating the expression of Zfp36 in 
response to multiple agonists are located and are spread out within this small region. In 
addition, it cannot be ruled out that significant regulatory elements are located within the 
Med29 or Plekhg2 genes, or even further away.  
As a tool to investigate transcriptional responses of the Zfp36 gene, we created a mimic-
gene, based on the Zfp36 locus but containing a luciferase cDNA in place of the two 
endogenous Zfp36 exons.  The construct contained the naturally occurring locus sequence 
from the 3’ UTR of upstream Med29 (Chr7:28,378,549-28,393, 218) to the Zfp36 5’UTR, 
followed by a short 18bp LUC sequence, the endogenous Zfp36 intron, the remainder of the 
LUC2CP sequence, Zfp36 3’UTR and downstream sequence leading up to the 5’UTR of 
Plekhg2 (Chr7:28,365,845-28,380,514 ). The interrupted Luciferase sequence was designed 
to splice exactly as the endogenous Zfp36. Following amplification of the appropriate 
sequences from murine genomic DNA using the primers described in Chapter 2.1.4, four 
cloning steps were required and are outlined in Figure 4.9. The final construct was 
transfected into RAW264.7 cells using the adapted protocol previously optimised for ECR-
luciferase constructs and cells were stimulated with LPS, DEX or LPS+DEX for 6 hours.  
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Although luciferase was induced by LPS in RAW264.7 cells containing the mimic-gene, the 
results were not as expected. Most notably, the maximum quantified fluorescence following 
6 hours of LPS stimulation was only induced 5 fold over the unstimulated control. This result 
was lower than that observed following LPS stimulation RAW264.7 containing ECR2, ECR3, 
ECR4 and ECR3-4, for which the relative luciferase were 5, 10, 5 and 12 fold the negative 
control respectively. Furthermore, endogenous Zfp36 showed around 10-20 fold response 
to pro-inflammatory stimuli LPS and IL1. In order to determine whether an experimental 
error had occurred, the protocol was repeated. However, four independent experiments 
yielded the closely comparable results shown in Figure 4.9. The transcriptional response of 
the (ΚB)3 construct following LPS stimulation was saturated, indicating that the unexpected 
result(s) were specific to the Zfp-LUC construct. Extensive diagnostic digestion of the Zfp-
LUC reporter at various steps of construction revealed that the downstream region had, in 
the three way ligation step, become repeated and inverted. This significant rearrangement 
of regulatory sequences could potentially cause transcriptional interference, either by 
rendering the involved sequences inoperative or preventing the functionality of distally 
located motifs. Due to time constraints and given that this piece of work was late on in the 
project, we were unable to continue with this section of research, or indeed carry out any 
further diagnostic checks. For these reasons we could not confidently rely on the data 
produced from this part of the study. 
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Figure 4.8 Effect of dexamethasone on LPS-induction of a Zfp36 mini-gene luciferase 
reporter 
(A) Schematic diagram of the Zfp36 mini gene reporter construct (Zfp-Luc) comprising 
the entirety of the murine Zfp36 locus (chr7:28371243 – 28386589) excluding the two 
exons, which were replaced by a Luc2CP luciferase sequence (pgl4.26), separated by the 
endogenous Zfp36 intron at an appropriate splice motif. (B) Zfp-Luc mini-gene 
organisation. (C) Luciferase reporter assay. HEK293 human embryonic kidney epithelial 
cells transformed with pUNO-TLR4 and pDUO2-MD2-CD14 plasmids were transfected 
with Zfp-Luc and the following day stimulated with LPS (10ng/ml), DEX (100nM) or both 
for 6 hours. Following passive lysis, luciferase assays were performed. Data are 
expressed as mean ± SEM for four separate experiments. 
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4.2.8 Chromatin Immunoprecipitation (ChIP) 
The effects of DEX on Zfp36 transcription are most enhanced at the 1 hour time point, when 
maximum recruitment of RNAPII and RelA is observed (Chapter3.2.9-11). For this reason 
ChIP was carried out on cells that were left unstimulated or treated with DEX, LPS or 
LPS+DEX for 1 hour before fixation with formaldehyde. The optimisation of ChIP and the 
specifics of primer design are described in Chapter 3.2.8. The primers used for ChIP allow 
detection of transcription factor recruitment to within approximately 100-200bp of genomic 
DNA. 
For each experiment an aliquot of chromatin was immunoprecipitated with an isotype 
control in order to account for background protein-DNA association. The values for protein 
enrichment were calculated by normalising the percent input values of experimental 
antibodies to that of the isotype control.  
4.2.8.1 GR binds to discrete elements at the Zfp36 locus 
Chromatin immunoprecipitation with glucocorticoid receptor was carried out in primary 
BMM treated with DEX (100nM), LPS (10ng/ml) or both for one hour (Figure 4.10). Included 
in the figure is a schematic corresponding to the relative location of the primers and Zfp36 
gene region. 
In the absence of ligand, GR is found mostly cytoplasmic and bound to an inhibitory complex 
of chaperone proteins. Therefore in response to stimulation with LPS alone GR remains 
inactive in the cytoplasm and cannot interact with cognate DNA motifs. Nuclear GR has 
been observed at small concentrations in the absence of ligand in human monocyte derived 
primary macrophages; however the cytoplasmic-nuclear shift of GR is functional in response 
to DEX. Putative GR binding motifs are located distally upstream and downstream of Zfp36, 
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corresponding to primer pairs 2, 8 and 25 respectively. In this study, we showed that DEX 
facilitated GR binding to various sequences across the Zfp36 locus in addition to the 
predicted sites. Of particular interest is the DEX-induced enrichment of GR observed at the 
upstream sites of evolutionary conservation previously investigated and analogous to 
sequences within primer amplicons 4, 6-7, and 10-12. Furthermore, GR also associated with 
the Zfp36 intron (primer 15), which is an essential component of Zfp36 transcription (Lai 
Blackshear 1998) and may have NFκB binding potential (Chen Chang 2013).  
When stimulated with both agonists, GR binding was not only enhanced but shifted towards 
a more discrete pattern than observed in DEX-alone stimulated cells. Enrichment of GR was 
increased by LPS most significantly at MmECR2 (primers 6-7), a conserved region directly 
downstream of neighbouring gene Med29 (primer 4), MmECRs 3 and 4 and at the putative 
GR-motif associated primer pair 25. On the other hand LPS inhibited DEX-dependent 
enrichment of GR at numerous loci including at primers 8-9, 11, the intron region and the 
3’UTR which corresponds to primers 16-17. 
From these data, it is clear that GR motif classification and prediction alone is insufficient to 
determine regulatory binding. In the presence of DEX, GR was enriched for at the reputed 
upstream (primer pairs 2 & 8) and downstream (primer pair 25) sites. However this binding 
context was not optimally functional given that, according to the RNAPII readout, 
transcriptional elongation was enhanced by co-stimulation. The increased transcriptional 
elongation observed in co-treated macrophages was accompanied by a discrete re-
distribution of GR to the putative enhancer regions previously described in this study. 
Furthermore and especially interesting are the sites of induced GR and NFκB co-occupancy 
and GR association with putative NFκB sites within the MmECR4 and intron. 
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Figure 4.9 The GR consensus binding motif at the Zfp36 locus 
Generally the GR binding motif exists as inverted repeats of the ½ site sequence AGAACA, with a 
separation of 3bp. However, in reality GR binding specificity is relaxed and only 5 bps (underlined) 
are consistently present at authentic binding sites with the idealised 15 bp consensus sequence 
AGAACANNNTGTTCT. On inspection of the Zfp36 locus there are 4 putative GR binding sites which 
imitate the consensus motif.  The genome alignment above (taken from 
www.ecrbrowser.dcode.org) shows human ZFP36 in parallel with the murine locus and highlights 
areas of evolutionary conservation between the two species. Text details the murine (mm10) and 
human (hg19) ‘GR motif’ aligned sequences (black text), ‘essential’ sites are underlined and 
consensus corresponding bps are in red. 
 
15bp GR idealised consensus sequence:
AGAACANNNTGTTCT
/TCTTGTNNNACAAGA
mm10 CTCTCTAGCTGTTCT
hg19 - - - - - - - - - - - - - - -mm10 AAGGTGACA-GTTCT
hg19 AAAATCTCATGTTCT
mm10 AGAACAAGAGTGTGA
hg19 - GAGACAGTGCATT -
mm10 GGAACAGGCAACCTT
hg19 - GCACA TGCAGTCTC
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Figure 4.10 Cooperative transcription requires GR binding to discrete regions at the 
Zfp36 locus 
(A) Cells were stimulated with LPS (white bars), DEX (black bars) or LPS + DEX (green 
bars) for 1 hour. After which ChIP was performed using antibodies to GR or an isotype 
control and primers spanning the entire locus of the murine Zfp36 gene. Data are 
represented as fold enrichment over the unstimulated control and represent the 
accumulation of GR antibody (y-axis) at each oligonucleotide (x-axis numbers) across the 
Zfp36 locus. Data points are expressed as the mean +/- SD of triplicate QPCR 
measurements and represent 3 similar separate experiments. (B) A schematic of the 
Zfp36 locus representing primer locations. 
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4.2.8.2 Dexamethasone alters the LPS-dependent RelA binding repertoire at the 
Zfp36 locus 
Given the apparent mutual cooperativity of GR and NFκB, we considered the possibility that 
DEX exerts its synergistic effects on LPS-induced Zfp36 transcription at the level of NFκB 
recruitment to target sites. We therefore used ChIP to investigate the recruitment of NFκB 
component RelA (p65) to the Zfp36 locus in vivo upon stimulation with LPS, DEX or LPS+DEX. 
ChIP will provide insight into the mechanisms occurring in context of genome and chromatin 
and also generate information pertaining to multiple NFκB sites that are mutually 
responsive to GR. 
To examine the effect of DEX on NFκB recruitment to the Zfp36 locus, ChIP assays were 
performed as described in Chapter 3.2.11, using a RelA specific antibody and PCR primers 
designed across the Zfp36 locus (Figure 4.11). Dexamethasone alone induced RelA binding 
adjacently upstream of and within ECR2; regions denoted by primer pairs 6-7 and 8-9 
respectively. There are no identified NFκB predicted tracks within ECR2, there is however a 
consensus GR motif. What is remarkable is that this RelA association with the sequence 
determined by primers 6-9 was almost entirely dependent on DEX, given that LPS treatment 
does not replicate the amplitude of this accumulation. DEX also strongly induced RelA 
enrichment within the Zfp36 promoter (primer 14) and intron (primer 15) both of which 
contain NFκB but not GR, motifs. Following administration of LPS for 1 hour, RelA was not 
observed to associate with ECR2, as with stimulation by DEX but, rather focused at  discrete 
sites; upstream (primer 3); within ECR4 (primers 12-13), which contains a number of 
repetitive cognate NFκB motifs; and around consensus sequences within the promoter 
(primer 14) and intron (primer 15). Two specific downstream sequences, represented by 
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primers 21 and 24 were also enriched for by RelA ChIP. Neither of which two sequences are 
known to contain NFκB binding sites, although nearby primer 25 encloses a GR element.  
After 1 hour under conditions of LPS + DEX, RelA associations with the Zfp36 locus differed 
somewhat to those mediated by either stimulant alone. This is particularly interesting. Most 
strikingly, the effect of LPS+DEX stimulated RelA accumulation across ECR2, ECR3, ECR4, 
within the promoter and intron. The strong LPS+DEX mutual accrual of RelA at ECR2 is 
particularly prominent because either LPS or DEX alone were only able to induce protein 
binding by 2 and 5 fold respectively. Similarly, binding of RelA at primer pair 7 appears to be 
dependent on DEX. Altonsy et al. (2014) recently described the ‘cooperative induction’ of 
novel sites for either NFκB or GR, or both upstream of alternative feedback node gene 
TNFAIP3. The enrichment between primers 12 to 15 looks to be an additive effect of both 
agonists acting in concert. The relative underrepresentation of ECR4 is unexpected, since 
this region contains a repeat of NFκB consensus binding sequences. Conversely, although 
the nucleotide sequences at locations 3, 4, 21, 24 and 25 do not contain cognate sites there 
appears to be an association of NFκB with the locus. Primers 3 and 25 describe ECR1 and 
ECR5 respectively which is likely to be significant. Although there is a chance that chromatin 
looping and promoter-enhancer elements interactions result in false positive DNA-
transcription factor associations. Overall, these data suggest that the cooperative up-
regulation of Zfp36 by LPS and DEX is driven by context-dependent NFκB association with 
novel DNA elements. 
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Figure 4.11 DEX increases the recruitment of RelA to κB and GR sites upstream of Zfp36. 
Chromatin from the same experiment as Figure 4.10 was immunoprecipitated with antibody 
for RelA. The figure shows fold enrichment over unstimulated control in macrophages 
stimulated with dexamethasone (black bars), LPS (white bars), or both (red bars) for one 
hour. Data are represented as the fold enrichment of RelA in response to agonist over the 
unstimulated values. Data points are expressed as the mean +/- SEM of two QPCR separate 
experiments.  
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4.2.8.3 Dexamethasone enhances RNAPII binding at the Zfp36 locus 
The RNAPII ChIP approach for analysing productivity of transcription consists of the 
detection of RNAPII – DNA interactions at specific sites, in this case at the Zfp36 locus, 
designated by the primer pairs selected. RNAPII is essential for transcription and by 
quantifying its association with specific regions of DNA under discrete circumstances, we 
can analyse the effects on gene transcription. Specifically, an association of RNAPII with the 
coding region of a locus suggests active transcription and the elongation phase of nascent 
DNA sequences. Whereas interactions of RNAII with upstream sequences might be 
indicative of enhancer sequences, regulatory regions and sites of active chromatin. In order 
to determine if GR recruitment was able to enhance the transcription elongation stage of 
Zfp36, we used RNAPII ChIP and interpreted the result as a direct measure of transcriptional 
activity under conditions of LPS, DEX or both.  DEX increased RelA binding to putative 
enhancer regions and the promoter of Zfp36, suggesting that the transcriptional response 
would be quickened. As a way of estimating the effects of DEX on Zfp36 gene transcription, 
chromatin was immunoprecipiteded with antibody specific to RNAPII and probed with 
primers spanning the Zfp36 locus. As highlighted previously (Chapter 3), we observed 
RNAPII pausing at the Zfp36 promoter as well as at regions further upstream; a mechanism 
that allows for almost instantaneous gene transcription following stimulation (Hargreaves et 
al. 2009). A 5’ to 3’ progression of RNAPII represents transcript elongation and as RNAPII 
accumulates at the 3’ end of the gene region it has already transcribed a molecule of RNA. 
An increase of RNAPII association within the gene region is associated with active 
transcription. 
Shown in Figure 4.12 (A), RNAPII accumulated at the Zfp36 locus in unstimulated 
macrophages, suggesting that they are ‘paused’ for the initiation of cofactors and the 
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elongation complex. On stimulation with DEX, the recruitment of RNAPII was enhanced 
within the Zfp36 coding region and downstream of the 3’UTR, indicating that GR activation 
and proximal localisation (4.2.9.1) was able to enhance transcription elongation.  
Figure 4.12 (B) shows enrichment of RNAPII at the Zfp36 locus in macrophages stimulated 
with LPS or LPS + DEX. In response to LPS, RNAPII recruitment was both increased and 
shifted downstream as the active subunit of RNAPII (pSer2) progressed 5’ to 3’ and 
transcribed the RNA (Chapter 3.2.10) (Hargreaves et al. 2009). With the addition of DEX, 
RNAPII association with the coding region and the 3’UTR was greatly enhanced and 
indicated the cooperative increase in transcription kinetics that we observed in 
macrophages stimulated with both Zfp36 agonists (Chapter 4.2.3). Enrichment of RNAPII 
was also observed upstream at primer regions 3 and 9 and within MmECR3-4, suggesting 
that these regions are associated with improved gene transcription. Distally located RNAPII 
enrichment could be a consequence of chromatin looping, whereby enhancer regions are 
brought into close proximity to the promoter favouring transcriptional elongation 
(Grzechnik et al. 2014; Stees et al. 2012).  These data indicate that DEX, whether alone or in 
combination with LPS enhances RNAPII interaction with the Zfp36 locus and subsequently 
increases the rate of transcription. 
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Figure 4.12 Effects of dexamethasone on RNAPII enrichment at the Zfp36 locus  
Again, chromatin from the same experiment as Figure 4.10 was analysed by ChIP using 
antibodies specific to RNAPII or rabbit isotype control (IgG) and primers targeted at the 
mouse Zfp36 locus. Primary murine macrophages were left unstimulated (light blue 
bars), stimulated for 1 hour with dexamethasone (Black bars), LPS (white bars) or a 
combination of both (dark blue bars) (A) RNAPII enrichment normalised to the isotype 
control for each data point. Data is shown as the mean ± SEM of two independent 
experiments using separate cultures of BMM. (B) Is a schematic of the Zfp36 locus which 
illustrates the location of each primer pair with respect to the ECRs and gene-coding 
regions. 
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4.3 Discussion 
For decades, synthetic glucocorticoids have been the cornerstone of treatment for a 
multitude of autoimmune and immunosuppressive conditions. However, the anti-
inflammatory mechanisms of glucocorticoid action are diverse and not fully understood.  
In this chapter I have demonstrated that glucocorticoids may selectively spare and even 
augment the expression of three critical negative feed-back regulators of inflammation. This 
is contradictory to the well described repressive effects of GR on NFκB and pro-
inflammatory gene transcription. When administered with LPS or IL1α, synthetic 
glucocorticoid dexamethasone synergistically induced the expression of DUSP1, TTP and 
A20 transcripts. Previous studies have described GR-mediated co-activation of NFκB driven 
promoters, including synergistic up-regulation of cellular inhibitor of apoptosis 2 (cIAP2) by 
DEX and TNFα (Webster et al. 2002), cooperative regulation of NFκB reporters (Hofmann & 
Schmitz 2002), super-induction of DUSP1, TNFAPI3, TNIP1 and NFKBIA (Abraham et al. 2006; 
Altonsy et al. 2014). However there have been no conclusive studies describing GR/NFκB 
cooperative induction of TTP.   
Dysregulation of TTP is strongly associated with autoimmune disease and knockout studies 
have revealed its importance in post-transcriptional regulation of pro-inflammatory 
mediators, particularly Tnfα. The mechanism of TTP induction has not been studied in detail, 
although NFκB is implicated (King, Kaur, et al. 2009; Carayol et al. 2006; Chen et al. 2013) 
and Chapter 3.2.5). Previously, DEX has been shown to up-regulate Zfp36 gene expression. 
However the mechanism of GR is unknown and must be context dependent given that NFκB 
and GR are generally considered to be mutually repressive. LPS and DEX co-treatment 
synergistically enhanced luciferase activity in expression vectors containing TTP-locus ECRs, 
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identifying three putative enhancer regions and their responsiveness to GR. When in 
isolation, reputed κB motifs upstream of Zfp36 were inhibited by DEX. However, when 
proximally located to glucocorticoid responsive enhancer sequences NFκB binding element 
containing ECR4 super-induced luciferase activity. Endogenously, GREs are often found in 
close proximity to NFκB and AP1 binding sites that may be associated with glucocorticoid-
activated or repressed genes. Thus the transcriptional outcome of GR association cannot be 
predicted based simply on sequence or the proximity of NFκB but is context dependent. 
That is, GR occupancy may confer gene-responsiveness but the receptor itself may not 
participate in the regulatory effects (Uhlenhaut et al. 2013).  
Chromatin immunoprecipitation is an invaluable tool for identifying protein-DNA 
interactions in vivo and unlike reporter constructs represents the result of endogenous 
interactions between DNA, transcription factors, cofactors and the chromatin environment. 
In the presence of LPS, DEX directed GR and RelA co-localisation at ‘gained’ GR sites within 
ECR3-4, upstream of Zfp36. The mutual dependence of GR and p65 binding at shared sites in 
response to TNFα and the synthetic GC triamcinolone acetonide (TA) has been described 
previously on a genome wide scale (Rao et al. 2011). The same study identified a number of 
common binding sites that were ‘maintained’ i.e. binding of GR and p65 was unaffected by 
treatment with TA, TNFα or both. These maintained elements were associated with anti-
inflammatory genes, including NFKBIA and TNFAIP3 (Rao et al. 2011). Through 
reorganisation of chromatin structure, inflammatory signalling may create additional 
domains of GR accessibility therefore priming for subsequent termination of the 
inflammatory response (Uhlenhaut et al. 2013).  
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ChIP also highlighted accumulation of GR, RelA and RNAPII, upstream of Zfp36 in the distal 
ECR1 (primers 2-3). Distant genomic elements can selectively promote gene transcription 
through chromatin looping which creates a ‘hub’ for the recruitment of transcription 
factors, cofactors and ancillary proteins. Remotely located GR has been shown to promote 
transcription through chromatin looping and may be a mechanism for enabling co-
occupancy with NFκB which facilitates cooperative regulation of gene expression in a 
stimulus and cell specific manner (Grzechnik et al. 2014; Rao et al. 2011; Hakim et al. 2009). 
The transcriptional outcome of GR is not indicated by motif classification but rather depends 
on a number of context-dependent factors including epigenetic regulation, chromatin 
context and so far unrecognised regulatory determinants. LPS induction of TLR signalling 
causes a change in chromatin environment that favours transcription factor binding. 
Additionally to this, in response to DEX, GR-activated genes are enriched for H3K9 
acetylation marks whereas GR-repressed genes are not (Uhlenhaut et al. 2013); therefore 
providing a cooperative mechanism for localised relaxation of chromatin configuration and 
expression of anti-inflammatory genes including DUSP1, TNFAIP3 and ZFP36 in a context-
dependent manner. 
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5.0 EFFECTS OF PGE2 IN INFLAMMATORY RESPONSES OF 
MACROPHAGES 
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5.1 Introduction 
Prostaglandin E2 (PGE2) is an autocrine lipid mediator derived from the successive 
metabolism of arachidonic acid (AA) and PGH2 by cyclooxygenase (COX) and PGE synthase 
enzymes respectively (Hata & Breyer 2004). The most ubiquitous prostanoid, PGE2 has 
central roles in a number of physiological systems and biological processes including pain, 
fever, renal function, angiogenesis, vascular tone and inflammation (Konya et al. 2013). Not 
surprisingly therefore, aberrant expression of PGE2 is associated with complications such as 
atherosclerosis (Tang et al. 2012), myocardial inflammation & cardiovascular disease 
(Hishikari et al. 2009; Xiao et al. 2004), cancer, hypertension and immune dysfunction 
(Konya et al. 2013).  
Cyclooxygenase conversion of arachidonic acid to PGH2 is the rate-limiting step of 
prostaglandin synthesis. Constitutively expressed, COX1 is responsible for basal prostanoid 
biosynthesis, whereas COX2 is inducible and increases arachidonic acid metabolism in 
response to cellular stresses and TLR agonists like LPS (Díaz-Muñoz et al. 2012; Higaki et al. 
2012). Generally, prostaglandins are considered as pro-inflammatory. PGE2 expression is 
elevated at sites of inflammation (Amer et al.) and under certain conditions may be 
pyrogenic and induce hyperalgesia. PGE2 also stimulates macrophage mobility (Tajima 
Murata 2009) yet, however at the same time reduces secretion of inflammatory cytokines 
(Tang et al. 2015). PGD2 is bronchoconstrictive and correlates strongly with the 
pathogenesis of asthma and PGI2 is vasodilatory and activates immune cell function. 
Non-steroidal anti-inflammatory drugs (NSAIDs) are a very successful group of therapeutic 
compounds used for their powerful analgesic, antipyretic and anti-inflammatory properties. 
Given that NSAIDs function by instigating blockage of COX activity and therefore directly 
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inhibit prostanoid synthesis (Amer et al.), it is logical to assume that prostanoids are 
inflammation promoting. However, whilst the analgesic properties of NSAIDs undoubtedly 
reduce arthritic joint pain and improve the mobility of rheumatoid patients they do not slow 
disease progression(Page et al. 2010). In fact, NSAIDs have been shown to induce TNFα 
production in synovial fibroblasts and LPS-stimulated monocytes. Furthermore, these 
effects were reversed by administration of exogenous PGE2 and subsequent signalling via 
the E-type prostanoid receptor-2 (EP2). The biological effects of prostanoids are clearly 
diverse and spatiotemporally specific. PGE2 alone mediates its effects through four 
divergent receptors, each differing in affinity, sensitivity and coupled to separate signalling 
pathways (Kalinski 2012). Therefore, the diversity of receptors responsive to PGE2 is likely to 
account for its multitude of actions, which may be mutually overlapping and often 
contradictory.  
Specific to activation by PGE2, EPs1-4 are G-protein coupled receptors which, with the 
exception of EP1, may have either stimulatory (Gαs) or inhibitory (Gαi) effects on adenylate 
cyclase and intracellular cAMP (Kalinski 2012). Receptor EP1 is ubiquitously expressed and 
signals predominantly through Gαq proteins, which elevate intracellular Ca
2+ and activate 
phospholipase Cβ and Protein kinase C (PKC). Coupled to Gαi and, less predominantly Gαs/q, 
EP3 is represented in cells of the pancreas, kidney and the vena cava. On activation, both EP1 
and EP3 facilitate immune processes, increasing mast cell degranulation and T-cell 
proliferation as well as causing inflammatory hyperalgesia (Regard et al. 2008). Both EP2 and 
EP4 on the other hand, are associated with Gαs and elevate intracellular cAMP through 
enhanced adenylate cyclase metabolism (Alfranca et al. 2006). Transcripts encoding EP4 
have been identified in the uterus, skin, gastrointestinal and hematopoietic tissues whilst 
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EP2 is expressed predominantly in airway, ovary, bone marrow and olfactory epithelium 
(Regard et al. 2008; Konya et al. 2013). The resultant increase in cAMP following EP2/4 Gαs 
stimulation in turn initiates protein kinase A (PKA) phosphorylation and activation of cAMP 
responsive element binding (CREB) transcription factor (Tang et al. 2012; Konya et al. 2013). 
Contributing to the up-regulation of numerous immune related genes including IL12, IL6, 
IL10 and TNFα, CREB promotes the survival signal in macrophages and, when 
phosphorylated can inhibit NFκB signaling and pro-inflammatory gene expression (Wen et al. 
2010; Fujino et al. 2005). Despite sharing similar nominal functions, EP2 and EP4 differ not 
only in tissue-specificity but also in ligand affinity and susceptibility to receptor sensitisation. 
Like EP3, EP4 has a high affinity for PGE2 and is activated by much lower concentrations of 
ligand than EP2. Perhaps consequently, EP4 is also subject to receptor sensitisation whereas 
EP2 is not. Interestingly, EP2 has been shown to stimulate GSK3β which, through 
phosphorylation of CREB and inhibition of CBP binding to RelA may inhibit NFκB mediated 
gene activation (Wen et al. 2010; Ollivier et al. 1996; Parry & Mackman 1997). Furthermore, 
EP4 alternatively triggers PI3K dependent ERK1/2 signaling (Fujino et al. 2003) at the 
expense of PKA activation (Fujino et al. 2005). There is some evidence to implicate PI3K-
dependent signaling by EP4 and a lack of detectable increase in cAMP in the growth and 
motility of mouse colon adenocarcinoma cells (Sheng et al. 2001; Pozzi et al. 2004; Fujino et 
al. 2005). Therefore, it is thought to be stimulation of cAMP and subsequent signaling 
through the PKA/CREB pathway that dominates the anti-inflammatory and suppressive 
actions of PGE2 and EP2/4 in myeloid cells (Fujino et al. 2005; Regan et al. 1994; Honda et al. 
1993; Fujino et al. 2003).  
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Based on microarray data from our lab, the transcript encoding EP2, that is Ptger2, is 
expressed only at low levels in mouse macrophages, whereas Ptger4 is strongly expressed 
and upregulated by LPS. The EP1 and EP3 transcripts Ptger1 and Ptger3 respectively, are not 
expressed in mouse macrophages. Therefore, at least in murine macrophages, it is likely 
that anti-inflammatory effects of PGE2 are mediated by EP4. 
Compounds that elevate cAMP have been used in combination with glucocorticoids to treat 
patients with asthma and COPD, with significant beneficial effects (Giembycz et al. 2009). 
MAPKs are critical to the airway remodelling and chronic-inflammation attributed to the 
pathogenesis of asthma (Pelaia et al. 2005; Pelaia et al. 2011; Duan & Wong 2006). A 
negative regulator of MAPK signalling, Dusp1 is induced by both glucocorticoids (Quante et 
al. 2008; Issa et al. 2007; Kang et al. 2008) and long-acting β2-agonists (Giembycz et al. 2009). 
Furthermore, dex-induced Dusp1 expression is enhanced and extended by co-stimulation 
with the long-acting β2-adrenoceptor agonist Formoterol via the PKA pathway (Manetsch et 
al. 2012). The activity of cAMP is degraded by phosphodiesterase type 4 (PDE4), a 
hydrolyzing enzyme prevalent in immune cells and cells of the central nervous system. Due 
to the anti-inflammatory potential of compounds that enhance cAMP signaling, inhibitors of 
PDE4 are being increasingly investigated for use as novel anti-inflammatory drugs. Rolipram 
is a prototypical PDE4 inhibitor and has been investigated for the treatment of a diverse 
group of diseases including inflammatory conditions such as COPD, asthma and rheumatoid 
arthritis. In a study by Korhonen et al. (2013), Rolipram was shown to significantly down 
regulate TNFα expression in activated macrophages and furthermore attenuated 
carrageenan-induced paw inflammation in WT mice but not in Dusp1-/-. Therefore 
indicating that the therapeutic effects of this cAMP-enhancing compound require DUSP1 
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(Korhonen et al. 2013). TTP is a downstream target, activated by DUSP1 and rather 
interestingly, there is tentative data to suggest that activators of adenylate cyclase might 
increase Zfp36 mRNA levels (Jalonen et al. 2007). In fact, the anti-inflammatory, mRNA 
down-regulating effects of long-acting β2-adrenoceptor agonists and cholinergic stimulation 
require TTP expression (Joe et al. 2011; Geyer et al. 2012; Jalonen et al. 2007; Brahma et al. 
2012).  
Studies on cAMP-induced expression of A20 are few. However, Litvak et al. (2009) identified 
a C/EBPβ motif within the TNFAIP3 promoter and showed that C/EBPβ acts as an amplifier 
of NFκB signaling in activated murine primary macrophages. C/EBPβ acts as a co-activator of 
transcription and has been shown to be dependent on interaction with other transcription 
factors, including NFκB, SP1 and Fos/Jun (Lekstrom-Himes & Xanthopoulos 1998; Lee et al. 
1997; Serio et al. 2005). Furthermore, Tnfaip3 is co-regulated by both NFκB and C/EBPβ in 
LPS-activated macrophages (Lai et al. 2013). 
In this chapter we investigated the effects of PGE2 on feedback node gene expression and its 
potential to initiate transcription via three putative Zfp36 enhancer sequences. 
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5.2 Results 
5.2.1 PGE2 inhibits expression of pro-inflammatory mediators at the level of 
mRNA and protein 
In order to identify the effects of PGE2 in our system of cells, firstly the effect of PGE2 on 
expression of inflammatory mediators was examined. As can be seen in Figure 5.1, PGE2 had 
no effect on resting levels of TNFα but was able to significantly enhance COX2 and IL6 
transcript up to 12 and 8 times basal levels of expression respectively. These effects 
however are masked by the strong fold induction observed in response to LPS and LPS + 
PGE2 in combination. PGE2 has previously been described as IL-6 inducing in a number of cell 
types (P. Wang et al. 2010; Pu Wang et al. 2010) including macrophages (Shacter et al. 1992; 
Ogle et al. 1994; McCoy et al. 2002) and DCs pre-treated with IL-10 neutralising antibody 
(Harizi et al. 2004). In addition, PGE2 has been suggested to induce COX2 expression as a 
positive feedback mechanism (Mancini & Di Battista 2011). 
When administered in combination, PGE2 had a significant inhibitory effect on the LPS-
mediated induction of both TNFα and COX2 mRNA in myeloid cells. These results reflect -
previous findings by Pang & Hoult (1997). Interestingly, PGE2 acted cooperatively with the 
LPS-induced production of IL6 transcript, whereas TNFα and COX2 transcript levels were 
strongly inhibited by the same treatment.  
The amount of secreted inflammatory protein was quantified by sandwich ELISA. This was to 
determine whether the observed regulation at the level of mRNA was translated to the 
protein level and whether the effects of PGE2 were functional. Protein secretion was 
measured from primary macrophage cell supernatants collected at 4 and 8 hours of 
stimulation as well as from unstimulated cells. COX2 is not a secreted protein and the 
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method used to detect relative levels of COX2 is to quantify PGE2 in cell supernatants by 
ELISA. However clearly this was not a suitable method of detection in this experiment since 
cells were stimulated with exogenous PGE2 by direct addition to the cell media. However, 
TNFα, CXCL1 and IL6 were all measured (Figure 5.2). Again, we observed significant PGE2-
mediated inhibition of the LPS-driven pro-inflammatory TNFα and CXCL1 release in primary 
murine macrophages. However, PGE2 alone did not induce significant expression of IL6 
protein, neither did PGE2 significantly affect LPS-induced IL6 release. 
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Figure 5.1 PGE2 up-regulates IL6 and inhibits LPS-induced TNFα and IL1α at the level of 
mRNA in macrophages 
Primary macrophages and RAW264.7 cells were seeded at a density of 1x106/ml and 
6x105/ml and established adherence overnight. The next day, macrophages were 
unstimulated (black bars), treated with LPS 10ng/ml (white bars) or LPS and PGE2 10ng/ml 
(blue bars) for the times indicated. Whereas PGE2 alone had no effect on TNFα transcript 
expression, it was inhibitory to LPS-induced transcription when cells were co-treated. 
Conversely, PGE2 was able to up-regulate Cox2 and IL6 mRNA and had a cooperative 
effect on the LPS-induced IL6 message. Data represent mean ± SEM of three and four 
separate experiments in primary macrophages and RAW264.7 respectively. **p<0.01, 
***p<0.001 
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Figure 5.2 PGE2 inhibits LPS-mediated secretion of pro-inflammatory proteins IL6, TNFα 
and CXCL1 in primary macrophages 
Supernatant was collected from time course experiments in primary human and murine 
macrophages either unstimulated (black bars unseen), stimulated with LPS (white bars) or 
LPS+PGE2 (blue bars). Supernatants were diluted accordingly and applied to sandwich 
ELISA with antibodies for TNF, IL6 and CXCL1 (KC). Data show mean ± SEM for three 
separate experiments in both cell types. 
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5.2.2 PGE2 cooperatively induces DUSP1, ZFP36 and TNFAIP3 transcript 
expression in primary macrophages and RAW cells 
The anti-inflammatory effects of PGE2 were also investigated by identifying the effect on 
anti-inflammatory feedback node gene expression. PGE2 alone strongly induced DUSP1 gene 
expression up to 10, 8 and 3 fold in human, murine and RAW macrophages respectively. 
This effect of PGE2 was also observed at the level of protein in murine primary macrophages 
activated with LPS (Figure 5.2). The promoter of Dusp1 contains two functional cAMP-
responsive elements (Zhang et al. 2005) that have been reported to induce Dusp1 
expression through a cAMP-PKA-CREB dependent pathway (Shipp et al. 2010; Brion et al. 
2011; Lee et al. 2012; Korhonen et al. 2013). 
Additionally, in response to co-activation with LPS and PGE2 the expression of Dusp1 mRNA 
was both enhanced and extended as the two agonists acted synergistically. This effect was 
more significant (p<0.001) at the one hour time point in all cell types used and was also 
observed after two hours incubation in primary murine macrophages. 
The effects of PGE2 on TNFAIP3 gene expression were also determined by QPCR (Figure 5.4). 
Although PGE2 alone did not up-regulate Tnfaip3 mRNA levels, when in combination with 
LPS, we observed a significant increase the amount of LPS-induced message after one and 
two hours in primary macrophages. The transformed mouse macrophage like cell line 
RAW264.7 did not demonstrate significant cooperative regulation of Tnfaip3 expression by 
LPS and PGE2. Protein data shows potential cooperative up-regulation of A20 by PGE2 and 
LPS at 4 hours post stimulation in primary murine macrophages (Figure 5.3).  Agonists of 
cAMP, for example β2 adrenoceptor ligands, are known to have post-transcriptional effects 
on gene expression, particularly of TNFα and GM-CSF (Seldon et al. 1995; Clarke et al. 2004), 
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both of which are principal targets of TTP. Additionally, (Korhonen et al. 2013) showed that 
the effects of a phosphodiesterase inhibitor, Rolipram were downstream of DUSP1 
signalling. Therefore we hypothesised that PGE2 might up-regulate Zfp36 transcription and 
furthermore, act cooperatively with LPS. 
  
      217
  
(A) 
 
 
 
 
 
(B) 
 
 
 
 
 
(C) 
 
 
 
 
 
 
Figure 5.3 The effects of PGE2 on feedback node gene transcript expression in macrophages  
Primary macrophages and RAW264.7 cells were seeded at a density of 1x106/ml and 6x105/ml and 
established adherence overnight. The next day, macrophages were unstimulated (striped bars), treated 
with PGE2 (black bars) LPS 10ng/ml (white bars) or LPS and PGE2 10ng/ml (blue bars) for the times 
indicated. (A) PGE2 increased Dusp1 alone and acted cooperatively with LPS to super-induce gene 
expression. (B) Zfp36 was up-regulated by PGE2 alone and in cooperation with LPS at the level of mRNA 
and protein in primary macrophages (C) Tnfaip3 transcript levels were unaffected by PGE2 alone but 
were significantly increased by co-treatment with LPS. Data represent mean ± SEM of three and four 
separate experiments in primary macrophages and RAW264.7 respectively. ***p<0.001  
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5.2.3 The anti-inflammatory effects of PGE2 are largely dependent on DUSP1 
As aforementioned, the attenuation of inflammatory signalling by Rolipram requires DUSP1. 
In lieu of this, the effects of PGE2 that we observed in WT macrophages were tested in 
Dusp1-/- cells. Time course experiments were carried out in parallel with WT experiments 
detailed earlier in this chapter.  
The repressive effect of PGE2 on TNFα observed in WT cells were abrogated by the 2 hour 
time point and thereafter in Dusp1-/- macrophages (Figure 5.4A). In fact, at later time points, 
simultaneous activation of Dusp1-/- cells with the two agonists appeared to have a 
cooperatively augmenting effect on Tnfα transcript production. These data are reflected 
similarly in ELISA experiments, where PGE2 was less able to reduce TNFα protein secretion in 
Dusp1-/- cells.  
In Dusp1-/- BMMs the LPS-induced expression of Cox2 mRNA was enhanced and prolonged 
and inhibitory effects of PGE2 were not evident. 
Although CXCL1 protein secretion was greatly increased in Dusp1 knock out macrophages, 
there was little observed difference between the relative inhibition of LPS-induction 
mediated by PGE2 (Figure 5.4B). 
In wild type BMMs the induction of Il6 mRNA by LPS was characteristically delayed, 
reflecting the requirement for chromatin remodelling for maximal expression. From the 2 h 
time point onwards there was cooperative up-regulation of Il6 mRNA by LPS and PGE2, as 
previously shown (Fig. 5.1). Several aspects of this response were altered in Dusp1-/- BMMs. 
Maximal induction of Il6 mRNA occurred more rapidly, and reached a higher level than in 
wild type control cells. Furthermore, the cooperative induction of Il6 mRNA by LPS and PGE2 
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was no longer evident. However, when secreted IL6 protein was measured, I did not find 
significant effects of PGE2 in either Dusp1+/+ or Dusp1-/- BMMs, or significant differences of 
LPS response between the two genotypes. 
The cooperative up-regulation of FNG mRNA expression by PGE2 and LPS simulation 
observed in WT macrophages (Figure 5.5) was significantly altered and at times almost 
completely abrogated in Dusp1-/- cells. For example, after 1 hour of co-treatment, PGE2 had 
no effect on the quantity of LPS-induced Tnfaip3 mRNA in knockouts. After 2 hours of 
incubation however, cooperative induction of Tnfaip3 was observed in both WT and Dusp1 
knockouts. Co-regulation at the 2-hour time point thus does not appear to depend on Dusp1 
expression. Then again, post 4 hours of co-stimulation PGE2 has a significant inhibitory effect 
on the LPS-mediated regulation of Tnfaip3. With respect to these data it is reasonable to 
suggest that Tnfaip3 is under differential regulatory control depending on time after LPS 
stimulation.  
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Figure 5.4(A) The PGE2-mediated regulation of inflammatory mediators is abrogated in 
Dusp1-/- primary macrophages 
In parallel with WT experiments, primary macrophages were isolated from age and sex-
matched Dusp1-/- mice. Cells were seeded at a density of 1x106/ml overnight. The next 
day, cultures were either unstimulated (striped bars), treated with PGE2 (black bars) LPS 
10ng/ml (white bars) or LPS and PGE2 10ng/ml (blue bars) for the times indicated. mRNA 
was harvested and subjected to QPCR using probes for TNFα, COX2 and IL6.  
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Figure 5.4(B) The PGE2-mediated regulation of inflammatory mediators is abrogated in 
Dusp1-/- primary macrophages 
In parallel with WT experiments, primary macrophages were isolated from age and sex-
matched Dusp1-/- mice. Cells were seeded at a density of 1x106/ml overnight. The next 
day, cultures were either unstimulated (striped bars), treated with PGE2 (black bars) LPS 
10ng/ml (white bars) or LPS and PGE2 10ng/ml (blue bars) for the times indicated.  
Supernatant was collected from each experiment and applied to ELISAs for TNFα, CXCL1 
(KC) and IL6. Data represent mean ± SEM of three separate experiments. Both QPCR and 
ELISA were carried out in triplicate within one experiment. *p<0.05, ***p<0.001 
      222
As described previously, LPS induction of Zfp36 was both enhanced and extended in Dusp1-
/- macrophages when compared to WT. This was also observed at the level of protein 
(Figure 5.6). In the absence of Dusp1, prolonged activation of p38 MAPK leads to 
accumulation of inactive TTP. Zfp36 mRNA contains an ARE and is a target of its own protein 
product. We know from data in our lab (as yet unpublished) that Dusp1-/- induced TTP 
inactivity increases the stability of Zfp36 transcript levels in these macrophages when 
compared to WT macrophages. When normalised to the WT data for unstimulated cells, 
PGE2 had a significantly greater effect on Zfp36 transcript induction in Dusp1-/- 
macrophages compared to WT. This effect was approximately two to three fold WT 
expression and observed at one and two hours following PGE2 treatment. In WT 
macrophages, PGE2 may stimulate Dusp1 to inactivate p38 MAPK signalling and 
subsequently the dephosphorylation that activates TTP. In the knockout macrophages 
however, PGE2 cannot drive TTP activation via Dusp1 and therefore the Zfp36 transcript 
becomes stabilised and more highly expressed in comparison to WT. In addition the β-
adrenergic receptor agonist isoproterenol has been shown to induce Zfp36 expression in 
adipocytes, via cAMP-dependent signalling (Brahma et al. 2012). This mechanism may or 
may not be differentially affected by the WT and Dusp1-/- genotypes. 
The effects of PGE2 on Zfp36 mRNA expression in activated macrophages differ depending 
on genotype and time point. At the one-hour time point of PGE2 agonism, Zfp36 expression 
is comparable between the two genotypes. However, following this initial quantification of 
transcript expression, the effects of PGE2 on the LPS-induction of Zfp36 are significantly 
inhibitory in Dusp1-/- macrophages, which is in contrast to the observed co-operative 
induction observed in WT macrophages. Compounds that enhance the cAMP pathway are 
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increasingly being investigated for the treatment of various inflammatory and autoimmune 
conditions. A number of these novel therapeutic agents mediate their anti-inflammatory 
effects via mechanisms dependent on the up-regulation of DUSP1 (Korhonen et al. 2013). It 
is possible that the effects of PGE2 on Zfp36 transcript expression in an inflammatory setting 
i.e. under conditions of LPS, act via DUSP1 to enhance TTP activation and therefore pro-
inflammatory cytokine destabilisation. At the same time, via additional mechanisms pro-
inflammatory stimuli and PGE2 must cooperate to drive Zfp36 transcript expression, perhaps 
at the level of NFκB, AP1, AP2 or C/EBPβ. Indeed, TTP expression is critical to the 
posttranscriptional anti-inflammatory effects of cAMP-stimulating compounds (Joe et al. 
2011; Geyer et al. 2012; Jalonen et al. 2007; Brahma et al. 2012).  
 
5.2.3 Cooperative up-regulation of DUSP1 protein expression by PGE2 and LPS in primary 
murine macrophages 
In the previous section, we showed that PGE2 was able to up-regulate LPS-induced FNG 
expression at the level of mRNA and also that this expression appeared to be partly 
dependent on DUSP1. Therefore in order to complete this set of experimental data and 
observe the biological implications, protein quantification was performed.  
As expected, the expression of DUSP1 is absent in knock out mice. LPS was able to induce all 
three proteins in a transient manner and was similar to the expression profile for each FNG 
mRNA. PGE2 was able to augment the LPS-induced expression of DUSP1 and TTP from as 
early as 1 hour in WT macrophages, however this effect was less evident and perhaps 
unconvincing for A20. However, in Dusp1-/- macrophages, the cooperative effect of PGE2 on 
LPS-induced TTP was abrogated.  
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Figure 5.5 Cooperative regulation of anti-inflammatory feedback node genes by LPS and 
PGE2 is abrogated in Dusp1-/- macrophages. 
Tnfaip3 and Zfp36 transcripts were quantified by QPCR of cDNA from Dusp1-/- 
macrophages unstimulated (striped bars) or incubated with PGE2 (black bars) LPS 10ng/ml 
(white bars) or LPS and PGE2 10ng/ml (blue bars) for the times indicated. (A) Cooperative 
induction of Tnfaip3 by PGE2 and LPS was abolished at the 1 hour time point but 
maintained at 2 hours in macrophages null for Dusp1. (B) PGE2-mediated induction of 
Zfp36 was augmented in Dusp1-/- macrophages and although synergistic regulation of 
Zfp36 remained at 1 hour of co-stimulation, this effect was reversed from two hours and 
onward. ***p<0.001 
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Figure 5.6 PGE2 enhanced LPS-induced DUSP1 and TTP in WT but not in Dusp1-
/- primary murine macrophages 
Experiments were carried out on primary macrophages isolated from age and 
sex-matched WT and Dusp1-/- mice. Macrophages were seeded at a density of 
1x106/ml in 6 well plates. Following stimulation with LPS, PGE2 or both agonists 
for the times indicated, cells were harvested form protein by cell lysis. 
Antibodies against DUSP1, TTP (SAK21) and A20 were used subsequently on the 
same blot. Protein concentration was controlled for by β-actin as a loading 
standard.  
(Figure courtesy of T.Tang; Clark group ) 
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5.2.4 PGE2 transcriptional induction of a reporter containing upstream ECRs of 
TTP 
Using the reporter constructs described previously (Chapter 3.2.6-7), our aim was to identify 
whether PGE2 alone or in combination with a pro-inflammatory stimulus, was capable of 
inducing a luciferase response via functional elements within ECRs 2, 3 and 4.  
The initial observation, when considering the luciferase activity of cells containing the 
control plasmids, was the effect of PGE2 on LPS and IL1 induction of these constructs in both 
cell lines. PGE2 significantly inhibited the relative luciferase by approximately 30% in 
RAW264.7 macrophages and 75% in HeLa cells. These data highlight the ability of PGE2 to 
down regulate the expression of NFκB in both human and mouse cell lines. 
Concurrent with other data, ECR3-4 was the most strongly induced by the pro-inflammatory 
stimulus in both human and murine cell lines. Fittingly, this was the region that mounted the 
maximal response for PGE2 alone and in combination with LPS or IL1 in murine and human 
cells respectively. In response to PGE2 treatments, human and murine ECRs appeared to 
function similarly, something that hasn’t necessarily been observed when using other 
agonists. When isolated, conserved regions 3 and 4 were each induced by PGE2 alone and 
show only additive transcriptional potential in cells treated with both Zfp36 agonists. 
Similarly MmECR2 responds to the two agonists together with an additive effect on 
transcriptional induction.  
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Figure 5.7 PGE2 and LPS co-induction of a luciferase reporter construct containing evolutionarily 
conserved regions of the Murine and Human Zfp36 locus 
(A) RAW264.7 and (B) HeLa cells were transiently transfected with luciferase reporter constructs 
containing Murine and Human Zfp36 sequences accordingly. The following day cells were left 
unstimulated (black bars), activated with (A) LPS 10ng/ml (white bars) or (B) IL1α 1ng/ml (white 
striped bars), PGE2 10ng/ml (purple bars) or mutually ( A-blue bars/ B-blue striped bars) for an 
optimum of 6 hours. Following passive lysis, luciferase assays were performed. Data are expressed 
as mean ± SEM for three separate experiments, each carried out in triplicate for RAW264.6 and 
HeLa cells.  (C) is a schematic of the Zfp36 locus illustrating the location of each ECR. 
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5.3 Discussion 
In the present study, we investigated the effects of PGE2 on pro- and anti-inflammatory 
gene expression in primary human and murine macrophages and RAW 264.6 cells. We also 
studied the role of Dusp1 in mediating those effects of PGE2. 
The results of this work present PGE2 as an anti-inflammatory agent with the ability to 
down-regulate macrophage pro-inflammatory gene expression and cytokine secretion when 
in combination with LPS. Additionally, in the same experiments, PGE2 was able to up-
regulate three critical feedback node genes at the mRNA level when administered alone and 
had a cooperative effect when combined with LPS.  
These data provide evidence pertaining to a potential mechanism for PGE2-mediated 
immune-suppression. Most critically, PGE2-mediated down-regulation of inflammatory 
mediators in activated macrophages relied strongly on the expression of Dusp1. 
Concurrently so did the cooperative regulation of Zfp36 and Tnfaip3. Similarly in a recent 
study, a PDE4 inhibitor named Rolipram was shown to require Dusp1 in facilitating its anti-
inflammatory actions. A handful of other studies have implied PGE2 mediated up-regulation 
of Dusp1 in Fibroblast and epithelial cell lines and mouse peritoneal macrophages (Zhang et 
al. 2008; Brion et al. 2011; Lee et al. 2012; Korhonen et al. 2013). However, here we have 
identified this mechanism in primary human and murine macrophages and also quantified 
the cooperative up-regulation of Dusp1, Zfp36 and Tnfaip3 by LPS and PGE2. 
The promoter of Dusp1 is known to contain two cAMP regulatory elements and studies have 
confirmed that cAMP mediated induction of Dusp1 is via the PKA/CREB pathway. Agonists of 
cAMP have been widely successful in the treatment of asthma and their therapeutic actions 
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rely in part on posttranscriptional control of gene expression. Indeed, in a number of in vitro 
studies identified that TTP was required for the functional down-regulation of numerous 
pro-inflammatory mRNAs. However, analyses of sequence elements in the TTP promoter of 
mouse human and rat have not identified cAMP response element consensus sequences.  
One study, by Jalonen et al. (2007) suggests that cAMP enhancing compounds might 
manipulate Zfp36 transcription through AP2. Required for full serum inducibility of TTP, a 
number of AP2 binding sites border the Zfp36 region, particularly within the promoter and 
intron. Furthermore, the same study highlighted that compounds inducing cAMP-mediated 
Zfp36 mRNA expression facilitated nuclear translocation of AP2 but not NFκB. Downstream 
of EP4, Zfp36 transcription could also be enhanced by PI3K activation and C/EBPβ mutual 
recriutment of CBP (CREB) and p300, therefore eliminating the need for proximally located 
CRE sites. In the second element to this chapter, we show that PGE2 may initiate 
transcription via sequences isolated from distally upstream islands of conservation. Up-
regulation of luciferase reporters by PGE2 was mediated by murine ECRs 2 and 4 and human 
ECR 4. Which suggests that additional cAMP activated regulatory elements lie within these 
regions. Additionally, the juxtaposition of ECRs 3 and 4 triggered cooperatively induced 
transcription in cells co-treated with LPS and PGE2, despite the inability of ECR3 to initiate 
transcription independently. Sequence analysis identifies conserved sequences for AP2(x2) 
in ECR3 and for CREB(x1) in both ECR3 and 4, the latter of which encompasses a number of 
AP2-like DNA motifs also. These important sequences are illustrated in figure 5.8. 
Tnfaip3 is a potential target for numerous effectors of inflammatory and apoptotic 
pathways, each of which presenting with different signalling affinities depending on cell 
type and stimulus type, effect and duration. In this chapter we show that PGE2 has divergent 
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effects on LPS-induced Tnfaip3 induction depending on stimulus duration. It would appear 
that the cooperation between LPS and PGE2 observed at 1 hour in WT BMMs requires Dusp1. 
The synergism observed in WT at 2 hours however is maintained and enhanced in Dusp1-/- 
macrophages, yet PGE2 dampens the LPS response at 4 hours post stimulation. The 
transcription of Tnfaip3 is strongly dependent on NFκB (Chapter 3, Figure 3.4), most 
prominently at the 1-hour time point. As is often the case, it is possible that Tnfaip3 mRNA 
up-regulation depends on NFκB associations with accessible coactivators of transcription.  
The activated macrophage is subject to dynamic alterations in cellular microenvironment 
and thus the ready availability of various signalling effectors including coactivators and 
corepressors of transcription. Therefore it is likely that during the time course of LPS-
induced Tnfaip3 expression, NFκB interacts with a number of different transcription factors 
which together control Tnfaip3 expression. Lai et al. (2013) identified that C/EBPβ 
enrichment at the Tnfaip3 promoter was most significant after 4 hours of LPS stimulation 
and at this time cooperated most strongly with NFκB. If C/EBPβ availability is dependent on 
DUSP1 then, putatively, in Dusp1-/- cells, PGE2 could be inhibitory to Tnfaip3 transcription, 
which is most prevalent at the 4-hour time point. Another factor to consider is the 
phosphorylation status and activation of TTP in cells lacking DUSP1. The Tnfaip3 may be a 
posttranscriptional target of TTP (Verstrepen et al. 2014; Bakheet et al. 2006; Balkhi et al. 
2013)   and in the absence of DUSP1 is likely subject to increased degradation due to 
prolonged TTP activation. The expression if Zfp36 is biphasic and dips at 2 hours post 
induction in both WT and Dusp1-/- macrophages. We observed cooperative expression of 
Tnfaip3 at 2 hours in both WT and KOs and therefore the mechanism at this time point 
doesn’t require DUSP1 expression. It is possible that Tnfaip3 mRNA stability and therefore 
expression is increased at 2 hours due to a reduction in TTP expression. 
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The next step in this chapter would be to carry out a Zfp36 locus ChIP using antibodies 
specific for CBP/P300 in macrophages activated with both agonists individually and in 
conjunction. We expect that such an experiment would enrich for DNA within ECR 4 in the 
presence of PGE2 and both ECR3 and 4 in cells stimulated with LPS and PGE2.  
 
The findings within this chapter are novel and potentially important, regarding therapeutic 
intervention. In order to continue investigating the biological effect of PGE2 on FNG 
expression and truly understand the functional consequences, it would be useful to look at 
the pattern of protein expression for each TNFAIP3 and DUSP1 as well as TTP. In addition, 
for the purpose of identifying the signalling pathways involved it might be beneficial to 
utilise chemical inhibition or even siRNA knockdown of some implicated pathways. Elevation 
of Dusp1 by cAMP-agonists may be dependent on PKA (Brion et al. 2011; Lee et al. 2012). 
Similarly PDE4 inhibition might reveal that this pathway also applies to up-regulation of 
Figure 5.8 Putative cAMP- induced binding sites within the Zfp36 locus  
In addition to previously identified binding motifs for AP2 within the promoter and 
intron, sequence analysis predicts binding sites for AP2 within ECR3 and possibly ECR4, 
both of which were transcriptionally responsive to PGE2 stimulation. There are also a 
putative CREB motifs located in ECRs 3 and 4, the patter of which is surrounded by the 
aforementioned novel AP2-like binding sequence. 
 
(AP2)2                                                          AP2/ AP2
Zfp36
AP2/CREB/AP2
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other FNGs, Tnfaip3 and Zfp36. Some studies support a role for the PI3K/AKT pathway in 
PGE2 signalling via EP4 and ERK1/2 (Fujino et al. 2003; Fujino et al. 2005). Dusp1 acts 
primarily on MAPKs p38 and JNK (Abraham & Clark 2006) and therefore this putative 
mechanism might help to explain the up-regulation of FNG expression at the level of 
transcription in Dusp1-/- macrophages, regardless of mRNA stability. 
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6.0 EFFECTS OF TGFβ IN INFLAMMATORY RESPONSES OF 
MACROPHAGES  
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6.1 Introduction 
TGFβ is a multifunctional cytokine and growth factor capable of modulating gene expression 
via signalling thorough two trans-membrane serine/ threonine receptors, TβRI and TβRII (Shi 
& Massagué 2003; Kamato et al. 2013). Activation of TβRI may be direct or secondary to 
TβRII activation and subsequent trans-phosphorylation. Either way, TGFβ receptor 
stimulation induces signal specific smads 2 and 3 by phosphorylation to form hetero-
oligomeric complexes with smad4, triggering translocation to the nucleus (Shi & Massagué 
2003; Zi et al. 2012). Once nuclear, smad complexes may activate gene transcription either 
directly or by associations with additional sequence specific transcription factors. N-terminal 
MAD homology (MH) domain 1 is primarily responsible for smad DNA binding and direct 
control of gene regulation whereas MH2 facilitates TGFβ-mediated transactivation and 
often associates with CBP/P300 (Tan et al. 2004). 
In normal epithelia, TGFβ functions through smad dependent and independent pathways to 
control the expression of numerous genes (Achyut & Yang 2011). Given that many targets of 
TGFβ are growth-promoting and immunomodulatory, it is important that they are 
controlled at both the transcriptional and posttranscriptional level. An important function of 
the TGFβ signalling pathway is the stringent control of these potentially injurious growth 
factors and cytokines and many of its target genes contain AREs in their 3’UTR (Zavadil et al. 
2001; Kang et al. 2003; Kanies et al. 2008). The potent immunosuppressive functions of 
TGFβ have been highlighted in studies in which smads and/ or TGFβ have been disrupted in 
mice, resulting in a severe and multifocal inflammatory response in viable pups (Yang et al. 
1999; Roberts et al. 2003; Shull et al. 1992; Kulkarni et al. 1993; Levéen et al. 2002). 
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Originally identified as a target of TGFβ1 and so called TGFβ-activated kinase 1, TAK1 is key 
to the regulation of numerous biological processes including development, innate immunity, 
cell survival and carcinogenesis (Roh et al. 2014). TAK1 is now a known downstream target 
of TGFβR, TNFR1, IL1R, T cell and B cell receptor signalling (Huang et al. n.d.). Deletion of 
TAK1, and its associated proteins TAK1-binding protein (TAB) 1, 2 and 3 is embryonic lethal, 
highlighting a critical role for this pathway in development (Komatsu et al. 2002; Sanjo et al. 
2003; Shim et al. 2005). The activity of TAK1 is mostly controlled by posttranslational 
modifications including phosphorylation and ubiquitination, which depend on the upstream 
pathway that is engaged. TAK1 belongs to a highly conserved protein family of MAP3Ks and 
acts as an upstream stimulatory molecule to JNK, p38 MAPK and NFκB (Singhirunnusorn et 
al. 2005). In response to cellular stressors, TAB1 associations increase the kinase activity of 
TAK1 whereas TAB2 and the closely related TAB3 facilitate interaction with TRAF2 and 
TRAF6 in response to TNFα and IL1 respectively (Ishitani et al. 2003; Singhirunnusorn et al. 
2005). TAK1 is also subject to stimulation by K63 ubiquitination in a TRAF6 dependent 
manner (Freudlsperger et al. 2013; Chen 2012). Following polyubiquitination, TAK1 becomes 
an IKK kinase and phosphorylates IKKβ leading to the dissociation, ubiquitination and 
degradation of IκBα that precedes nuclear translocation of NFκB. Ubiquitinated TAK1 may 
also phosphorylate MAP2Ks including MKK6/3 and MK74/7 leading to p38 MAPK and JNK 
activation respectively (Wang et al. 2001; Chen 2012). 
A handful of studies have identified the ability of TGFβ to up-regulate Zfp36 expression in 
epithelial cells (Blanco et al. 2014; Sohn et al. 2010) and T-cells (Ogawa et al. 2003). Sohn et 
al. (2010) identified that TTP is frequently down-regulated in hepatocellular carcinoma (HCC) 
due to methylation at a specific CpG site located within the TGFβ-responsive region of the 
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Zfp36 promoter. Methylated TRR was found to be associated with a transcription repressor 
complex which proved sufficient to block TGFβ- mediated and basal levels of Zfp36 
induction (Sohn et al. 2010). 
Blanco et al. (2014) on the other hand showed that smad-dependent expression of TTP was 
required for the formation of p-bodies in intestinal epithelial cells stimulated with TGFβ. A 
smad-responsive element has been identified immediately upstream of the Zfp36 promoter 
-550bp from the start site that responds to TGFβ signal transduction in epithelial cells (Sohn 
et al. 2010). In this study we set out to identify the effects of TGFβ on feedback node gene 
expression and immunomodulation during an inflammatory response and therefore in 
macrophages activated by LPS.  
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6.2 Results 
6.2.1 TGFβ inhibits pro-inflammatory mRNA expression in activated primary 
human and murine macrophages and RAW264.7 cells.  
Following on from work by (Ogawa et al. 2003) and the work in this study we carried out 
stimulation time course experiments in which primary and cell line macrophages were un-
stimulated, activated by LPS, TGFβ or the two agonists together. Isolation of RNA was 
followed by cDNA synthesis and quantitative PCR using a selection of primers targeted at 
transcripts of interest. We set out to investigate the immunosuppressive effect of TGFβ on 
pro-inflammatory mediators in macrophages. 
Whereas TGFβ had a small inhibitory effect on very low levels of resting TNFα and IL1α 
mRNA expression, LPS induced both pro-inflammatory mediators strongly (Figure 6.1). LPS 
induction of TNFα and IL1α was transient and peaked within 1 hour of LPS incubation in all 
types of macrophage. When treated with LPS and TGFβ in combination, macrophages 
showed a significant decrease in TNFα and IL1α mRNA that was maintained until pro-
inflammatory mRNA expression had dissipated or the last measured time point (8 hours). 
Known for its immunosuppressive actions, here we show that administration of exogenous 
TGFβ is capable of dampening the expression of two key inducers of inflammation in human 
and murine primary macrophages as well as in RAW264.7 cells. It would be useful as a next 
step to explore whether this significant effect translates to a functional output at the 
protein level.  
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Figure 6.1 Inhibition of TNFα and IL1α gene synthesis by TGFβ in primary macrophages 
and RAW264.7 cells activated with LPS 
Human monocyte-derived and murine bone-marrow derived macrophages (M-MDM and 
BMM) and RAW264.7 murine macrophage-like cells were seeded at a density of 
1x106cells/ml and 5x105cells/ml respectively and either left un-stimulated (black bars), 
treated with 10ng/ml TGFβ (green bars), 10ng/ml LPS (white bars) or LPS and TGFβ (blue 
bars) for the times indicated. All data points were normalised to the unstimulated control 
and show the mean +/- SEM for three and four separate experiments in primary and RAW 
macrophages respectively. Each QPCR was carried out in triplicate. *** p< 0.001 **p<0.01 
*p<0.05 
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6.2.2 TGFβ and LPS cooperatively regulate feedback node genes DUSP1, ZFP36 
and TNFAIP3 expression at the mRNA level 
Previous work in this study has highlighted a group of feedback node genes that escape 
inhibition by inflammation-quenching factors that reduce inflammatory signalling. As seen 
in 6.2.1, TGFβ reduced the expression of key pro-inflammatory mRNAs. It is possible that 
TGFβ facilitates up-regulation of critical negative-regulators of inflammation in order to 
deliver its immunosuppressive functions. Here we quantified the LPS and TGFβ –induced 
expression of feedback node gene mRNA transcripts in macrophages. As can be seen in 
Figure 6.2 TGFβ alone was able to induce Dusp1 in small quantities in primary macrophages. 
However, when administered in combination with LPS, the effect on Dusp1 mRNA 
expression was cooperative suggesting that the two agonists act synergistically to increase 
Dusp1 transcription. This effect was mirrored in the expression profile of Zfp36 mRNA 
(Figure 6.2). TGFβ plus LPS had a significant inducing effect on Zfp36 transcription, above 
that of LPS alone at 1 and 4 hours of co-incubation. TGFβ has previously been described as 
able to induce Zfp36 transcription in epithelial cells. The cooperative effect between LPS and 
TGFβ was less prominent when quantifying Tnfaip3 mRNA expression (Figure 6.2). However 
cooperative regulation of Tnfaip3 was clear in both human primary macrophages and RAW 
cells at the 1-hour time point. 
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Figure 6.2 Cooperative regulation of feedback node gene expression in macrophages by 
TGFβ and LPS  
In parallel with 6.2.1, the level of feedback node gene mRNA was quantified by QPCR in 
macrophages untreated or treated with LPS or LPS and TGFβ for the times indicated. All 
data points were normalised to the unstimulated control and represent the mean ± SEM 
for three and four separate experiments in primary and RAW macrophages respectively. 
*** p< 0.001 *p<0.05 
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6.2.3 TGF activates transcription in a reporter construct containing Zfp36 
upstream conserved regions 3 and 4 
RAW macrophages and HeLa cells transfected with murine and human reporter constructs 
were treated with LPS or IL1α, TGFβ or a combination for 8 hours before passive lysis. 
Luciferase assay reagent was added to lysates and the resulting fluorescence was measured 
using a luminometer. We have shown previously the capability of LPS and IL1 to up-regulate 
luciferase transcription via murine and human ECRs upstream of Zfp36. Initial observation 
drew attention to the effect of TGFβ on LPS and IL1 induction of the RAW and HeLa positive 
control reporters (Figure 6.3). Simultaneous stimulation of RAW or HeLa cells transfected 
with a TNFα enhancer or (ΚB)3 elements inhibited  luciferase expression by approximately 
one third and by more than half respectively, when compared to LPS/IL1α treatment alone. 
There is little recent data highlighting the inhibition of NFκB by TGFβ which makes this 
observation potentially quite an important one. One study by Arsura et al. (1996) 
demonstrates that TGFβ significantly down regulates the binding activity of NFκB at 6 hours, 
with maximal inhibitory effects observed at 9 hours post treatment. The same study 
highlights the potential of TGFβ to induce Iκβ mRNA synthesis (Arsura et al. 1996). Similarly 
GCs are also known to up-regulate Iκβ expression as a means of NFκB inhibition (Auphan et 
al. 1995; Robert I. Scheinman et al. 1995; Castro-Caldas et al. 2003). This notion of NFκB 
inhibition by TGFβ is somewhat controversial to studies describing TGFβ-mediated up-
regulation of NFκB activity via smad independent mechanisms (Gingery et al. 2008). 
Taking into consideration the experimental ECR reporters, we show that TGFβ is able to 
induce luciferase transcription in cells transfected with constructs containing murine and 
human ECRs 3, 4 and 3-4 (Figure 6.3). However murine ECR2 showed no transcriptional 
activity in response to TGFβ.  
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Simultaneous stimulation of RAW or HeLa cells transfected with a TNFα enhancer or (ΚB)3 
elements inhibited  luciferase expression by approximately one third and by more than half 
respectively, when compared to LPS/IL1α activation alone. These results confirm the 
inhibitory potential of TGFβ and that signalling in the transfected cells remains intact (Figure 
6.3).  
However, the transcriptional activity directed by Zfp36 ECRs 3, 4 and ECR 3-4 from both 
species was significantly enhanced in cells treated with the two agonists simultaneously. 
The respective increase in luciferase expression as a result of dual stimulation was mostly 
additive of the two agonists in cells containing constructs 3 and 4. However, HeLa cells 
containing HsECR3-4, that is a luciferase expression vector containing both ECR3 and 4 
juxtaposed, produced a much greater amount of fluorescence in response to co-treatment 
that was multiplicative of either IL1α or TGFβ alone. 
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Figure 6.3 Human and murine Zfp36 ECRs respond to transcriptional regulation by TGFβ and TGFβ plus 
LPS in HeLa epithelial and RAW macrophage like cells 
(A) RAW264.7 and (B) HeLa cells were transiently transfected with luciferase reporter constructs. The 
following day cells were left un-stimulated (black bars); RAW cells activated with 10ng/ml LPS (white bars) 
and HeLa cells with 1ng/ml IL1α (white-striped bars); 10ng/ml TGFβ (green bars) or in combination (blue 
bars for RAW and Blue striped bars for HeLa) for an optimum of 8 hours. Following passive lysis, luciferase 
assays were performed. Data are expressed as mean ± SEM for three separate experiments. Cartoon (C) 
represents murine evolutionary conservation against a human-base genome and the ECRs 2-4 which were 
cloned for the reporter constructs above are represented here in red (blue is conservation of the Zfp36 
coding sequence). Location of the ‘TRR’ identified by Sohn et al (2010) is shown in green. 
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6.3 Discussion 
In this chapter we showed that TGFβ has the potential to up-regulate the expression of 
three feedback node genes, DUSP1, ZFP36 and TNFAIP3, and cooperates synergistically with 
the TLR agonist LPS to enhance and extend their expression further. Two groups previously 
highlighted that TGFβ increases DUSP1 protein in rat vascular smooth muscle and human 
epithelial cell lines (Tong & Hamel 2007; Mikami et al. 2006). Here we have shown that TGFβ 
not only increases DUSP1 mRNA but also enhances and extends the LPS-induced expression 
of Dusp1 transcript in primary macrophages and RAW cells. Additionally, TGFβ has been 
shown to up-regulate A20 protein via tyrosine phosphorylation and cause further inhibition 
of NFkB signalling (Das et al. 2012). Neither Tnfaip3 nor Dusp1 have been investigated for 
smad binding elements located within their promoter, or indeed, further up-stream. Clearly 
this area needs some further investigation. Alternatively (and without mutual exclusivity), it 
is possible that TGFβ increases transcription of these two targets in a smad-independent 
manner or even by modifying the chromatin environment to facilitate the binding of other 
co-activators of gene synthesis. TTP is induced by various stimuli, including TGFβ (Lai et al. 
1990; Ogawa et al. 2003) and a TGFβ regulatory region (TRR) between -531 and -471 
contains four functional smad binding elements (Sohn et al. 2010). However, in a luciferase 
assay, these promoter-proximal smad sequences were only able to elevate fluorescence 1.5 
to 2 times that of the un-stimulated, basal expression. In a previous study, TGFβ raised 
Zfp36 mRNA levels more than 4-times basal expression in epithelial cells (Blanco et al. 2014) 
and 5 to 6-times in primary bone marrow macrophages (Figure 6.2). These data suggest that 
there are other important sequences required for full TGFβ inducibility of Zfp36. Our results 
indicate that signalling through the TGFβ /smad pathway promotes Zfp36 transcription via 
enhancers positioned distally upstream. Although between these highly conserved regions 
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there are no conserved consensus smad binding elements, sequence analysis predicts smad 
binding within HsECR4 (+82), MmECR2 (+29) and MmECR3 (+181). 
 
 
 
 
 
 
  
(-531 to -471)
TRR
Mm -4062 to -1725
Hs -4175 to -2590 
Figure 6.4 Predicted smad binding elements within evolutionarily conserved regions 
upstream of murine and human ZFP36  
The above cartoon demonstrates the location of each predicted smad binding sequence 
upstream of Zfp36 in mouse (Mm-above) and human (Hs-below) sequence. The ‘TRR’ 
identified by Sohn et al (2010) is in green. There are two putative Zfp36 upstream smad 
binding elements in the murine sequence, located within ECRs 2 and 3 at -4033bp and -
329bp respectively. The human sequence contains one predicted smad motif within ECR4 
at position -2954bp. 
 
Mm  -4033      -3259   -531(TRR) 
5’            Zfp36     3’ 
                ZFP36 
Hs           -2954 
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Unfortunately it was not possible to carry out ChIP following TGFβ stimulation, due to time 
constraints. Sohn et al. (2010) used antibodies specific to RNAPII C-terminal phosphorylation 
status to identify the effect of TGFβ on Zfp36 transcription pre-initiation (un-phosphorylated 
RNAPII), promoter escape (serine-5 phosphorylation) and elongation (serine-2 
phosphorylation) in epithelial cells. They found that RNAPII binding was enhanced at the 
each stage of Zfp36 transcription in response to TGFβ and DNA was specifically enriched for 
in the promoter region and the 3’UTR by the un-phosphorylated, phosphor-ser5 and 
phosphor-ser2 forms respectively. RNAPII was not found to associate within the TRR domain 
(Sohn et al. 2010). However, the TRR is associated with H3 and H4 acetylation in response to 
TGFβ stimulation. More often, it is acetylation of histones within the promoter region of 
target genes that couples to enhanced transcript synthesis (Clayton et al. 2006). In fact Ross 
et al. (2006) identified that TGFβ-mediated transcriptional activation requires promoter-
located H3 acetylation. We hypothesise that due to the complexity of Zfp36 transcriptional 
regulation and the compactness of its locus that the majority of intragenic conserved 
sequence is required for full inducibility. Therefore we expect that a ChIP of the whole locus 
using antibodies specific for histone acetylation patterns would enrich for ECR3 and ECR4 in 
response to TGFβ and TGFβ plus LPS. However ECR2 was not responsive to TGF stimulation 
and therefore is not likely to play a role in TGF-mediated Zfp36 up-regulation.  
These experiments were undertaken close to the end of the project. However, given the 
time and resources, I would wish to follow up by examining their biological significance. 
Firstly it would be valuable to identify protein regulation by TGFβ and pro-inflammatory 
stimuli. The cooperative effect of TGFβ and LPS was subsequently confirmed at the protein 
level for TTP in murine primary macrophages by western blot, using an antibody for SAK21b 
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(data not included). The synergistic effects of co-stimulation on ZFP36 mRNA production 
were greatest in human primary macrophages, therefore it would be interesting to identify 
whether this was also true for TTP protein biosynthesis. Furthermore, provided with the 
appropriate antibodies, to probe for DUSP1 and TNFAIP3 protein is also key to validation of 
the biological importance of FNG regulation by TGFβ alone and in the presence of an 
inflammatory stimulant. Similarly, the inhibitory effect of TGFβ on TNFα and IL1 activation 
by LPS should also be investigated at the level of protein, this could be done by ELISA. The 
robust inhibition of NFκB-driven positive control reporter constructs in Figure 6.3 is a 
potentially novel finding and if also confirmed endogenously and at the level of protein 
expression could be particularly important. Through activation of TAK1, TGFβ is generally 
considered to have a positive effect on NFκB activation. However it would appear that TGFβ 
may have negative effects on NFκB targets, at the level of transcript expression. 
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7.0 DISCUSSION 
7.1 Methodology 
 
This study was conducted to investigate the regulation of expression of three feedback node 
genes (FNGs) induced by pro-inflammatory stimuli in macrophages, with a particular focus 
on TTP. Macrophages are central to inflammatory signalling and play a significant role in the 
pathogenesis of chronic inflammatory syndromes including rheumatoid arthritis, asthma 
and cancer (Welte & Groneberg 2006; Sabroe & Whyte 2007; Szekanecz & Koch 2007). LPS 
has been shown to induce the expression of DUSP1, A20 and TTP at the level of mRNA and 
protein in murine bone marrow derived macrophages (BMMs), the transformed 
macrophage cell line RAW264.7 and in primary human macrophages. Induction of DUSP1 
and TTP expression in the human epithelial HeLa and A549 cell lines however is via 
stimulation with IL1α. The use of primary murine and, particularly human macrophages 
strengthens this study in terms of applicability to human physiology. In the majority of 
endogenous mRNA experiments, the expression patterns observed were recapitulated not 
only between primary cells and cell lines of equivalent species but also between species. 
However there were some discrepancies in gene induction between primary human 
macrophages and the human cell lines and this may have been due to differences in cell 
type or inflammatory stimulus used i.e. LPS or IL1α. In addition there was some contrast 
between species in the transcriptional ability of evolutionarily conserved regions. Again 
however, this may be a stimulus specific effect. THP1 cells are a human leukaemic monocyte 
line commonly used as a model and also human derived lymphoblast lines HL60 and U937. 
Perhaps it would be interesting to carry out the reporter analyses in either of these cell 
types. However the fold induction of luciferase by pro-inflammatory stimulation of Zfp36 
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ECRs was significant, mirrored the endogenous response and yielded reliable results in both 
HeLa and RAW cells. HEK293s are a human kidney epithelial transformed cell line and are 
notoriously easy to transfect. This study focused on pro-inflammatory signalling through 
TLR4 and the IL1R and therefore HEK 293 cells transformed with pUNO-TLR4 and pDUO2-
MD2-CD14 plasmids were used for Zfp36 mini gene reporter assay. 
Standard molecular and cellular biology techniques were used to detect and quantify mRNA 
(real-time quantitative PCR), protein (western blot) and cytokine (ELISA) expression. QPCR is 
a precise method of DNA transcript quantification and the expression levels of Cox1, Dusp1, 
IL1, IL6 TNFα, Tnfaip3 and Zfp36 were measured by this method. As is common, Gapdh was 
used for normalisation. There is tentative evidence to suggest that LPS induces Gapdh 
expression in liver and lung. However in the present study Gapdh levels remained constant 
between treatment group and time period following pro-inflammatory stimulation whereas 
levels for the induced genes of interest varied by several cycles between treatment groups. 
Cellular protein expression was detected by western blot, which is an efficient and reliable 
method. However, it would have been more conclusive to obtain quantitative data from 
densitometry of the western blots. Sandwich ELISA was used to quantify the expression of 
cytokines and chemokines which are secreted by macrophages and other cells of the 
immune system.  
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7.2 Involvement of NFκB in the regulation of FNG expression 
 
Feedback node genes Dusp1, Tnfaip3 and Zfp36 are acknowledged for their rapidly up-
regulated transcriptional response pro-inflammatory agonists such as LPS. The extent of 
NFκB involvement in these mechanisms however, is generally ill understood. This study 
provides evidence that although Tnfaip3 mRNA synthesis is strongly dependent on NFκB 
signalling pathways, the expression of both Dusp1 and Zfp36 transcripts was only 
moderately affected by chemical inhibition of NFκB. This result was contrary to findings by 
Chen et al 2013 and King et al 2009 who showed a strong dependency of TTP mRNA 
expression on NFκB signalling in the RAW 264.7 and A549 cell lines respectively. Dusp1 is 
induced by the stress response, serum and pro-inflammatory stimuli such as IL1 (Li et al. 
2001; Lasa et al. 2002; Toh et al. 2004; Charles et al. 1993). In this study, chemical inhibition 
of NFκB augmented LPS-induction of Dusp1 mRNA, suggesting that NFκB is inhibitory to 
Dusp1 transcription mediated by other transcription factors. Therefore it is likely that a 
multitude of transcription factors are involved in FNG induction in response to a variety of 
cellular stimuli and signalling pathways. For example Dusp1 is subject to up-regulation by 
heat shock, oxidative stress (Keyse & Emslie 1992) and UV light (Li et al. 2001). Whereas TTP 
is induced by numerous factors including growth factors (Ogawa et al. 2003; Sohn et al. 
2010; Tan & Elowitz 2014), cytokines (Suzuki et al. 2003), agonists of cAMP and even green 
tea and cinnamon. Indeed, Leppanen et al. (2008; 2010) conducted studies that indicate 
AP2-dependent as opposed to NFκB dependent mechanisms of TTP induction, in response 
to pro-inflammatory stimulation. 
This study also highlighted the LPS-induced biphasic expression pattern of Zfp36 transcript 
in human and murine primary macrophages previously observed in RAW264.7 cells by 
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Tchen (2004) and, more recently Chen (2013). This observation was taken further in this 
study and, in an attempt to characterise the mechanism of the second wave of Zfp36 
transcript expression ChIP was carried out in BMMs unstimulated or activated with LPS for 
1, 2 and 4 hours. Immunoprecipitation with RelA after 4 hours of LPS stimulation implied 
that Zfp36 transcript up-regulation at this time was unlikely to involve NFκB-mediated 
mechanisms. Zfp36 is a target of destabilisation by its own protein product, TTP. Transient 
activation of p38 MAPK during the inflammatory response is inversely proportional to 
activation of TTP and therefore it is unlikely that the increase in Zfp36 transcript at 4 hours is 
due to increased mRNA stability.  
Results from this study show strong PGE2 mediated Zfp36 expression at 4 hours post 
stimulation. Therefore it may be constructive to immunoprecipitate for cAMP induced 
transcription factors including CREB or p300 and also C/EBPβ and AP2 which are associated 
with cAMP signalling. However these data came late in the project and time was too limited 
for further investigation.  
The putative enhancer elements investigated in this study may well be separately important 
in their actions, for example in response to different stimuli and duration of activation, as 
well as cell and tissue type. ECR4 contains an NFκB consensus motif and strongly induced a 
luciferase reporter gene in response to LPS and IL1. Predictably, this construct was inhibited 
by MLN4924. Whereas ECRs 2 & 3 were able to elicit a transcriptional response following 
cell stimulation with IL1 or LPS but are unresponsive to MLN4924. These data suggest that 
sequences within ECR 2 & 3 up-regulate ZFP36 expression via mechanisms independent of 
NFκB and are responsible for the induction of Zfp36 mRNA in the presence of LPS and 
MLN4924. 
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All of the FNGs described in this study have been identified as immediate early genes (IEGs) 
and therefore exist in a state of open chromatin that is accessible to transcription factors 
and associated transcriptional machinery. Even in un-stimulated primary macrophages, 
RNAPII is found associated with Zfp36 upstream elements including ECRs 1 to 4 and within 
the promoter region. Transcription of TTP is precipitous with pro-inflammatory stimulation 
and transcripts can be detected as early as 15 minutes post stimulation with LPS (Brooks et 
al. 2004). After 1 hour of activation we observed RNAPII accumulation within the coding 
region and downstream, within the 3’UTR of Zfp36. Concurrent with mRNA quantification 
time course data, RNAPII association with the Zfp36 locus is most significant at 1 hour post 
stimulation, is reduced at 2 hours and peaks again after 4 hours. In this study we used an 
antibody directed against the major subunit of RNAPII. An interesting future experiment 
would be to immunoprecipitate for RNAPII phosphor-serine-5, the posttranslational 
modification of the major subunit associated with transcriptional elongation. Phospho-
serine-2 on the other hand is associated with inactive RNAPII and might be enriched 
upstream of Zfp36 in unstimulated macrophages. 
The focus on ChIP with primary human cells was to carry out siRNA and identify the effects 
on RNAPII accumulation at the human Zfp36 locus however time constraints limited this 
work. Preliminary experiments confirmed RelA knock down in siRelA treated cells and 
association of RelA with enhancer regions in control human primary macrophages.  
 
7.3 Endogenous expression of FNGs in response to Anti-inflammatory 
stimuli 
Glucocorticoids are routinely used for the treatment of virtually all chronic inflammatory 
syndromes (Clark & Belvisi 2012; Hillier 2007) including RA (Kirwan & Power 2007; Gorter et 
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al. 2010; Hoes et al. 2010) and asthma (Barnes 2006). In addition they may also be 
prescribed for their immunosuppressive effects in patients undergoing transplantation or 
their antiproliferative effects in haematological malignancy (Clark & Belvisi 2012). However 
the mechanisms of glucocorticoid action remain largely unknown. Previous studies have 
highlighted the induction and importance of DUSP1 in glucocorticoid-mediated anti-
inflammatory mechanisms (Clark 2007; Newton & Holden 2007; Owens & Keyse 2007). In 
Dusp1-/- macrophages, the majority of glucocorticoid-mediated anti-inflammatory effects 
are abrogated. This is partially due to increased pro-inflammatory mRNA stability (Lasa et al. 
2001; Lasa et al. 2002; Quante et al. 2008) and in addition the continued activation of NFκB/ 
AP1 and pro-inflammatory gene expression (Diefenbacher et al. 2008; Bladh et al. 2009; 
King, Holden, et al. 2009a). Whereas the regulation of A20 mRNA expression has not been 
investigated in this context, previous study in elucidating the mechanism by which 
glucocorticoids edit the expression kinetics of Zfp36 have largely been inconsistent (Jalonen 
et al. 2005; Bergmann et al. 2004; Smoak & Cidlowski 2006). We hypothesised that 
dexamethasone would up-regulate FNGs at the level of mRNA. Glucocorticoid stimulation 
induced expression of each FNG in primary human and murine macrophages as well as in 
cell lines. Furthermore, this effect was augmented in cells simultaneously activated with LPS 
or IL1. However in Dusp1-/- macrophages the cooperative regulation of Tnfaip3 and Zfp36 
observed in WT cells was abolished. Indeed, as recognised by previous studies, the anti-
inflammatory effects of dexamethasone on Tnfα, Il1 and Il6 were also lost in Dusp1 knock 
out cells. These data could suggest that glucocorticoids, via DUSP1, utilise the mRNA 
destabilising effects of TTP and the NFκB inhibitory actions of A20 in order to mediate their 
full anti-inflammatory function.  
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Similarly, PGE2 a cAMP-enhancing compound was able to up-regulate the expression of all 
three FNGs whilst inhibiting expression of pro-inflammatory cytokines at the level of mRNA 
and protein secretion. Again, PGE2 required the expression of Dusp1 to mediate its up-
regulatory effects on FNG expression and, interestingly, its anti-inflammatory abilities. In 
agreement with previous studies (Diefenbacher et al. 2008; Quante et al. 2008; Bladh et al. 
2009; King, Holden, et al. 2009b; Hong Yu et al. 2011; H Yu et al. 2011), these data further 
identify Dusp1 as a central mediator of negative feedback regulation of inflammation that, 
in all probability, acts via Zfp36 and perhaps also Tnfaip3. Indeed, the anti-inflammatory 
effects of cAMP-agonists have been shown to require the expression of TTP (Joe et al. 2011; 
Geyer et al. 2012; Jalonen et al. 2007; Brahma et al. 2012).  
  
As aforementioned, glucocorticoids are the conventional treatment for asthma patients. 
However, glucocorticoid therapy is often ineffective in the treatment of pronounced 
inflammation of the airway, or indeed in COPD. In such cases often a combination therapy 
of glucocorticoids and long-acting β2-adrenoceptor agonists (LABAs) or the PDE4-inhibitor 
Roflumilast is administered. This combination increases bronchodilation at the same time as 
promoting glucocorticoid effects in a cAMP-dependent manner. Part of this mechanism is to 
do with the additive up-regulation of DUSP1 mediated by the two agonists and an enhanced 
and extended DUSP1 expression profile is key to augmenting the signalling pathways that 
induce and activate A20 and TTP (as represented in this thesis as well as in Smallie et al. 
2015; Ross et al. 2015). 
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TGFβ induced Zfp36 mRNA expression in human and murine primary macrophages and 
augmented the effects of LPS on all three FNGs. As well as wound healing, TGFβ is also 
associated with the development of cancer. TTP and A20 are reputed tumour suppressors 
and may play roles in TGFβ signalling.  Indeed, a mutation in the TTP promoter that confers 
insensitivity to the anti-proliferative effects of TGFβ is associated with HCC (Sohn et al. 
2010). A20 on the other hand negatively regulates TAK-1 mediated NFκB activation through 
ubiquitination. MAPKs are activated via TAK1 Ras and Rho A proteins downstream of TGFβ 
signalling (Ding et al. 2014; X.-L. Yuan et al. 2011; Gui et al. 2012; Yamaguchi et al. 1995). 
Therefore through induction of DUSP1 and A20, LPS and TGFβ form an anti-inflammatory 
and potentially anti-tumourogenic negative feedback loop.  
 
It is clear the DUSP1 is central to the anti-inflammatory and therapeutic effects of numerous 
compounds. In addition it would appear that DUSP1 mediates its effect not only by 
inhibition of MAPK signalling but via activation of TTP and possibly A20. However what is 
most intriguing is the mechanism of cooperative up-regulation of each of these FNGs. 
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7.4 Novel putative enhancer regions and maintained and composite 
transcription factor binding sites 
 
Although the majority of transcriptional studies investigating Zfp36 have focused on the 
promoter region, here we have potentially identified a number of novel transcription factor 
binding motifs and putative enhancer sequences located distally upstream of the Zfp36 
sequence. The evolutionarily conserved regions described here were responsive to pro-
inflammatory stimuli in both human and murine cells and are likely to be involved in Zfp36 
induction in vivo. The compound ECR 3-4 was transcriptionally responsive to anti-
inflammatory stimulation by dexamethasone, TGFβ and PGE2 in both human and murine 
cells. Furthermore co-stimulation with pro-inflammatory and anti-inflammatory stimuli was 
able to cooperatively induce transcription from ECR3-4. ECR2 on the other hand did not 
respond to either agonist alone, however was cooperatively activated by co-stimulation 
with inflammatory agonist and either dexamethasone or PGE2. ECR2 contains a GR-like 
motif which is occupied in the presence of dex. During combined treatment with dex, this 
motif was bound by both GR and RelA in primary murine macrophages. Similarly, ECR 4, the 
promoter and intron were all found associated with both GR and RelA during co-treatment. 
Of these composite sites, only ECR4 contains an NFκB binding motif. These data suggest that 
mutual binding of NFκB and GR at novel, context dependent sites induces Zfp36 
transcription in a cooperative manner. This kind of context-dependent regulation of gene 
expression in response to GC and LPS co-stimulation has been observed in RAW cells at an 
upstream region of TNFAIP3 (Altonsy et al. 2014). Both ECR1 and ECR5 contain 
glucocorticoid elements and are associated with GR under conditions of dexamethasone, as 
is the 3’UTR. 
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A TGFβ responsive region (TRR) was identified upstream of Zfp36 and mutations to this CpG-
rich sequence associate with HCC (Sohn et al. 2010). Additionally, the promoter region of 
Zfp36 contains a functional smad element. In this study we identified two TGFβ-driven 
transcriptionally responsive sequences further upstream of these sites, within ECR3 and 4 
which responded to TGFβ individually and were cooperatively activated by LPS and TGFβ co-
stimulation. Sequence analyses of the Zfp36 locus do not highlight putative smad motifs 
within these evolutionarily conserved regions. However, as can be seen from the ChIP with 
GR in dex and lps+dex activated macrophages, smad/ TGFβ-induced transcription factor 
binding in vivo cannot be ruled out. It would be of great benefit to carry out chromatin 
immunoprecipitation of the Zfp36 locus with antibodies against smads2/3 in order to 
confirm in vivo up-regulation of Zfp36 in response to TGFβ and combination treatment of 
TGFβ and pro-inflammatory stimulus LPS. Similarly, this would be a beneficial experiment to 
do with regards to PGE2-mediated regulation of Zfp36.  
A number of studies have identified consensus motifs for the cAMP-responsive transcription 
factor AP2 in the TTP promoter (DuBois et al. 1990; Heximer & Forsdyke 1993; Lai et al. 
1995; Kaneda et al. 2000) and intron (Lai et al. 1998). Deletion of the AP2 site within the 
promoter significantly reduced the serum inducibility of TTP in NIH3T3 cells (Lai et al. 1995). 
Inducers of cAMP-signalling pathways include β2 agonists, forskolin and Db-cAMP which 
have been shown to upregulate TTP mRNA and protein expression in 3T3 fibroblasts, rat 
secondary astrocytes and PC12 pheochromocytoma cells (DuBois et al. 1990; Arenander et 
al. 1989; Kaneda et al. 1992). Transcription factor AP2 is activated downstream of cAMP and 
numerous studies have identified the presence of AP2 consensus motifs within the TTP 
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promoter (DuBois et al. 1990; Heximer & Forsdyke 1993; Lai et al. 1995; Kaneda et al. 2000) 
and intron (Lai et al. 1998). Deletion of the promoter but not the intron AP2 consensus 
sequence significantly reduced serum responsiveness of Zfp36 expression. Forskolin induces 
the nuclear translocation of AP2 and this has been postulated as a mechanism for cAMP-
mediated TTP up-regulation. In addition to these factors and PGE2  
Given the evidence supporting cAMP up-regulation of and functional dependency on Dusp1 
it would also be very interesting to investigate the in vivo interactions between C/EBP, P300 
& other cAMP associated transcription factors and the Dusp1 locus. 
 
7.5 Summary and Conclusions 
Feedback node genes (FNGs) are essential for negative feedback control of inflammatory 
responses and by definition are controlled by both pro- and anti-inflammatory stimuli. In 
this study, I have shown that the pro-inflammatory induction of three FNGs is cooperatively 
induced by anti-inflammatory agonists dexamethasone, PGE2 and TGFβ. In addition, 
experiments in primary mouse knock-out macrophages suggest that Dusp1 may be required 
for the anti-inflammatory effects of PGE2 and indeed other anti-inflammatory agents. 
Finally, I identified three novel putative enhancer sites upstream of the Zfp36 locus that also 
demonstrated cooperative transcriptional regulation by various combinations of pro- and 
anti-inflammatory agonists (Figure 7.1). Further to this, Chromatin immunoprecipitation 
highlighted dynamic remodelling of the Zfp36 locus in response to pro-inflammatory stimuli 
and the anti-inflammatory agonist dexamethasone.  
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There is increasing evidence to suggest that modulation of the expression of FNGs could be 
a powerful therapeutic strategy. Therefore it is important to gain more knowledge of the 
mechanisms involved in regulation of anti-inflammatory feedback node genes such as 
DUSP1, TTP and A20. Not only for the purpose of understanding current therapies but also 
to develop the potential for novel gene-targeted techniques.   
 
 
Figure 7.1 Novel regulatory elements and super-enhancer sequences involved in the 
complex regulation of Zfp36 
A schematic of the TTP gene locus showing putative regulatory regions highlighted by 
previous work (shown above) and those functional elements identified in this study 
(shown below). The red bars represent the evoulutionarily-conserved regions, 
exhibiting super-enhance potential. 
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